Methods of treating eosinophilic esophagitis

Low-dose, locally active corticosteroids administered in specific phases address the ineffectiveness and side effects of current EoE treatments, improving esophageal function and symptom relief with reduced systemic impact.

JP2024164004AInactive Publication Date: 2024-11-26ADARE PHARMACEUTICALS INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024115475
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-04-24
Filing Date
2024-07-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for eosinophilic esophagitis (EoE), such as systemic corticosteroids, have significant side effects and are not effective in reducing esophageal inflammation, leading to misdiagnosis with gastroesophageal reflux disease (GERD) and complications like dysphagia and food intrusion.

Method used

Administering low-dose, locally active corticosteroids, such as budesonide, fluticasone, or ciclesonide, in an induction and maintenance phase, with specific dosing and timing to improve esophageal function and morphology without systemic side effects.

Benefits of technology

The method effectively reduces eosinophil counts, improves esophageal function and morphology, and alleviates symptoms like dysphagia and food intrusion, with minimal systemic side effects, enhancing patient quality of life and reducing relapse.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024164004000001_ABST
    Figure 2024164004000001_ABST
Patent Text Reader

Abstract

To provide methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid.SOLUTION: In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and / or while the patient is lying down.SELECTED DRAWING: Figure 6
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 376,703, filed August 18, 2016, U.S. Provisional Patent Application No. 62 / 461,317, filed February 21, 2017, and U.S. Provisional Patent Application No. 62 / 489,292, filed April 24, 2017, the entire contents of each of which are incorporated herein by reference in their entirety for all purposes. [Background technology]

[0002]

[0002] The number of diagnoses of inflammatory disorders of the esophagus, such as eosinophilic esophagitis (EoE), a disease characterized by high eosinophil levels and thickening of the basal cell layer in the esophagus, is increasing in children and adults. Many aspects of the disease remain unknown, including its etiology, natural history, and optimal treatment. EoE affects all age groups, but is most commonly seen in individuals between the ages of 20 and 50. Symptoms of EoE often mimic those of gastroesophageal reflux disease (GERD) and include vomiting, dysphagia, pain, and food impaction. The disease is painful, causes difficulty in swallowing, and predisposes patients to other complications. EoE is often misdiagnosed as GERD, which delays appropriate treatment for EoE patients.

[0003]

[0003] Currently, there are no locally administered anti-inflammatory drugs approved for the treatment of conditions associated with inflammation of the upper gastrointestinal tract, particularly esophageal inflammatory conditions such as EoE. Although systemic treatment with corticosteroids such as prednisolone is effective, these medications have adverse effects, including suppression of the hypothalamic-pituitary-adrenal (HPA) axis as reflected by salivary cortisol levels, and general suppression of immune function. There are significant adverse effects, particularly in children, and troublesome side effects from long-term systemic exposure include developmental delays. Summary of the Invention [Problem to be solved by the invention]

[0004]

[0004] The present disclosure provides a method of administering a pharmaceutical composition comprising a low-dose locally active corticosteroid to treat, prevent, ameliorate or delay symptoms and / or inflammation associated with a gastrointestinal inflammatory disorder. In some embodiments, the gastrointestinal inflammatory disorder is in the esophagus. In some embodiments, the gastrointestinal inflammatory disorder is eosinophilic esophagitis. [Means for solving the problem]

[0005] In some embodiments, the present disclosure provides a method of treating eosinophilic esophagitis (EoE) in a patient in need thereof, comprising administering an oral corticosteroid in an induction phase and a maintenance phase. In some embodiments, the induction phase results in an improvement in peak eosinophil (Eos) counts in at least one esophageal biopsy sample, and the treatment (e.g., during the induction phase) is (treatment) does not result in a worsening of the patient's average weekly score on patient-reported outcome assessments, including assessment of days free of dysphagia. In some embodiments, the patient exhibits substantial improvement in esophageal function and morphology, including reduction in esophageal groove, reduction in focal esophageal stricture, increase in esophageal diameter, increase in esophageal compliance, increase in distensibility of the esophageal body, increase in ease of swallowing, reduction in edema, improved vascularity, reduction in esophageal rings, reduction or absence of exudate, and / or absence of stricture.

[0006] In some embodiments, the present disclosure provides a method of treating eosinophilic esophagitis (EoE) in a patient in need thereof, comprising administering an oral corticosteroid in an induction phase and a maintenance phase. and the induction phase comprises administering to the subject a peak eosinophil count in at least one esophageal biopsy sample. In some embodiments, the patient experiences at least one episode of food impaction during the induction phase. In some embodiments, the patient exhibits active symptoms of EoE during the induction phase. In some embodiments, the induction phase results in a histological response of >= 15 peak eosinophils per high power field (HPF). In some embodiments, the induction phase results in a histological response of >= 15 peak eosinophils per high power field (HPF). In some embodiments, the patient does not demonstrate substantial improvement in esophageal function and / or morphology during the induction phase. In some embodiments, by continuing treatment after an ineffective induction phase, the patient demonstrates improvement in peak eosinophil counts in at least one esophageal biopsy sample, and the continued treatment does not result in a worsening of the patient's average weekly score on patient-reported outcome assessments, including assessments of days free of dysphagia.

[0007] In some embodiments, the maintenance phase includes a dose at least equal to, greater than, or less than the induction phase. In some embodiments, the induction and maintenance doses are between about 1.5 mg and about 3 mg, administered, for example, once or twice daily.

[0008] In some embodiments, the induction phase includes administration for at least about 6 weeks, at least about 8 weeks, at least about 10 weeks, or at least about 12 weeks. In some embodiments, administration occurs twice daily. In some embodiments, the induction phase results in a histological response of <6 Eos per HPF. In some embodiments, the induction phase does not result in food impaction episodes.

[0009]

[0009] In some embodiments, the patient on maintenance therapy does not recur active symptoms of EoE. In some embodiments, the maintenance dose is substantially the same as or less than the induction dose. In some embodiments, the continuation dose is higher than the induction dose. In some embodiments, the patient in the withdrawal phase does not recur active symptoms of EoE. In some embodiments, the patient remains in the withdrawal phase until active symptoms of EoE recur. In some embodiments, after the recurrence of active symptoms of EoE, the patient takes an induction dose of oral corticosteroid. In some embodiments, after the recurrence of active symptoms of EoE, the patient takes a maintenance dose of oral corticosteroid. In some embodiments, after the recurrence of active symptoms of EoE, the patient takes an induction dose of oral corticosteroid, followed by a maintenance dose.

[0010]

[0010] In some embodiments, the disclosure provides for administration of an oral corticosteroid composition to a patient while lying down. In some embodiments, the corticosteroid is administered to the patient while lying down and before falling asleep (e.g., about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, or about 30 minutes, including all values ​​therein). In some embodiments, the pharmaceutical composition is administered to the patient at least about 2 hours after dinner. In some embodiments, the corticosteroid is administered to the patient at least about 4 hours after dinner.

[0011]

[0011] In some embodiments, the corticosteroid is formulated into an orally dissolving dosage form. In some embodiments, the corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, tixocortol, and salts or esters and mixtures thereof. In some embodiments, the orally dissolving dosage form is a tablet or wafer. In some embodiments, the corticosteroid is The adrenergic receptors are deposited locally in the upper gastrointestinal tract. In some embodiments, the patient has previously been administered proton pump inhibitor (PPI) therapy. In some embodiments, the patient has previously been administered proton pump inhibitor (PPI) therapy. The patient has previously received 8 weeks of PPI therapy. In some embodiments, the PPI therapy has not been effective in substantially improving one or more symptoms of EoE. In some embodiments, the patient has not previously received PPI therapy.

[0012] In some embodiments, the present disclosure provides a method for evaluating a subject's suitability for a clinical trial to measure the effect of oral corticosteroids on EoE after administration in both induction and maintenance phases. The present invention provides a method for determining whether or not a patient has a peak eosinophil count per HPF of greater than 15, wherein recruitment of subjects into a clinical trial is assessed based on: (i) the patient having a peak eosinophil count per HPF of greater than 15, and (ii) prior treatment with a PPI for at least about 8 weeks has been ineffective in substantially ameliorating one or more symptoms of EoE.

[0013]

[0013] In some embodiments, the present disclosure provides a method of treating EoE in a patient in need thereof, comprising administering an oral corticosteroid to the patient, wherein the patient is lying down when the oral corticosteroid is administered or the patient lies down immediately after administration of the oral corticosteroid. In other embodiments, the present disclosure provides a composition comprising an oral corticosteroid for use in treating EoE in a patient in need thereof, wherein the patient is lying down when the composition is administered or the patient lies down immediately after administration of the composition. In yet other embodiments, the present disclosure provides a use of a composition comprising an oral corticosteroid for the manufacture of a medicament for therapeutic application to EoE in a patient in need thereof, wherein the patient is lying down when the medicament is administered or the patient lies down immediately after administration of the medicament.

[0014] In various embodiments, the present disclosure provides a method (or composition for use in a method) of locally treating EoE with an oral corticosteroid in a patient in need thereof, comprising: (a) administering the oral corticosteroid while the patient is bedridden or immediately prior to the patient becoming bedridden. In embodiments, a therapeutically effective amount of the oral corticosteroid contacts the esophagus, thereby locally treating EoE.

[0015] In embodiments, the bed rest is in a supine, prone or lateral position. In embodiments, the oral corticosteroid is administered within about 30 minutes before the target bedtime. In embodiments, the oral corticosteroid is administered at least about 30 minutes after a meal. In embodiments, the patient does not eat or drink for at least about 30 minutes after administration of the oral corticosteroid.

[0016] In embodiments, the oral corticosteroid is administered (i) once daily, or (ii) twice daily, with the first daily dose administered while the subject remains upright. In embodiments, the corticosteroid has a systemic bioavailability of about 20% or less of the dose. In embodiments, the oral corticosteroid provides a mean maximum plasma concentration (Cmax) of about 500 pg / mL or less following oral administration of about 0.01 mg to about 20 mg of oral corticosteroid. In embodiments, the oral corticosteroid provides a mean AUC of about 3,000 pg·h / mL or less following oral administration of about 0.01 mg to about 20 mg of oral corticosteroid. 0~24In embodiments, the oral corticosteroid is budesonide, fluticasone, flunisolide, ciclesonide, mometasone or beclomethasone, or a pharma- ceutically acceptable salt, solvate, ester, polymorph or prodrug thereof. In embodiments, the oral corticosteroid is (i) formulated as a liquid composition, (ii) formulated as a solid composition, (iii) formulated to form a solution or suspension prior to oral administration, or (iv) formulated to form a solution, suspension or gel after oral administration, whereby (i)-(iv) deliver a therapeutically effective amount of the oral corticosteroid to the esophagus. In embodiments, (i) the liquid composition is in the form of a solution, suspension or slurry, and (ii) the solid composition is in the form of a gel, lozenge, lollipop, effervescent tablet, powder, granules, or orally disintegrating composition. In embodiments, the orally disintegrating composition is a tablet, wafer, film, or lyophilized matrix. In an embodiment, the orally disintegrating composition is a tablet comprising: (a) an oral corticosteroid in an amount of about 1.5 mg to about 7.5 mg; (b) a pharma- ceutically acceptable carrier in combination with the corticosteroid; and (c) rapidly dispersing microgranules, the orally disintegrating tablet being in a dosage form conforming to the USP <701> When tested for disintegration time using the method, it disintegrates within 60 seconds.

[0017] In an embodiment, the patient has a Cmax of the oral corticosteroid of about 200 pg / mL or less after oral administration of 1.5 mg to about 7.5 mg of the oral corticosteroid. In an embodiment, the oral corticosteroid is fluticasone propionate and the bedridden patient has a Cmax within about 80% to about 125% of about 15 pg / mL to about 45 pg / mL after oral administration of 6 mg fluticasone propionate or 3 mg fluticasone propionate to the bedridden patient. In an embodiment, the Cmax of the corticosteroid for the bedridden patient is lower than the Cmax of the oral corticosteroid for a postprandial patient who is upright and not lying down immediately after administration of the oral corticosteroid. In embodiments, the Cmax of the oral corticosteroid for a bedridden patient is reduced by about 10% to about 30% compared to the Cmax of the oral corticosteroid for a postprandial patient who is upright and not reclining immediately after administration of the oral corticosteroid.

[0018] In embodiments, the mean time to maximum plasma concentration (Tmax) is in the range of about 80% to about 125% of about 12 hours to about 15 hours. In embodiments, the Tmax of the corticosteroid for a patient who is bedridden is delayed as compared to the Tmax of the oral corticosteroid for a patient who is upright and not lying down immediately after administration of the oral corticosteroid. In embodiments, the Tmax of the corticosteroid for a patient who is bedridden is delayed by at least about 1 hour as compared to the mean Tmax of the oral corticosteroid for patients who are upright and not lying down immediately after administration of the oral corticosteroid. In embodiments, the Tmax of the corticosteroid for a patient who is bedridden is delayed by a time ranging from about 4 hours to about 9 hours as compared to the Tmax of the oral corticosteroid for a patient who is upright and not lying down immediately after administration of the oral corticosteroid.

[0019] In an embodiment, after 12 weeks of daily administration of oral corticosteroids, there is a reduction in eosinophil count, an increase in dysphagia-free days, a reduction in dysphagia episodes, an improvement in EREFS score, an EndoFLIP record of improved esophageal compliance, an assessment of biomarkers, a reduction in food impaction episodes, an improvement in EEsAI score (patient, physician, endoscopy, pathology score), EoE-QOL-A, Visual Dysphagia Questionnaire (VDQ), Avoidance, Modification and Slow Eating (AMS) score, or a reduction in esophageal inflammation as measured by histology. In an embodiment, the patient's eosinophil count is reduced by at least about 50%.

[0020]

[0020] In an embodiment, the patient has a lactose allergy or a starch allergy. [Brief description of the drawings]

[0021] [Figure 1]

[0021] Figure 1 shows an exemplary schematic overview of parts 1 and 2 of the Phase 2b study design, illustrating the screening and run-in period in part 1 (run-in stage) and the randomized washout in part 2. [Diagram 2]

[0022] FIG. 1 shows an exemplary schematic overview of part 3 (maintenance) and follow-up of a Phase 2b study. [Diagram 3]

[0023] FIG. 2 shows another exemplary schematic overview of parts 1 and 2 of the Phase 2b study design, illustrating the screening and run-in period in part 1 (run-in stage) and the randomized washout in part 2. [Figure 4]

[0024] FIG. 2 shows another exemplary schematic overview of part 3 (maintenance) and follow-up of the Phase 2b study. [Diagram 5]

[0025] FIG. 1 shows a schematic of the study providing an overview of the treatment each subject received throughout the FLUTE study. [Figure 6]

[0026] FIG. 1 shows mean linear plasma concentration-time profiles for APT-1011 (fluticasone propionate) for postprandial, fasted and HS administration. [Figure 7]

[0027] FIG. 1 shows mean log plasma concentration-time profiles for APT-1011 (fluticasone propionate) for postprandial, fasted and HS administration. [Figure 8]

[0028] FIG. 1 shows a spaghetti plot of APT-1011 (fluticasone propionate) (fasting conditions). [Figure 9]

[0029] FIG. 1 shows a spaghetti plot of APT-1011 (fluticasone propionate) (post-prandial conditions). [Figure 10]

[0030] FIG. 1 shows spaghetti plots of APT-1011 (fluticasone propionate) (HS conditions). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022]

[0031] Gastrointestinal inflammatory disorders such as eosinophilic esophagitis (EoE), an allergic / immune condition in which a subject suffers from inflammation and / or swelling of the esophagus, affect a patient's ability to swallow food, This can result in impaired nutrition and growth. Normally, eosinophils are not found in the esophagus, but in EoE, these cells accumulate and cause swelling that reduces the internal diameter of the esophagus, making swallowing and eating very difficult. Often, patients experience episodes of food impaction, in which food gets stuck in the patient's esophagus, which may require emergency treatment. Due to the difficulty in swallowing and the fear of food impaction, many patients with EoE refrain from eating soft foods such as yogurt, soups, and smoothies. In severe cases of EoE, patients receive parenteral nutrition (e.g., intravenous feeding), which can provide essential nutrition but can limit the patient's activity and lead to increased infection at the catheter site.

[0023]

[0032] EoE most commonly affects white males and can occur at any age, although symptoms vary with age. Infants with EoE may refuse food, fail to thrive, or experience "regurgitation" and / or vomiting. Young children commonly report heartburn / regurgitation, abdominal pain, vomiting, food aversion, and / or poor growth. The hallmark symptom for adults is dysphagia (trouble swallowing), and EoE is associated with more than 50% food impaction. Adult patients less frequently present with heartburn or chest pain. Adults with EoE also exhibit changes in eating behavior, such as dietary changes, slow feeding, excessive chewing, and increased liquid intake with food.

[0024]

[0033] Although the cause of EoE is unknown, many EoE patients have a family history of allergies, asthma, and / or symptoms of allergic disorders (e.g., asthma, allergic rhinitis, atopic dermatitis, and food allergies). In addition, environmental allergens such as dust mites, animals, pollen, and molds may contribute to the development of EoE. Because of the association between EoE and allergies, especially food allergies, elimination of allergens may help relieve symptoms. However, these types of elimination can be difficult to achieve.

[0025]

[0034] There are no medications currently approved to treat EoE, but some medications, such as glucocorticosteroids, leukotriene antagonists, mast cell stabilizers, immunomodulators, biologics, and small molecules, may help alleviate symptoms. Proton pump inhibitors (PPIs), which control the amount of acid produced, have also been used to treat symptoms in patients, but the effects of these drugs on the patient's condition are unclear. They fail to reduce the amount of inflammation. Furthermore, recent studies have linked long-term PPI use to dementia, making their use less desirable in EoE patients. Endoscopic therapy (dilation) is also sometimes used to relieve symptoms, but again, this has no effect on the underlying inflammation that causes esophageal swelling.

[0026]

[0035] Although these treatments may help relieve symptoms for a time in some patients, they are often insufficient to treat EoE. For example, current topical steroids are suboptimal, with 5-50% of patients classified as non-responders. Similarly, patients with significant endoscopic Dietary elimination requiring surveillance has a failure rate of approximately 30%.

[0027]

[0036] There is a need for new methods that not only alleviate symptoms of esophageal inflammatory disorders such as EoE, but also address the inflammation that causes the symptoms. The present disclosure provides a method of administering a pharmaceutical composition that includes a locally active corticosteroid to treat symptoms and / or inflammation associated with gastrointestinal inflammatory disorders. Also disclosed herein are pharmaceutical compositions that include a locally active corticosteroid for use in such methods.

[0028]

[0037] In various embodiments, the methods disclosed herein include at least two phases: induction phase and maintenance phase. During the induction phase, the patient is administered a dose of the pharmaceutical composition of the present disclosure. Based on the patient's response at the end of the induction phase (e.g., histological response and absence of worsening symptoms or episodes of food impaction), the patient can enter the maintenance phase. The doses of the pharmaceutical composition during the maintenance and induction phases can be the same or different. If symptoms improve or decrease, the patient can enter a withdrawal phase and not take a dose of the pharmaceutical composition until symptoms recur.

[0029]

[0038] The present disclosure relates to a method for treating eosinophilic esophagitis (EoE) in a patient in need thereof. The method includes administering an oral corticosteroid in an induction phase and a maintenance phase, wherein the induction phase results in an improvement in peak eosinophil count in at least one esophageal biopsy sample, and wherein the treatment does not result in a worsening of the patient's average weekly score on patient-reported outcome assessments, including an assessment of days free of dysphagia.

[0030]

[0039] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Preferred methods and materials are described herein, although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure.

[0031]

[0040] Singular forms such as "a," "an," and "the" are used throughout this specification for convenience, but it should be understood that the singular forms are intended to include the plural unless otherwise indicated by context or clear statement. All numerical ranges are to be understood to include each and every numerical point within that numerical range and are to be interpreted as each and every numerical point individually. The endpoints of all ranges relating to the same component or property are intended to be inclusive and independently combinable.

[0032]

[0041] As used herein, the term "include" and variations thereof means, but are not limited to, The terms "can" and "may" and their variations are intended to be non-limiting, and thus the recitation of an item in a list is not a statement to the exclusion of other similar items that may also be useful in the materials, compositions, devices, and methods of the present technology. Similarly, the terms "can" and "may" and their variations are intended to be non-limiting, and thus a statement that an embodiment can or may include certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features. The non-limiting term "comprising," as synonymous with terms such as including, containing, or having, is intended to be used to describe and claim the present disclosure, technology, or embodiments thereof. As used herein, the compositions may instead be described using more restrictive terminology such as "consisting of" or "consisting essentially of" the described components.

[0033]

[0042] As used herein, the terms "drug", "active" or "active ingredient" include pharma- ceutically acceptable locally acting corticosteroids, their pharma- ceutically acceptable salts, esters, solvates (including hydrates), polymorphs, stereoisomers and / or prodrugs, and mixtures. The term "salts" refers to compounds that are formed by reaction of the "free base" of a drug with a suitable inorganic or organic acid. The term "acid" refers to the product formed by the above. Suitable acids include those with sufficient acidity to form stable salts, such as low toxicity acids, such as salts approved for human or animal use. Non-limiting examples of acids that can be used to form salts of orally active drugs include inorganic acids, such as HCl, H3PO4, H2SO4. Non-limiting examples of organic acids include alkylsulfonic acid and propionic acid.

[0034]

[0043] The terms "pharmaceutical composition" and "pharmaceutical dosage form" are used interchangeably herein to refer to oral dosage forms (suspensions, solutions, powders, solids, etc.) that can be used to administer a corticosteroid. Non-limiting examples of dosage forms include orally disintegrating compositions, such as tablets, lyophilized matrices, films and wafers, liquid compositions, gels, slurries, lozenges, lollipops, sachets, effervescent tablets, etc.

[0035]

[0044] The terms "oral corticosteroid" and "corticosteroid" are used interchangeably to refer to corticosteroids that are administered orally, e.g., in the pharmaceutical compositions described herein.

[0036]

[0045] The terms "orally disintegrating dosage form," "orally disintegrating tablet," "orally dispersible tablet," or "ODT" refer to solid dosage forms / tablets of the present disclosure that, after administration, rapidly disintegrate in the patient's mouth without the need for chewing to form a suspension containing the corticosteroid. The rate of oral disintegration varies, but is significantly faster than the rate of oral disintegration of conventional solid dosage forms or chewable solid dosage forms (i.e., tablets or capsules) that are intended to be swallowed immediately after administration.

[0037]

[0046] As used herein, the terms "treating," "treatment," and "treat" include (i) preventing a particular disease or disorder from occurring in a subject who may be predisposed to the disease or disorder but has not yet been diagnosed as having the disease or disorder, (ii) curing, treating, or inhibiting the disease, i.e., arresting its onset, or (iii) ameliorating the disease by reducing or eliminating the symptoms, condition, and / or causing regression of the disease. In some embodiments, "treating," "treatment," and "treat" may also include administering a therapeutically effective regimen as defined herein.

[0038]

[0047] The term "about" as used herein refers to a quantity, including "strictly" within plus or minus 10% of its recited numerical designation. When the term "about" is used in relation to a range of values, the term "about" refers to both the minimum and maximum values ​​of that range (e.g., "about 1-50 μm" means "from about 1 μm to about 50 μm"). The term "intimate association" as used herein to describe the spatial relationship between two or more components of a composition refers to components that are intimately mixed, such as, for example, mixtures, coatings, and matrices.

[0039]

[0048] All percentages and ratios are calculated by weight unless otherwise indicated. All percentages and ratios are calculated based on the total composition unless otherwise indicated.

[0040]

[0049] The term "having no significant systemic glucocorticoid or mineralocorticoid activity" as used herein refers to a corticosteroid composition that produces a local effect by local contact with diseased tissue, but does not produce a systemic effect in the body by absorption into the blood circulation. Examples include fluticasone, flunisolide, budesonide, circlezone, mometasone, tixocortol, and beclomethasone. Corticosteroids that have high systemic glucocorticoid potency when administered orally include, for example, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, etc. or mineralocorticoid potency (e.g., aldosterone). Corticosteroids that normally have systemic glucocorticoid or mineralocorticoid activity when administered orally can also be used in the dilute compositions of the present disclosure, whereby systemic uptake of the corticosteroid is reduced or prevented.

[0041]

[0050] A "histological responder" may be defined as a subject who achieves a histological response (as the primary determinant) of a peak eosinophil / HPF count < 6. An HPF may be defined as a standard area of ​​0.237 square millimeters under a microscope with a 40x lens and a field number of 22 mm.

[0042]

[0051] A "histological non-responder" may be defined as a subject who does not have a histological response (ie, does not achieve a histological response of peak eosinophils / HPF count <6).

[0043]

[0052] Subjects who develop food impaction with or without esophageal dilation at any time during the study may be considered "treatment failures."

[0044] Pharmaceutical Compositions and Administration

[0053] The pharmaceutical composition used in the methods described herein (or for use in the methods described herein) can be in any dosage form that can be used to locally administer a therapeutic agent (e.g., a corticosteroid) to the esophagus. Suitable dosage forms include liquid compositions (e.g., solutions, suspensions and slurries), gels, and solid compositions that form a liquid or gel after oral administration. For example, oral disintegrating compositions (e.g., ODTs, films, lyophilized matrices, or oblates), lozenges, and lollipops can form a solution, suspension, or gel containing the therapeutic agent in the patient's oral cavity, and after the solution or suspension is swallowed, the corticosteroid dissolved or suspended therein contacts the esophagus as the liquid passes through the esophageal tract. In a preferred embodiment of the present invention, the pharmaceutical composition is in the form of an ODT.

[0045]

[0054] In some embodiments, the present disclosure provides oral solid pharmaceutical compositions comprising a corticosteroid (e.g., about 10 mg or less, including 7.5 mg, 6.0 mg, 4.5 mg, 3.0 mg, 1.5 mg, or 0.75 mg) and at least one pharma- ceutically acceptable carrier, wherein the corticosteroid is combined with (e.g., adsorbed onto or suspended in) such a pharma- ceutically acceptable carrier. In some embodiments, the drug is present in an amount of less than about 5% (weight of drug / weight of composition), particularly less than 3% by weight. The pharmaceutical compositions disclosed herein are in accordance with the USP <701> It can be formulated as an orally disintegrating tablet (hereinafter referred to as an ODT) that disintegrates within 60 seconds (e.g., within 30 seconds) when tested using a disintegration test and / or disintegrates within 60 seconds when placed in a human mouth.

[0046]

[0055] In some embodiments, the corticosteroid used in the compositions and methods described herein is a locally acting corticosteroid. In some embodiments, the corticosteroid has low or substantially no systemic effect. In some embodiments, the corticosteroid with low or no systemic effect is one that has no significant systemic glucocorticoid or mineralocorticoid activity after oral administration in humans. A corticosteroid that has "no significant systemic glucocorticoid or mineralocorticoid activity after oral administration in humans" refers to a corticosteroid that has less than about 20%, e.g., less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of systemic glucocorticoid or mineralocorticoid activity after oral administration, or a pharmaceutical composition that includes such a corticosteroid. Systemic glucocorticoid or mineralocorticoid activity can be determined using methods known in the art, for example, by measuring morning cortisol levels. can.

[0047]

[0056] In some embodiments, the corticosteroid for use in the methods and compositions described herein has a systemic bioavailability of about 20% or less of the administered dose.Non-limiting examples of oral corticosteroids with a bioavailability of about 20% or less include fluticasone, flunisolide, budesonide, circlezone, mometasone, tixocortol and beclomethasone, and their pharmaceutically acceptable salts, solvates, esters, polymorphs or prodrugs.In a preferred embodiment, the oral corticosteroid used in the methods and compositions described herein is fluticasone propionate.

[0048]

[0057] In some embodiments, oral corticosteroids for use in the methods and compositions described herein are formulated to provide a pharmacokinetic profile that reduces the likelihood that a patient will experience side effects associated with systemic corticosteroid administration, including, but not limited to, osteoporosis, weight gain, immune system suppression (i.e., increased incidence of infections), high blood pressure, hyperglycemia, muscle weakness, skin problems (e.g., poor wound healing, thinning skin, easy bruising, striae, etc.), mood and behavior changes, increased risk of developing cataracts, and increased risk of duodenal ulcers. That is, the pharmacokinetic profile of the corticosteroid can be modified to provide a mean maximum plasma concentration (Cmax), mean time to maximum plasma concentration (Tmax) and / or AUC that reduces systemic side effects. The pharmacokinetic profile can be measured by methods known in the art, such as those described in Example 5.

[0049]

[0058] In some embodiments, an oral corticosteroid for use in the methods and compositions described herein is formulated to provide a mean maximum plasma concentration (Cmax) of about 10,000 pg / mL or less, e.g., about 9,000 pg / mL, about 8,000 pg / mL, about 7,000 pg / mL, about 6,000 pg / mL, about 5,000 pg / mL, about 4,000 pg / mL, about 3,000 pg / mL, about 2,000 pg / mL, about 1,000 pg / mL, about 900 pg / mL, about 800 pg / mL, about 700 pg / mL, about 600 pg / mL, or about 500 pg / mL, including all values ​​and subranges therebetween, following an oral administration of about 0.01 mg to about 20 mg of oral corticosteroid. In a preferred embodiment, the oral corticosteroid is formulated to provide a Cmax of about 500 pg / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid.

[0050]

[0059] In some embodiments, an oral corticosteroid for use in the methods and compositions described herein has a serum corticosteroid concentration of about 15,000 pg·h / mL or less, e.g., about 14,000 pg·h / mL, about 13,000 pg·h / mL, about 12,000 pg·h / mL, about 11,000 pg·h / mL, about 12,000 pg·h / mL, about 13,000 pg·h / mL, about 14,000 pg·h / mL, about 15,000 pg·h / mL, or about 16,000 pg·h / mL, or about 17,000 pg·h / mL, or about 18,000 pg·h / mL, or about 19,000 pg·h / mL, or about 20,000 pg·h / mL, or about 21,000 pg·h / mL, or about 22,000 pg·h / mL, or about 23,000 pg·h / mL, or about 24,000 pg·h / mL, or about 25,000 pg·h / mL, or about 26,000 pg·h / mL, or about 27,000 pg·h / mL, or about 28,000 pg·h / mL, or about 30,000 pg·h / mL, or about 31,000 pg·h / mL, or about 32,000 pg·h / mL, or about 33,000 pg·h / mL, or about 34,000 pg·h / mL, or about 35,000 pg·h / mL, or about 36,000 pg·h / mL, or about 37,000 pg·h / mL, or about 38 000pg·h / mL, about 9,000pg·h / mL, about 8,000pg·h / mL, about 7,000pg·h / mL, about 6,000pg·h / mL, about 5,000pg·h / mL, about 4,000pg·h / mL, about 3,000pg·h / mL, about 2,000pg·h / mL, and about 1,000pg·h / mL, including all values ​​and subranges therebetween. 0~24 In a preferred embodiment, the oral corticosteroid for use in the methods and compositions described herein is formulated to provide a mean AUC of about 3,000 pg h / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid. 0~24 It is formulated to provide.

[0051]

[0060] In some embodiments, the pharmaceutical compositions described herein improve the systemic bioavailability, glucocorticoid activity and / or mineral quality of oral corticosteroids following oral administration. Corticosteroids can be formulated to reduce their corticoid activity (or a combination thereof). By reducing systemic bioavailability, corticosteroids can be made to have a local therapeutic effect rather than being absorbed systemically. For example, corticosteroids that otherwise have high systemic bioavailability (e.g., >20% systemic bioavailability) can be formulated into ion exchange resins to reduce systemic bioavailability while simultaneously increasing local therapeutic effect.

[0052]

[0061] Salts, solvates, polymorphs and prodrugs can be used to modify corticosteroids that would otherwise have a systemic bioavailability of greater than about 20% to obtain "locally active corticosteroids" that have less than about 20% systemic activity and greater than about 80% local activity by reducing the systemic bioavailability of the corticosteroid.

[0053]

[0062] Non-limiting examples of corticosteroids that can be modified to reduce systemic bioavailability and increase local effect (e.g., by forming a salt or prodrug, or by formulating oral corticosteroids into ion exchange resins) include hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, aldosterone, and the like.

[0054]

[0063] The compositions of the present disclosure may also include water-soluble or water-swellable pharma- ceutically acceptable excipients, such as in vivo gelling or bioadhesive polymers that will enhance the bioadhesion of the corticosteroid to the inflamed esophageal mucosa.

[0055]

[0064] Suitable locally acting corticosteroids that can be included in the pharmaceutical compositions of the present disclosure include budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, tixocortol, and salts, esters, solvates, polymorphs or prodrugs thereof, and mixtures thereof.

[0056]

[0065] In a preferred embodiment, the composition of the present disclosure comprises fluticasone (e.g., fluticasone propionate). In a preferred embodiment, the pharmaceutical composition is an ODT comprising fluticasone or a pharma- ceutically acceptable salt thereof (e.g., fluticasone propionate). In other embodiments, the composition of the present disclosure comprises budesonide. In certain other embodiments, the composition of the present disclosure comprises ciclesonide.

[0057]

[0066] In some embodiments, the corticosteroid may be in the form of a crystal having an average particle size of about 100 μm or less, about 75 μm or less, about 50 μm or less, more particularly about 25 μm or less, or about 15 μm or less. Certain embodiments of the present disclosure provide corticosteroids that are micronized to achieve an average particle size of less than about 10 μm, less than or equal to about 8 μm, less than about 6 μm, or particularly less than about 4 μm.

[0058]

[0067] Alternatively, such crystals may have an average size in the submicron range (e.g., an average particle size of about <1 μm), i.e., may exist as nanoparticles (e.g., an average particle size in the range of about 1-100 nm). In some embodiments, the corticosteroid may be in amorphous form, e.g., in the presence of a stabilizer that limits recrystallization of the drug, e.g., polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPMC), or a combination of both. It may also be present in association with cellulose, hydroxyethyl cellulose, Soluplus®, Kollidon® VA64, sodium lauryl sulfate, Tween surfactants, Eudragit® EPO polymers and mixtures thereof.

[0059]

[0068] The amount of corticosteroid present in the pharmaceutical composition of the present disclosure is selected to maximize therapeutic benefit from local administration while minimizing side effects from systemic absorption. For solid pharmaceutical compositions of the present disclosure, the amount of corticosteroid in the composition is less than about 5% w / w (weight of drug / weight of composition). In some embodiments, the amount of corticosteroid in the pharmaceutical composition is less than about 4%. In other embodiments, it is less than about 3%. In some embodiments, it is less than about 2% by weight, less than about 1.5%, less than about 1%, less than about 0.5%, or less. In some embodiments, the amount of corticosteroid in the pharmaceutical composition is about 0.5 mg to about 18 mg. In some embodiments, the amount of corticosteroid in the pharmaceutical composition is about 0.75 mg to about 12 mg. In some embodiments, the amount of corticosteroid in the pharmaceutical composition is about 1.5 mg to about 9 mg. In still other embodiments, the amount of corticosteroid is about 0.01 mg, about 0.05 mg, about 0.1 mg, about 0.15 mg, about 0.1 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.35 mg, about 0.4 mg, about 0.45 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.75 mg, about 0.8 mg, about 1 mg, about 1.5 mg, about 2 mg, about 3 mg, about 4 mg, about 4.5 mg, about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 12 mg, about 18 mg, including all values ​​and sub-ranges therebetween.

[0060]

[0069] In a preferred embodiment, in the pharmaceutical compositions (e.g., ODTs) disclosed herein The amount of corticosteroid ranges from about 1.5 mg to about 7.5 mg, including about 3.0 mg, about 4.5 mg, and about 6.0 mg. In a preferred embodiment, the pharmaceutical composition is an ODT and the corticosteroid is present in an amount of about 1.5 mg. In other preferred embodiments, the pharmaceutical composition is an ODT and the corticosteroid is present in an amount of about 3.0 mg. In yet other preferred embodiments, the pharmaceutical composition is an ODT and the corticosteroid is present in an amount of about 4.5 mg. In yet other preferred embodiments, the pharmaceutical composition is an ODT and the corticosteroid is present in an amount of about 6.0 mg. In some other preferred embodiments, the pharmaceutical composition is an ODT and the corticosteroid is present in an amount of about 7.5 mg.

[0061]

[0070] In some embodiments, the rapidly disintegrating composition of the present disclosure swells, dissolves, or disintegrates an orally disintegrating dosage form (e.g., an ODT, a film, a lyophilized matrix, or an oblate). The formulation may include a pharma- ceutically acceptable excipient that disintegrates or otherwise aids in the disintegration of the micronized corticosteroid particles, thereby resulting in a smooth viscous suspension containing micronized corticosteroid particles for coating the inflamed esophageal mucosa to treat eosinophilic esophagitis. Examples of such pharma-ceutically acceptable excipients include disintegrants or fast-dispersing microgranules as described herein. The term "fast-dispersing microgranules" as used herein refers to granules comprising at least one sugar alcohol and / or saccharide particles in combination with at least one disintegrant particle, formed in a granulator. In embodiments, the corticosteroid (e.g., micronized corticosteroid particles) may be granulated with the alcohol and / or saccharide particles. Alternatively, in some embodiments, the corticosteroid (e.g., micronized corticosteroid particles) may be combined with a pharma-ceutically acceptable carrier and then blended with fast-dispersing microgranules comprising at least one sugar alcohol and / or saccharide particles in combination with at least one disintegrant particle.

[0062]

[0071] In certain embodiments of the present disclosure, the total weight of the dosage form is kept in the range of 300-900 mg to contain as much fast-dispersing microgranules as possible, comprising at least one sugar alcohol and / or saccharide in combination with at least one disintegrant, to maximize the coverage of the eosinophilic esophagitis surface with the micronized corticosteroid. In some embodiments, the fast-dispersing microgranules comprise at least one disintegrant in combination with a sugar alcohol and / or saccharide. The amount of sugar alcohol and / or saccharide in the fast-dispersing microgranules is about 99%-90%, or about 95%-90%, or all amounts therebetween, of the total weight of the disintegrant-containing granules. In some embodiments, the average particle size of the sugar alcohol and / or saccharide is less than about 30 μm, e.g., about 1-30 μm, about 5-30 μm, about 5-25 μm, about 5-20 μm, about 5-15 μm, about 5-10 μm, about 10-30 μm, about 10-25 μm, about 10-20 μm, about 10-15 μm, about 15-30 μm, about 15-25 μm, about 15-20 μm, about 20-30 μm, about 20-25 μm, or about 25-30 μm.

[0063]

[0072] In some embodiments, the dosage form has a total weight of 300 mg and contains 0.05 mg (0.16%), about 0.75 mg (0.25% w / w), about 1.5 mg (0.5% w / w), about 3 mg (1% w / w), about 4.5 mg (1.5%), about 6 mg (2% w / w), about 7.5 mg (2.5% w / w), about 9 mg (3% w / w), about 12 mg (4% w / w), or about 16 mg (5%) of corticosteroid.

[0064]

[0073] In some embodiments, the dosage form has a total weight of 600 mg and contains about 0.75 mg (0.125% w / w), about 1.5 mg (0.25% w / w), about 3 mg (0.5% w / w), about 4.5 mg (0.75%), about 6 mg (0.1% w / w), about 7.5 mg (1.25% w / w), about 9 mg (1.5% w / w), about 12 mg (2% w / w), or about 18 mg (3% w / w) of a corticosteroid. In some embodiments, the locally acting corticosteroid is fluticasone propionate and ranges from about 0.05 to about 15 mg in the pharmaceutical composition, with a drug content of 0.16% to 5% by weight of the composition.

[0065]

[0074] In some embodiments, fluticasone propionate ranges from about 0.75 to about 7.5 mg in the composition, with a drug content of about 0.25% to 2.5% by weight of the composition.

[0066]

[0075] In some embodiments, fluticasone propionate ranges from 0.05 to about 18 mg in the composition, with a drug content of about 0.125% to 5% by weight of the composition.

[0067]

[0076] The pharma- ceutically acceptable carriers used in the mixtures of the present disclosure are suitable for combination with the drug (e.g., adsorbing the drug or dissolving or suspending the drug in the pharma- ceutically acceptable carrier), and such carriers should have good carrier properties for dry blending, providing flowability and processability of the blend, as well as preventing separation. Such carriers can cooperate in providing corticosteroid content uniformity. Suitable pharma-ceutically acceptable carriers include, but are not limited to, microcrystalline cellulose, silicified microcrystalline cellulose, pregelatinized starch, corn starch, colloidal silica, or amorphous magnesium aluminum silicate (commercially available as VEEGUM™ or NEUSILIN™). In a preferred embodiment, the pharmaceutical carrier for adsorption of the corticosteroid is silicified microcrystalline cellulose. Such carriers are preferably silicified microcrystalline cellulose (PROSOLV® SMCC:MCC, 98%, and CSD, 2%), which is composed of intimately associated microcrystalline cellulose and colloidal silicon dioxide particles. ). The use of this component in the compositions of the present disclosure improves the flow and blending properties of the corticosteroid mixture and also achieves blend uniformity / homogenity and improved stability of the formulation during storage until final processing into a finished dosage form such as a tablet or capsule, i.e., avoiding or minimizing possible demixing and segregation of the corticosteroid microparticles. The presence of this carrier in admixture with the active ingredient also ensures reproducibility of the preparation of the compositions of the present disclosure, especially with the direct compression techniques applied. In some embodiments, low dose corticosteroid blends with carriers are disclosed that exhibit high blend uniformity, low segregation potential and excellent flow properties. The blends are particularly suitable for the production of fast disintegrating dilute corticosteroid compositions. In some embodiments, the blends of the present disclosure include fluticasone propionate adsorbed onto silicified microcrystalline cellulose and fast dispersing microgranules.

[0068]

[0077] In embodiments, the pharma- ceutically acceptable carrier for adsorption of corticosteroid is micronized. In some embodiments, the diameter of the micronized pharma- ceutically acceptable carrier is less than 20 microns, for example, less than 15 microns, less than 10 microns, less than 9 microns, less than 8 microns, less than 7 microns, less than 6 microns, less than 5 microns, less than 4 microns, less than 3 microns, less than 2 microns, or less than about 1 micron. In some embodiments, the micronized pharma- ceutically acceptable carrier has a diameter of less than 5 microns.

[0069]

[0078] In some embodiments, the pharma- ceutically acceptable carrier is a pharmaceutical composition (e.g., an ODT). In a preferred embodiment, the pharma- ceutical composition (e.g., ODT) is present in a range of about 1% w / w to about 20% w / w, such as about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, including all ranges and subranges therebetween. In a preferred embodiment, the pharma- ceutical composition (e.g., ODT) is present in a range of about 10% w / w.

[0070]

[0079] In some embodiments, the corticosteroid is combined with a pharma- ceutically acceptable carrier to provide a batch of orally disintegrable compositions having a corticosteroid content uniformity within about 85% to about 115% of the labeled corticosteroid dose (e.g., 1.5-7.5 mg, including 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg, and 7.0 mg). In some embodiments, the batch has a corticosteroid content uniformity within about 90% to about 110%, within about 95% to about 105%, or within about 96% to about 104%, or within about 97% to about 103%, or within about 98% to about 102%, or within about 99% to about 101% of the labeled corticosteroid dose.

[0071]

[0080] In some embodiments, the disintegrable composition of the present disclosure (e.g., ODT, The disintegration rate of the wafer, lyophilized matrix, film, etc. may be approximately about 60 seconds or less, about 50 seconds or less, about 40 seconds or less, about 30 seconds or less, about 20 seconds or less, or about 10 seconds or less.

[0072]

[0081] In some embodiments, the U.S.P. <701> Disintegration of the disintegrable compositions of the present disclosure (e.g., ODTs, wafers, lyophilized matrices, films, etc.) measured using the disintegration test The rate of disintegration is about 60 seconds or less, about 45 seconds or less, about 30 seconds or less, about 20 seconds or less, or about 10 seconds or less.

[0073]

[0082] In addition to the corticosteroid and carrier, the blend or oral dosage form of the composition of the present disclosure may further contain pharma- ceutically acceptable ingredients that swell, dissolve, or otherwise aid in disintegration. Such ingredients may include, but are not limited to, disintegrants, sugar alcohols, sugars, or mixtures thereof, water-soluble polymeric binders, in vivo gelling or bioadhesive polymers that may keep the corticosteroid particles adhered on the inflamed esophageal tissue for longer than would be possible without their presence.

[0074]

[0083] In some embodiments, the present disclosure provides a solid pharmaceutical composition comprising a corticosteroid and a pharma- ceutically acceptable in vivo gelling polymer that allows for longer retention of the corticosteroid in inflamed esophageal tissue. Components referred to herein as "in vivo gelling polymers" or "bioadhesives" are agents that promote adhesion of the corticosteroid to biological surfaces, particularly inflamed mucosa, by gelling under physiological conditions of the GI tract, e.g., upon contact with physiological fluids and / or at physiological temperatures, including, but not limited to, the in vivo gelling polymers listed below.

[0075]

[0084] The in vivo gelling polymer may be a thermosensitive polymer. Examples of thermosensitive polymers include polyacrylamides, such as poly(N-isopropylacrylamide), as well as poly(ether-ester) copolymers, such as poly(ethylene glycol-(DL-lactic acid-co-glycolic acid)-ethylene glycol). Such thermosensitive polymers can partially or completely cover the inflamed esophageal tissue while holding the corticosteroid particles in close proximity or intimate contact with the inflamed tissue, thereby increasing the local contact of the corticosteroid with the inflamed tissue.

[0076]

[0085] In some embodiments, the compositions of the present disclosure include a bioadhesive agent, such as a lipid or a polymer. Examples of such lipids are glycerophospholipids, such as phosphatidylcholine, and diacylglycerols, such as glycerol dioleate. Examples of bioadhesive polymers include chitosan, polyorthoesters, and copolymers, terpolymers, and mixtures thereof.

[0077]

[0086] In some embodiments, the solid pharmaceutical composition of the present disclosure comprises an adhesive. Suitable adhesives include sucrose-aluminum sulfate complex, chitosan and derivatives such as trimethylchitosan, polyvinylpyrrolidone, methylcellulose, hydroxypropylcellulose, crosslinked polyacrylic acid copolymers, polyvinylpyrrolidone, vinylpyrrolidone-polyvinyl acetate copolymers (e.g., Kollidon® VA 64 from BASF), Solupl us® (poly(ethylene glycol 6000-vinyl caprolactam-vinyl acetate) (13:57:30) copolymer from BASF), polyvinyl alcohol, polyethylene oxide, polyamides, alginic acid and its salts, carrageenan, xanthan gum, ammonio methacrylate copolymer, CARBOPOL polymer, maltodextrin, pectin, sucralose, and combinations thereof. In certain embodiments of the solid pharmaceutical composition of the present disclosure, the corticosteroid and adhesive are in intimate association. In some embodiments, the solid pharmaceutical composition comprises a corticosteroid surrounded or encapsulated by the adhesive. In some embodiments, the solid pharmaceutical composition comprises a corticosteroid deposited on the surface of the adhesive. In yet other embodiments, the solid pharmaceutical composition comprises a corticosteroid mixed with the adhesive or granulated with the adhesive.

[0078]

[0087] In certain embodiments, a solid pharmaceutical composition includes any solid dosage form that rapidly disintegrates in the mouth to form a suspension of powdered corticosteroid, which is hypothesized to coat or adhere onto the inflamed esophageal mucosa when swallowed.

[0079]

[0088] In some embodiments, the composition of the present disclosure is in the form of an ODT. The ODT comprises a drug in an amount of less than about 5% (weight of drug / weight of composition) and a pharma- ceutically acceptable carrier, and the composition has no significant systemic glucocorticoid or mineralocorticoid activity after oral administration in humans. The drug particles (e.g., the corticosteroid described herein, optionally coated with or optionally combined with an adhesive described herein) are combined with a fast-dispersing microgranule. The fast-dispersing microgranule comprises a sugar alcohol, a sugar, or a mixture thereof, and a disintegrant alone or in combination with a pharma- ceutically acceptable excipient having multifunctional activity (e.g., pregelatinized starch, hydroxypropyl cellulose, etc.).

[0080]

[0089] A non-limiting list of suitable disintegrants for fast dispersing microgranules includes crospovidone (cross-linked PVP), sodium starch glycolate, cross-linked sodium carboxymethylcellulose, Examples of such additives include calcium silicate, low-substituted hydroxypropyl cellulose, and calcium phosphate.

[0081]

[0090] The amount of disintegrant in the ODT is usually in the range of about 1% to about 10% by weight.

[0082]

[0091] Sugar alcohols are hydrogenated forms of carbohydrates in which the carbonyl group (i.e., aldehyde or ketone) has been reduced to a primary or secondary hydroxyl group. Non-limiting examples of sugar alcohols suitable for the fast dispersing granules of the pharmaceutical composition of the present disclosure include, for example, arabitol, isomalt, erythritol, glycerol, lactitol, mannitol, sorbitol, xylitol, maltitol, and mixtures thereof.

[0083]

[0092] The term "saccharide" is synonymous with the term "sugar" and includes, but is not limited to, monosaccharides such as glucose, fructose and ribose, and disaccharides such as sucrose, lactose, maltose, trehalose and cellobiose. Non-limiting examples of saccharides suitable for use in the compositions of the present disclosure include, for example, lactose, sucrose, maltose, and mixtures thereof. In a preferred embodiment, the composition does not contain lactose. In some embodiments, the fast-dispersing granules include at least one disintegrant in combination with a sugar alcohol. In some embodiments, the fast-dispersing microgranules include at least one disintegrant in combination with a sugar. In some embodiments, the disintegrant-containing granules include at least one disintegrant in combination with a sugar alcohol and a sugar.

[0084]

[0093] The amount of sugar alcohol and / or sugar in the fast dispersing granules ranges from about 99% to 90%, or from about 95% to 90%, of the total weight of the disintegrant-containing granules, including all ranges and subranges therebetween.

[0085]

[0094] The amount of sugar alcohol and / or sugar in the ODT ranges from about 30% to about 70% by weight.

[0086]

[0095] In some embodiments, the average particle size of the sugar alcohol and / or saccharide is 30 μm or less, e.g., about 1 to 30 μm, about 5 to 30 μm, about 5 to 25 μm, about 5 to 20 μm, about 5 to 15 μm, about 5 to 10 μm, about 10 to 30 μm, about 10 to 25 μm, about 10 to 20 μm, about 10 to 15 μm, 15 to 30 μm, about 15 to 25 μm, about 15 to 20 μm, about 20 to 30 μm, about 20 to 25 μm, or about 25 to 30 μm.

[0087]

[0096] The ratio of disintegrant to sugar alcohol, saccharide, or mixtures thereof in the fast dispersing microgranules ranges from about 90 / 10 to about 99 / 01, for example, about 90 / 10, about 91 / 9, about 92 / 8, about 93 / 7, about 94 / 6, about 95 / 5, about 96 / 4, about 97 / 3, about 98 / 2, about 99 / 1, including all ranges and subranges therebetween.

[0088]

[0097] The fast dispersing microgranules present in the ODT aid in the rapid disintegration of the tablet when placed in the oral cavity resulting in a smooth suspension containing the corticosteroid drug particles. It is desirable to include a sufficient amount of fast dispersing microgranules to provide extensive coverage of the esophageal mucosa. This creates a content non-uniformity problem with these low dose ODTs (e.g., 300 mg ODTs containing 12 mg or less of corticosteroid). Typically, this problem is overcome by granulation, which involves spraying a dilute solution of the corticosteroid onto a bed of excipient powders. Because the drug particles are embedded within the granules, they may not be exposed to the inflamed mucosa and are therefore less effective. It has surprisingly been observed that by adsorbing micronized locally acting corticosteroid drug particles onto a pharma- ceutically acceptable carrier (e.g., silicified microcrystalline cellulose) prior to blending with fast dispersing microgranules and other excipients and compressing into an ODT, it is possible not only to achieve the desired content uniformity, but also to improve the probability that the corticosteroid drug particles will remain primarily exposed to the inflamed mucosa.

[0089]

[0098] The dosage forms described herein are pharma- ceutically acceptable formulations commonly used in the formulation of disintegrating tablets. Excipients may also be included, such as fillers, diluents, glidants, disintegrants, binders and lubricants.

[0090]

[0099] Examples of suitable fillers, diluents and / or binders include, but are not limited to, lactose (e.g., spray-dried lactose such as FAST-FLO®), microcrystalline cellulose (e.g., various grades of Avicel®, CEOLUS®), hydroxypropyl cellulose, L-hydroxypropyl cellulose (low degree of substitution), low molecular weight hydroxypropyl methylcellulose (HPMC) (e.g., Methocel™ E, F and K from Dow Chemical, Metholose E SH from Shin-Etsu Chemical Co., Ltd.), hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl hydroxyethyl cellulose and other cellulose derivatives, sucrose, agarose, sorbitol, mannitol, dextrin, maltodextrin, starch or modified starch (including potato starch, corn starch and rice starch), calcium phosphate (e.g., basic calcium phosphate, calcium hydrogen phosphate, calcium phosphate hydrate), calcium sulfate, calcium carbonate, sodium alginate and collagen. A preferred filler for the compositions of the present disclosure is mannitol, such as spray-dried mannitol.

[0091]

[0100] Examples of suitable disintegrants include, but are not limited to, crospovidone (cross-linked PVP), sodium starch glycolate, cross-linked sodium carboxymethylcellulose, calcium silicate, and low-substituted hydroxypropyl cellulose. The preferred disintegrant for the compositions of the present disclosure is crospovidone.

[0092]

[0101] Specific examples of glidants and lubricants include stearic acid, stearic acid Magnesium, calcium stearate or other metal stearates, talc, glyceryl behenate, colloidal silica, corn starch, and optionally magnesium stearate or sodium stearyl fumarate (lubricants mixed intragranularly or used externally to lubricate die and punch surfaces). A preferred glidant for the compositions of the present disclosure is colloidal silica, and a preferred lubricant is sodium stearyl fumarate.

[0093]

[0102] In some embodiments, the methods and compositions described herein are directed to a patient suffering from EoE. It can be used to treat patients who also have lactose allergy and / or starch allergy. Pharmaceutical preparations containing lactose may exacerbate lactose allergy in patients who suffer from lactose allergy, which may cause increased discomfort in patients who also suffer from EoE. In certain embodiments, the pharmaceutical compositions described herein do not contain lactose. Similarly, pharmaceutical preparations containing starch may exacerbate starch allergy in patients who suffer from starch allergy, which may cause increased discomfort in patients who also suffer from EoE. In certain embodiments, the pharmaceutical compositions described herein do not contain starch. In a further preferred embodiment, the pharmaceutical compositions described herein do not contain lactose and sucrose.

[0094]

[0103] The solid pharmaceutical compositions of the present disclosure rapidly disintegrate in the mouth to provide a suspension of the corticosteroid. In addition to ODTs, wafers, films or other solid dosage forms that form liquids or dispersions, other dosage forms that can be easily swallowed and coat the mucosal surface of the eosinophilic esophagitis may be included.

[0095]

[0104] For example, oblates contain corticosteroids as active ingredients. dry or freeze-dried compositions, such as those using Zydis® freeze-drying technology (e.g. The solid composition may include oral disintegrating or dissolving dosage forms prepared using edible films containing a corticosteroid as an active ingredient, such as those described in U.S. Patent No. 6,316,027. The film dosage form may include edible films containing a corticosteroid as an active ingredient, such as those described in U.S. Patent No. 6,596,298 or U.S. Patent No. 6,740,332. In some embodiments, the solid composition includes a lyophilized matrix containing a corticosteroid, a carrier, and an excipient. Suitable excipients include, but are not limited to, mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof.

[0096]

[0105] Topical administration of corticosteroids to the oral cavity of an individual has been shown to reduce candidiasis infections and thrush. The present disclosure is designed not to promote such infection, but in some embodiments of the present disclosure, the pharmaceutical composition may include an antifungal agent. Suitable antifungal agents include, but are not limited to, mitotic inhibitor antifungal agents, pyrimidine analogue antifungal agents, polyene antifungal agents, benzimidazole antifungal agents, imidazole antifungal agents, polyene antifungal agents, triazole antifungal agents, thiazole antifungal agents, arylamine antifungal agents, echinocandin antifungal agents, and other "unclassified" antifungal agents recognized in the art that do not fall into any of the above categories (e.g., tolnaftate and ciclopirox). For example, suitable antifungal agents that may be included in the solid pharmaceutical compositions of the present disclosure include, but are not limited to, abafungin, amorolfine, anidulafungin, bifonazole, butenafine, butoconazole, candicin, caspofungin, ciclopirox, clotrimazole, econazole, fenticonazole, filipin, fluconazole, flucytosine, griseofulvin, isavuconazole, isoconazole, itraconazole, ketoconazole, micafungin, miconazole, miconazole nitrate, naftifine, natamycin, nystatin, oxiconazole, posaconazole, paramyconazole, ravuconazole, rimocidin, cetaconizole, sulconazole, terbafine, terconazole, tioconazole, tolnaftate, undecylenic acid, and voriconazole.

[0097]

[0106] In some embodiments, the pharmaceutical compositions of the present disclosure include an antiviral agent. Antiviral agents that can be included in the solid pharmaceutical composition include interferons, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, maturation inhibitors, guanosine analogs, puridine analogs, pyrimidine analogs, and other "generalized" antivirals recognized in the art that do not fall into any of the above classes (e.g., foscarnet and miltefosine). For example, suitable antiviral agents that can be included in the solid pharmaceutical compositions of the present disclosure include abacavir, aciclovir (also known as acyclovir), adefovir, amantadine, amdoxovir, amprenavir, aplaviroc, apricitabine, arbidol, atazanavir, bevirimat, BMS-488043, boceprevir, brivudine, cidofovir, DCM205, docosanol, delavirdine, didanosine, darunavir, efavirenz, erb ... Tegravir, Elvucitabine, Emtricitabine, Enfuvirtide, Epigallocatechin gallate, Etravirine, Famciclovir, Fosamprenavir, Ganciclovir, Globoidonan A, Griffithsin, Ibalizumab, Idoxuridine, Indinavir, Lamivudine, Lopinavir, Loviride, Maraviroc, Nelfinavir, Nevirapine, Oseltamivir, Pegylated interferon alfa-2a, Pegylated interferon alfa-2b, Penciclovir, Peramivir, Plerixafor, PRO 140, rasavir, raltegravir, ritonavir, ribavirin, rimantadine, rilpivirine, saquinavir, stampidine, stavudine, tenofovir, tipranavir, TNX-355, trifluridine, tromantadine, valacyclovir, valganciclovir, vicriviroc, vidarabine, viramidine, bibecon, zalcitabine, zanamivir, and zidovudine. However, it is not limited to these.

[0098]

[0107] Tablet dosage forms, including ODT dosage forms, comprising a locally acting corticosteroid having a low dosage strength (e.g., a corticosteroid having a systemic bioavailability of about 20% or less of the dose, or a corticosteroid that has been formulated to reduce systemic bioavailability, each of which is described above) and a pharma- ceutically acceptable carrier, wherein the drug is present in an amount of less than about 5% (weight of drug / weight of composition) and disintegrates in less than about 30 seconds (USP method) but is easy to handle, transport, and / or press. The ODT dosage forms described herein have a low friability so that they are durable enough to withstand packaging in a blister pack from which the ODT dosage forms are dispensed. In some embodiments, the friability of the ODT dosage forms described herein is less than about 1%, e.g., less than about 0.9%, less than about 0.8%, less than about 0.7%, less than about 0.6%, less than about 0.5%, less than about 0.4%, less than about 0.3%, etc. (including all ranges and subranges therebetween).

[0099]

[0108] In a preferred embodiment, the method described herein is used (or The ODT (for use in the methods described herein) comprises a corticosteroid in an amount of about 0.25% to about 2.5% w / w (or about 0.75 mg to about 7.5 mg), a pharma- ceutically acceptable carrier in an amount of about 5% to about 15% w / w (or about 20 mg to about 40 mg), and a rapidly dispersing microgranule in an amount of about 40% to about 60% w / w (or about 125 mg to about 175 mg), the rapidly dispersing microgranule having a ratio of sugar alcohol / sugar to disintegrant of about 90:10 to about 99:1. In an embodiment, the ODT optionally further comprises a disintegrant in an amount of about 5% to about 10% w / w (or about 5 mg to about 20 mg to about 30 mg), a sugar alcohol or sugar in an amount of about 20% to about 40% w / w (or about 80 mg to about 100 mg), and optional excipients.

[0100]

[0109] Preferred embodiments of the pharmaceutical formulations disclosed herein are those set forth in Table 1 or Table 2. will be done.

[0101] [Table 1]

[0102] [Table 2]

[0103] Gastrointestinal inflammation and methods of treatment

[0110] Treatment with locally acting corticosteroids (e.g., fluticasone propionate) The device produces fewer side effects than other treatments, such as highly systemically active corticosteroids. When the pharmaceutical composition of the present disclosure is administered to a patient, the composition disintegrates in the patient's mouth and contacts the esophagus without being absorbed systemically, thereby limiting systemic effects.

[0104]

[0111] In some embodiments, the present disclosure provides a method for treating symptoms associated with inflammatory disorders of the intestinal tract. In some embodiments, the present disclosure provides a method for treating inflammation associated with an inflammatory digestive disorder. In some embodiments, the present disclosure provides a method for treating both symptoms and inflammation associated with an inflammatory digestive disorder. In some embodiments, the inflammatory digestive disorder affects the upper digestive tract. In some embodiments, the upper digestive tract is the esophagus.

[0105]

[0112] In some embodiments, the oral corticosteroid contacts the upper part of the digestive tract and In some embodiments, the oral corticosteroid contacts and / or deposits in the esophagus. In some embodiments, the oral corticosteroid contacts and / or deposits in the distal portion of the esophagus. In some embodiments, the oral corticosteroid contacts and / or deposits in the distal portion of the esophagus. In some embodiments, the pharmaceutical composition contacts and / or deposits in the proximal portion of the esophagus. In some embodiments, the oral corticosteroid contacts and / or deposits in substantially equal amounts in the distal and proximal portions of the esophagus.

[0106]

[0113] Inflammatory digestive disorders that may be treated according to the present disclosure include inflammation of the esophagus, inflammation of the glottis, Inflammation, Inflammation of the epiglottis, Inflammation of the tonsils, Inflammation of the oropharynx, Eosinophilic Esophagitis (EoE), Gastroesophageal Reflux Examples of gastrointestinal disorders include, but are not limited to, GERD, non-erosive gastroesophageal reflux disease (NERD), erosive esophagitis, Barrett's esophagus, eosinophilic gastroenteritis, hypereosinophilic syndrome, corrosive (corrosive) chemical esophagitis, radiation-induced esophagitis, chemotherapy-induced esophagitis, transient drug-induced esophagitis (also known as drug esophagitis), persistent drug-induced esophagitis, esophageal Crohn's disease, and pseudomembranous esophagitis. In some embodiments, the present disclosure includes a method of treating food allergies where the allergen has been identified, such as "atopic IBS" and "atopic bowel." In some embodiments, the present disclosure provides a method of treating a patient with one or more of the above gastrointestinal disorders, including lactobacillus casei, ... In some embodiments, the inflammatory digestive disorder is eosinophilic esophagitis (EoE). In an embodiment, the disclosure includes a method of treating EoE in a patient who also has a lactose allergy and / or a starch allergy.

[0107]

[0114] In some embodiments, the pharmaceutical compositions disclosed herein are directed to treating gastrointestinal inflammation associated The pharmaceutical compositions disclosed herein are administered until the symptoms and / or inflammation associated with the gastrointestinal inflammation are treated. In some embodiments, the pharmaceutical compositions disclosed herein continue to be administered after the symptoms and / or inflammation associated with the gastrointestinal inflammation are treated. In some embodiments, the symptoms are dysphagia, episodes of food impaction, feeling of a lump in the throat, and / or elevated eosinophil counts in the esophagus.

[0108]

[0115] Treatment of gastrointestinal inflammation may be measured by any means known in the art. For example, tests used to evaluate patients with esophageal inflammation, such as EoE, include, but are not limited to, biopsies, symptom assessments (e.g., patient-reported outcomes (PROs)), and other tests. ) or physician questionnaire), quality of life measures, determination of dysphagia-free days in patients, endoscopy (e.g., EREFS), esophageal compliance and / or esophageal remodeling. Improvement in swallowing (e.g., using a suitable diagnostic test such as EndoFLIP (available from Crospon Inc.)), evaluation of biomarkers, reduction in peak eosinophil count, reduction in food impaction, EEsAI, Dysphagia Questionnaire (DSQ), MDQ-30, EoE-QOL-A, VDQ (Visual Dysphagia Questionnaire), Disability Questionnaire), Aversion, Regulation and Slow Feeding (AMS) scores, and / or organizational diagnosis Includes.

[0109]

[0116] In some embodiments, the patient's response to treatment is evaluated using a tissue diagnostic score (e.g., Dysphagia is determined by measuring changes in one or more questionnaire scores related to biological responses, such as eosinophil counts. Reliance on patient-reported symptoms can produce false-positive results, as patients may change their behavior to reduce the incidents of dysphagia (e.g., avoidance of problem foods, or other behavioral changes, such as increased chewing or liquid intake), which may alter questionnaire scores regardless of whether biological symptoms have improved.

[0110]

[0117] In some embodiments, the patient's response evaluates a tissue diagnostic score for the patient. In some embodiments, the histological score is assessed by one or more different histological features, including, but not limited to, eosinophilic inflammation, basal cell layer thickening, intercellular space widening, lamina propria fibrosis, eosinophilic abscess, surface stratification, surface epithelial changes, and dyskeratinized epithelial cells.

[0111]

[0118] In some embodiments, oral corticosteroids are administered by the methods disclosed herein. Administration of the pharmaceutical compositions disclosed herein reduces the histopathological score for a treated patient compared to an untreated patient or the same patient before treatment. In some embodiments, the histopathological score is measured between 1 week and 10 years for a treated patient. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the histopathological score at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years compared to an untreated patient or the same patient before treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the tissue diagnostic score by about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more compared to an untreated patient or the same patient prior to treatment.

[0112]

[0119] In some embodiments, the tissue diagnostic score is determined from a non-treated patient or the same patient prior to treatment. The tissue diagnostic score for is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to the tissue diagnostic score for In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the histopathological score at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to the histopathological score for an untreated patient or the same patient prior to treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the tissue diagnostic score by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% for about one week, about two months, about three months, about four months, about five months, about six months, about one year, about two years, about five years or about ten years or more, compared to the tissue diagnostic score for an untreated patient or the same patient prior to treatment.

[0113]

[0120] In some embodiments, oral corticosteroids are administered by the methods disclosed herein. Administration of the drug reduces peak eosinophil counts (e.g., per high power field (HPF) as described in Example 2) in at least one biopsy sample for treated patients compared to untreated or treated patients. The peak eosinophils per HPF is reduced compared to the peak eosinophils per HPF for the same patient before the procedure. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the peak eosinophils for at least one biopsy sample to less than 15 / HPF. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the peak eosinophils in at least one biopsy sample for the treated patient to less than about 14 / HPF, less than about 13 / HPF, less than about 12 / HPF, less than about 11 / HPF, less than about 10 / HPF, less than about 9 / HPF, less than about 8 / HPF, less than about 7 / HPF, less than about 6 / HPF, less than about 5 / HPF, less than about 4 / HPF, less than about 3 / HPF, less than about 2 / HPF, less than about 1 / HPF, or less (e.g., 0) in at least one biopsy sample for the treated patient. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the peak eosinophils in at least one biopsy sample to less than 1 HPF for the patient. In some embodiments, the peak eosinophil reduction in at least one biopsy sample for a treated patient is measured between about week 1 and about year 10. In some embodiments, the peak eosinophil reduction is measured at about week 1, about week 2, about week 3, about week 4, about week 5, about week 6, about week 7, about week 8, about week 9, about week 10, about week 20, about week 30, about week 40, about week 50, about week 60, about week 70, about week 80, about week 90, about week 100, about week 1, about year 2, or about year 3. In some embodiments, administration of a pharmaceutical composition disclosed herein results in at least one of about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years in a patient. Peak eosinophils in the biopsy sample are reduced to less than about 14 / HPF, less than about 13 / HPF, less than about 12 / HPF, less than about 11 / HPF, less than about 10 / HPF, less than about 9 / HPF, less than about 8 / HPF, less than about 7 / HPF, less than about 6 / HPF, less than about 5 / HPF, less than about 4 / HPF, less than about 3 / HPF, less than about 2 / HPF, less than about 1 / HPF, or less (e.g., 0).In some embodiments, administration of a pharmaceutical composition disclosed herein reduces peak eosinophils in at least one biopsy sample to less than about 14 / HPF, less than about 13 / HPF, less than about 12 / HPF, less than about 11 / HPF, less than about 10 / HPF, less than about 9 / HPF, less than about 8 / HPF, less than about 7 / HPF, less than about 6 / HPF, less than about 5 / HPF, less than about 4 / HPF, less than about 3 / HPF, less than about 2 / HPF, less than about 1 / HPF, or less than (e.g., 0) for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more in a patient.

[0114]

[0121] In some embodiments, oral corticosteroids are administered by the methods disclosed herein. Administration of the drug reduces peak eosinophil counts (e.g., per high power field (HPF) as described in Example 2) in at least one biopsy sample for treated patients compared to untreated or treated patients. The eosinophil count is reduced by at least about 10%, e.g., about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% or about 99%, including all values ​​and subranges therebetween, as compared to the peak eosinophils per HPF for the same patient prior to implantation. In some embodiments, the peak eosinophil count is reduced by about 50% to about 99%, e.g., about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, including all values ​​and subranges therebetween.

[0115]

[0122] In some embodiments, administration of the pharmaceutical compositions disclosed herein includes administering at week 12, In some embodiments, administration of a pharmaceutical composition disclosed herein reduces peak eosinophils in at least one biopsy sample from a treated patient at week 26 or week 52 to less than about 6 / HPF. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces peak eosinophils in at least one biopsy sample from a treated patient at week 12, week 26 or week 52 to less than about 6 / HPF. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces peak eosinophils in all tested biopsy samples from a treated patient at week 12, week 26 or week 52. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces peak eosinophils in all tested biopsy samples from a treated patient at week 12, week 26 or week 52 to less than about 6 / HPF.

[0116]

[0123] In some embodiments, administration of the pharmaceutical compositions disclosed herein is to a patient or Reduce the average score on a patient questionnaire completed by a physician. In some embodiments, the questionnaire is the Eosinophilic Esophagitis Activity Index (EEsAI), which can monitor the severity and frequency of dysphagia and any dietary changes using either a 7-day recall period or a daily recall period. In some embodiments, the questionnaire can monitor the incidence of dysphagia and any dietary changes using either a 7-day recall period or a daily recall period. The Dysphagia Symptoms Questionnaire (DSQ) is a daily symptom diary used to monitor the frequency of symptoms. In some embodiments, the questionnaire is a customer-reported questionnaire that includes a rating of dysphagia-free days. In some embodiments, the total score of a questionnaire, such as the EEsAI or PROSE, is used in combination with other patient assessments to measure the patient's response to treatment. In some embodiments, a correlation between the questionnaire score and improvement in histological measurements (e.g., eosinophil count) indicates the patient's response to treatment.

[0117]

[0124] In some embodiments, the mean questionnaire scores are calculated for treated patients from week 1 to year 10. The mean questionnaire score is measured between the first and second days of treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the mean questionnaire score at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years, compared to the mean questionnaire score in untreated patients or patients before treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the mean questionnaire score for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more, compared to the mean questionnaire score for untreated patients or the same patients before treatment. In some embodiments, the mean questionnaire score is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, compared to the mean questionnaire score in untreated or pre-treated patients. In some embodiments, the mean questionnaire score is reduced by about 1%, about 5%, about 10%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, compared to the mean questionnaire score in untreated or pre-treated patients. The mean questionnaire score at week 0, about week 80, about week 90, about week 100, about 1 year, about 2 years or about 3 years is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to the mean questionnaire score in untreated or pre-treatment patients. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the mean questionnaire score by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to the mean questionnaire score in untreated or pre-treated patients for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years or about 10 years or more.

[0118]

[0125] In some embodiments, the patient questionnaire is an EEsAI. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the mean EEsAI score to less than about 20. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the mean EEsAI score in treated patients to less than about 19, less than 18, less than about 17, less than about 16, less than about 15, less than about 14, less than about 13, less than about 12, less than about 11, less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1, or less than about 0. In some embodiments, the mean EEsAI score in treated patients is measured between week 1 and year 10. In some embodiments, the reduction in mean EEsAI score is measured at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the mean EEsAI score at about 1 week, about 2 week, about 3 week, about 4 week, about 5 week, about 6 week, about 7 week, about 8 week, about 9 week, about 10 week, about 20 week, about 30 week, about 40 week, about 50 week, about 60 week, about 70 week, about 80 week, about 90 week, about 100 week, about 1 year, about 2 years, or about 3 years to less than about 19, less than 18, less than about 17, less than about 16, less than about 15, less than about 14, less than about 13, less than about 12, less than about 11, less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1 or less (e.g., 0) in treated patients. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the mean EEsAI score in treated patients to less than about 19, less than 18, less than about 17, less than about 16, less than about 15, less than about 14, less than about 13, less than about 12, less than about 11, less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1 or less (e.g., 0) at about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more.

[0119]

[0126] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the mean EEsAI score at week 12, week 26, or week 52 in treated patients to less than about 20.

[0120]

[0127] In some embodiments, administration of the pharmaceutical compositions disclosed herein is performed using the methods described in Table 3. In some embodiments, the mean EoE Endoscopic Criteria Score (EREFS) for treated patients is reduced, which measures edema (e.g., hypovascularity or parrot), esophageal rings present, exudates (e.g., white spots), grooves and / or structures in the esophagus. The score correlates with histological response (eg, eosinophil count), and the EREFS score can be used in conjunction with the histological response to measure a patient's response to treatment.

[0121] [Table 3]

[0122]

[0128] In some embodiments, the compositions and methods disclosed herein are directed to treating edema. In some embodiments, the compositions and methods disclosed herein reduce the EREFS score for the ring to 2, 1, or 0. In some embodiments, the compositions and methods disclosed herein reduce the EREFS score for the exudate to 1 or 0. In some embodiments, the compositions and methods disclosed herein reduce the EREFS score for the exudate to 1 or 0. In some embodiments, the compositions and methods disclosed herein reduce the EREFS score for the groove to 1 or 0. In some embodiments, the compositions and methods disclosed herein substantially eliminate the stenosis.

[0123]

[0129] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic In some embodiments, the mean EREFS score in treated patients is measured between week 1 and year 10. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the EREFS score at about week 1, about week 2, about week 3, about week 4, about week 5, about week 6, about week 7, about week 8, about week 9, about week 10, about week 20, about week 30, about week 40, about week 50, about week 60, about week 70, about week 80, about week 90, about week 100, about week 1, about year 2, or about year 3. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the EREFS score in treated patients for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the EREFS score at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years to less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1, or less than about 0 in a treated patient. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the EREFS score in treated patients to less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1, or less than about 0 for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more.

[0124]

[0130] In some embodiments, administration of the pharmaceutical compositions disclosed herein is at about week 12. , reducing the mean EREFS score for treated patients at about week 26 or about week 52.

[0125]

[0131] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic In some embodiments, the treatment reduces episodes of dysphagia in treated patients. The reduction in episodes of dysphagia is measured by determining the number of days free of dysphagia in the patient. In some embodiments, the improvement in the number of days free of dysphagia in the patient is measured along with other patient measurements, such as improvement in histological scores (e.g., eosinophil count) to measure the patient's response to treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces dysphagia for the treated patient compared to dysphagia episodes for untreated subjects or for the same patient prior to treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces dysphagia episodes to less than about 6 episodes per week. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces dysphagia episodes to less than 6 episodes per week for a period of 2 weeks. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces dysphagia episodes to less than about 6 episodes per week, about 5 episodes per week, about 4 episodes per week, about 3 episodes per week, about 2 episodes per week, about 1 episode per week, or zero episodes per week. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces dysphagia episodes to less than about 6 episodes per week, about 5 per week, about 4 per week, about 3 per week, about 2 per week, about 1 per week, or zero per week over a two week period.

[0126]

[0132] In some embodiments, episodes of dysphagia are reduced by up to about 100%. In some embodiments, dysphagia episodes are reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100% compared to dysphagia episodes for untreated or pre-treated patients. In some embodiments, dysphagia is eliminated. In some embodiments, dysphagia is assessed between 1 week and 10 years for treated patients. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces episodes of dysphagia at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces dysphagia at about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more, as compared to the number of dysphagia episodes in an untreated patient or the same patient prior to treatment. In some embodiments, the incidence of dysphagia episodes at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, compared to dysphagia episodes in an untreated patient or the same patient prior to treatment. In some embodiments, the number of dysphagia episodes is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to the number of dysphagia episodes in an untreated patient or the same patient prior to treatment for about one week, about two months, about three months, about four months, about five months, about six months, about one year, about two years, about five years or about ten years or more.

[0127]

[0133] In some embodiments, administration of the pharmaceutical compositions disclosed herein includes administering at week 12, Dysphagia episodes for treated patients at weeks 26 or 52 are reduced compared to untreated patients or to the same patients prior to treatment.

[0128]

[0134] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic In some embodiments, administration of a pharmaceutical composition disclosed herein reduces food impaction episodes to less than 4 episodes per week. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces food impaction episodes to less than 4 episodes per week. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces food impaction episodes to less than 4 episodes per week. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces episodes of food impaction to less than about 4 episodes per week, about 3 episodes per week, about 2 episodes per week, about 1 episode per week, or no episodes per week for a period of 2 weeks. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces episodes of food impaction to less than about 4 episodes per week, about 3 episodes per week, about 2 episodes per week, about 1 episode per week, or no episodes per week for a period of 2 weeks.

[0129]

[0135] In some embodiments, episodes of food impaction are reduced by up to about 100%. In some embodiments, episodes of food impaction are reduced by up to about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to episodes of food impaction in untreated patients or the same patients prior to treatment. In some embodiments, episodes of food impaction are assessed between week 1 and year 10 for treated patients. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces episodes of food impaction at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces episodes of food impaction at about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years, or about 10 years or more, compared to the number of episodes of food impaction in an untreated patient or the same patient prior to treatment. In some embodiments, episodes of food impaction at about 1 week, about 2 week, about 3 week, about 4 week, about 5 week, about 6 week, about 7 week, about 8 week, about 9 week, about 10 week, about 20 week, about 30 week, about 40 week, about 50 week, about 60 week, about 70 week, about 80 week, about 90 week, about 100 week, about 1 year, about 2 years or about 3 years are reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to episodes of food impaction in an untreated patient or the same patient prior to treatment. In some embodiments, episodes of food impaction are reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to the number of episodes of food impaction in an untreated patient or the same patient prior to treatment for about one week, about two months, about three months, about four months, about five months, about six months, about one year, about two years, about five years or about ten years or more.

[0130]

[0136] In some embodiments, administration of the pharmaceutical compositions disclosed herein includes administering at week 12, Episodes of food impaction for treated patients at Week 26 or Week 52 are reduced compared to untreated patients or food impaction for the same patients prior to treatment.

[0131]

[0137] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic The global EoE score for the treated patient is reduced compared to the global EoE score for an untreated patient or for the same patient prior to treatment.

[0132]

[0138] In some embodiments, the reduction in the global EoE score for treated patients is measured within about 1 week. The EoE score is measured between about week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 20, week 30, week 40, week 50, week 60, week 70, week 80, week 90, week 100, week 1, year 2, year 3, or year 4, as compared to an untreated patient or the same patient before treatment. In some embodiments, the administration of a pharmaceutical composition disclosed herein reduces the global EoE score at about week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week 20, week 30, week 40, week 50, week 60, week 70, week 80, week 90, week 100, week 1, year 2, year 3, or year 4, as compared to an untreated patient or the same patient before treatment. In some embodiments, the administration of a pharmaceutical composition disclosed herein reduces the global EoE score at about week 1, week 2, month 3, month 4, month 5, month 6, month 1, year 2, year 5, year 10, or year 4, as compared to an untreated patient or the same patient before treatment. In some embodiments, the global EoE score is reduced by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% compared to an untreated patient or the same patient before treatment began.

[0133]

[0139] In some embodiments, administration of the pharmaceutical compositions disclosed herein is to a non-treated patient. or reduces the global EoE score at about 1 week, about 2 week, about 3 week, about 4 week, about 5 week, about 6 week, about 7 week, about 8 week, about 9 week, about 10 week, about 20 week, about 30 week, about 40 week, about 50 week, about 60 week, about 70 week, about 80 week, about 90 week, about 100 week, about 1 year, about 2 years, or about 3 years by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100%, compared to the patient's global EoE score before treatment began. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the global EoE score by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100% for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years or about 10 years or more compared to the global EoE score of an untreated patient or the same patient before treatment began.

[0134]

[0140] Global EoE is scored on a scale of 0 to 10, with 0 being no EoE symptoms. with 10 indicating the most severe EoE symptoms. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the global EoE score for a treated patient to less than about 5. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the global EoE score to less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1, or less than about 0. In some embodiments, administration of a pharmaceutical composition disclosed herein reduces the global EoE score for treated patients at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years to less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1, or less than about 0. In some embodiments, administration of the pharmaceutical compositions disclosed herein reduces the global EoE score for the treated patient to less than about 10, less than about 9, less than about 8, less than about 7, less than about 6, less than about 5, less than about 4, less than about 3, less than about 2, less than about 1 or less than about 0 for about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years or about 10 years or more.

[0135]

[0141] In some embodiments, administration of the pharmaceutical compositions disclosed herein is at about week 12. , the global EoE score for the treated patient at about week 26 or about week 52 is reduced compared to the global EoE score for an untreated patient or the same patient prior to treatment.

[0136]

[0142] In some embodiments, administration of the pharmaceutical compositions disclosed herein provides a therapeutic In patients with esophageal reflux, characteristics as measured by endoscopy (e.g., EndoFlip) are improved compared to untreated patients or the same patients before treatment began. These characteristics include esophageal diameter, esophageal compliance, focal narrowing of the esophagus, distensibility of the esophageal body, esophageal body cross-sectional area (CSA), and These include, but are not limited to, the diameter and lumen diameter.

[0137]

[0143] In some embodiments, the characteristic measured by endoscopy is In some embodiments, administration of the pharmaceutical compositions disclosed herein is evaluated at about week 1, about week 2, about week 3, about week 4, about week 5, about week 6, about week 7, about week 8, about week 9, about week 10, about week 20, about week 30, about week 40, about week 50, about week 60, about week 70, about week 80, about week 90, about week 100, about week 1, about week 2 ...100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, about week 100, In some embodiments, administration of a pharmaceutical composition disclosed herein improves the characteristic measured by endoscopy for about one week, about two months, about three months, about four months, about five months, about six months, about one year, about two years, about five years, or about ten years or more, compared to an untreated patient or the same patient before treatment. In some embodiments, the characteristic measured by endoscopy improves by about 100%. In some embodiments, the characteristic measured by endoscopy improves by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, compared to an untreated patient or the same patient before treatment. In some embodiments, administration of a pharmaceutical composition disclosed herein improves a characteristic as measured by endoscopy at about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%, compared to an untreated patient or the same patient prior to treatment. In some embodiments, administration of the pharmaceutical compositions disclosed herein improves a characteristic measured by endoscopy by about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or about 100%, about 1 week, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 1 year, about 2 years, about 5 years or about 10 years or more, compared to an untreated patient or the EndoFlip score in the same patient prior to treatment.

[0138]

[0144] In some embodiments, administration of the pharmaceutical compositions disclosed herein includes administering at week 12, At 26 or 52 weeks, characteristics measured by endoscopy are improved in treated patients compared to untreated patients or the same patients prior to treatment.

[0139]

[0145] In some embodiments, administration of the disclosed pharmaceutical compositions provides a therapeutic effect against a patient over a period of time. The number of EoE-related episodes experienced by the patient is reduced. Non-limiting examples of such episodes include difficulty in swallowing pills or food. The occurrence of such episodes may be reported by the patient as discomfort after swallowing pills or food, and may be measured after each swallowing of pills or food, or may be measured over 24 hours or more. Any method, including PROSE, may be used to assess or report the patient's discomfort.

[0140]

[0146] In some embodiments, the number of episodes occurring over said period is at least Also 1 episode, at least 2 episodes, at least 3 episodes, at least 4 episodes, at least 5 episodes, at least 6 episodes, at least 7 episodes, at least 8 episodes, at least 9 episodes, at least 10 episodes, at least 11 episodes, at least 12 episodes, at least 13 episodes, at least 14 episodes, at least 15 episodes, at least 16 episodes, at least 17 episodes, at least 18 episodes, at least 19 episodes, at least 20 episodes, at least 21 episodes, at least 22 episodes, at least 23 episodes, at least 24 episodes, at least 25 episodes, at least 26 episodes, at least 27 episodes, at least 28 episodes, at least 29 episodes, at least 30 episodes, at least 31 episodes, at least 32 episodes, at least 33 episodes, at least 34 episodes, at least 35 episodes, at least 36 episodes, at least 37 episodes, at least 38 episodes, at least 39 episodes, at least 40 episodes, at least 41 episodes, at least 42 episodes, at least 43 episodes, at least 44 episodes, The reduction is at least 45 episodes, at least 46 episodes, at least 47 episodes, at least 48 episodes, at least 49 episodes, or at least 50 episodes. In some embodiments, the period is about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 9 weeks, about 10 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 60 weeks, about 70 weeks, about 80 weeks, about 90 weeks, about 100 weeks, about 1 year, about 2 years, or about 3 years.

[0141] Dosage and Administration

[0147] The oral corticosteroids disclosed herein can be administered in any suitable dose, and and any suitable pharmaceutical composition can be used for administration. Although one of skill in the art can determine the desired dosage in each case, a suitable dosage for achieving therapeutic benefit of the therapeutic agent can be, for example, in the range of about 1 microgram (μg) to about 100 milligrams (mg) per kilogram of recipient body weight per day, preferably in the range of about 10 μg to about 50 mg per kilogram of body weight per day, and most preferably in the range of about 10 μg to about 50 mg per kilogram of body weight per day. In some embodiments, the pharmaceutical composition is administered at a low dose, for example, about 20 mg or less. In some embodiments, the oral corticosteroid is administered at about 1 mg per kilogram of body weight per day, about 3 mg per kilogram of body weight per day, and / or about 9 mg per kilogram of body weight per day. The desired dosage can be provided as a single dose or as two or more divided doses administered at appropriate intervals during the day. These subdoses can be administered in unit dosage forms, for example, containing about 10 μg to about 1000 mg, preferably about 0.05 mg to about 20 mg, and most preferably about 0.5 mg to about 7.5 mg. In some embodiments, the pharmaceutical composition is administered in a unit dosage form of 0.75 mg, 1.5 mg, 3.0 mg, 4.5 mg, 6.0 mg, or 7.5 mg.

[0142]

[0148] In some embodiments, the pharmaceutical compositions described herein (e.g., oral corticosteroids) are In some embodiments, the pharmaceutical composition is administered to the patient twice a day (BID). In some embodiments, the pharmaceutical composition is administered to the patient once in the morning and once in the evening. In some embodiments, the pharmaceutical composition is administered on an empty stomach (e.g., at least 2 hours after a meal or at least 1 hour before a meal, or at least 30 minutes before or after a meal). In some embodiments, the pharmaceutical composition is administered to the patient 30 minutes before breakfast and 30 minutes before bedtime. In some embodiments, administration of the pharmaceutical composition before bedtime reduces systemic absorption of the oral corticosteroid compared to systemic absorption observed after daytime dosing.

[0143]

[0149] Thus, in some embodiments, the pharmaceutical composition is administered between about 7 pm and about 10 pm. For example, at about 7 pm, 7:30 pm, about 8 pm, about 8:30 pm, about 9 pm, or about 9:30 pm, including all values ​​and subranges therebetween, during the night. In some embodiments, the pharmaceutical composition is administered about 30 minutes before the target bedtime. The term "target bedtime" can refer to the time that the patient expects to go to bed.

[0144]

[0150] Conventional oral administration of oral corticosteroids (i.e., while the patient is upright) A preliminary investigation of the therapeutic efficacy of EoE treatment following oral corticosteroids (i.e., in a bed rest position) revealed higher eosinophil clearance in the proximal portion of the esophagus (e.g., the portion closer to the oral cavity) and lower eosinophil clearance in the distal portion of the esophagus (e.g., the portion closer to the stomach). Without being bound by theory, these results suggested increased contact of corticosteroids with the proximal esophageal tissue and decreased contact of corticosteroids with the distal esophageal tissue. Various experiments were performed in an attempt to improve the contact of corticosteroids with the distal esophagus. It was surprisingly discovered that administration of oral corticosteroids while the patient was bed resting increased eosinophil clearance in the distal esophagus while maintaining high eosinophil clearance in the proximal esophagus. Without being bound by theory, When corticosteroids are administered while the patient is recumbent, esophageal passage of the drug is driven primarily by peristalsis, thereby increasing contact of the corticosteroid with the distal esophagus, whereas by assuming an upright position, drug passage is driven primarily by gravity and there is a continuous flow of fluid down the esophagus, thereby decreasing contact of oral corticosteroid with the distal esophagus.

[0145]

[0151] Contact of the corticosteroid with the esophagus was determined by scintigraphy as described in Example 6. The contact of the corticosteroid with the esophagus can be directly observed by performing a eosinophil clearance study. Alternatively, the contact of the corticosteroid with the esophagus can be indirectly determined by measuring eosinophil clearance in the proximal and distal parts of the esophagus. For example, eosinophil clearance can be measured by measuring the number of eosinophils (cells / mm high power field) in the proximal and distal esophagus before treatment as described in Example 2. 2 ) to establish a baseline and comparing said baseline to the eosinophil counts in the proximal and distal esophagus measured after 8 weeks of treatment.

[0146]

[0152] Thus, in certain embodiments, oral corticosteroids are administered once daily at night. In certain other embodiments, the oral corticosteroid is administered twice daily, with the patient lying down (or the patient lying down immediately after oral administration) during the first daily dose. In certain other embodiments, the oral corticosteroid is administered twice daily, with the patient remaining upright during the first daily dose, but the patient lying down (or the patient lying down immediately after oral administration) for the second daily dose. In further embodiments, the patient is lying down for both daily doses.

[0147]

[0153] In certain embodiments, the pharmaceutical composition is administered while the patient is bedridden or It may be administered immediately prior to the patient lying down, for example, within about 1 second, about 2 seconds, about 3 seconds, about 4 seconds, about 5 seconds, about 6 seconds, about 7 seconds, about 8 seconds, about 9 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, about 60 seconds, about 1.1 minutes, about 1.2 minutes, about 1.3 minutes, about 1.4 minutes, about 1.5 minutes, about 1.6 minutes, about 1.7 minutes, about 1.8 minutes, about 1.9 minutes, about 2 minutes, about 2.5 minutes, about 3 minutes, about 4 minutes, or about 5 minutes before the patient lying down, including all values ​​and ranges therebetween.

[0148]

[0154] In various embodiments, the pharmaceutical composition is administered to the HS while the patient is bedridden. In other embodiments, the pharmaceutical composition is administered (e.g., BID or QD) during the day while the patient is recumbent (or the patient lies down immediately after administration). In various embodiments, the patient remains recumbent after administration for an amount of time sufficient to allow local deposition and / or contact of the corticosteroid with the esophagus to treat esophageal inflammation (e.g., a time sufficient to result in improvement of EoE, e.g., reduction in episodes of dysphagia, using the measurements described herein). In some such embodiments, the patient is administered 5 min, 10 min, 15 min, 20 min, 25 min, 30 min, 35 min, 40 min, 45 min, 50 min, 55 min, 1 hr, 1.1 hr, 1.2 hr, 1.3 hr, 1.4 hr, 1.5 hr, 1.6 hr, 1.7 hr, 1.8 hr, 1.9 hr, 2 hr, 2.1 hr, 2.2 hr, 2.3 hr, 2.4 hr, 2.5 hr, 2.6 hr, 2.7 hr, 2.8 hr, 2.9 hr, 3 hr, 3.1 hr, 3.2 hr, 3.3 hr, 3.4 hr, 3.5 hr, 3.6 hr, 3.7 hr, 3.8 hr, 3.9 hr, 3.8 hr, 3.9 hr, 3.9 hr, 3.1 hr, 3.2 hr, 3.3 hr, 3.4 hr, 3.5 hr, 3.6 hr, 3.7 hr, 3.8 ... about 4 hours, about 4.1 hours, about 4.2 hours, about 4.3 hours, about 4.4 hours, about 4.5 hours, about 4.6 hours, about 4.7 hours, about 4.8 hours, about 4.9 hours, about 5 hours, about 5.1 hours, about 5.2 hours, about 5.3 hours, about 5.4 hours, about 5.5 hours, about 5.6 hours, about 5.7 hours, about 5.8 hours, about 5.9 hours, about 6 hours, about 6.1 hours, about 6.2 hours, about 6.3 hours, about 6.4 hours, about 6.5 hours, about 6.6 hours, about 6.7 hours, about 6.8 hours, about 6.9 hours, about 7 hours, about 7.1 hours, about 7.2 hours, about 7.3 hours, about 7.4 hours, about 7.5 hours, about 7.6 hours, about 7.7 hours, about 7.8 hours, about 7.9 hours, and all times in between. The patient remains recumbent for a time ranging from about 1 minute to about 8 hours, including all values ​​and subranges therebetween. In embodiments where the pharmaceutical composition is administered during the day, the patient remains recumbent for a time ranging from about 1 minute to about 60 minutes, including about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, including all values ​​and subranges therebetween. In certain embodiments, the patient remains recumbent for about 5 to about 10 minutes.

[0149]

[0155] As used herein, the terms "lying down" and "lying down" and their variants include The native term and variants refer to a patient lying supine, prone or on their side, e.g., on a bed or on the ground, i.e., in a substantially horizontal position, whereby the corticosteroid contacts the esophagus (when swallowed) and is deposited locally in the esophagus, e.g., in an inflamed portion of the esophagus. As used herein, "substantially horizontal" refers to a position that is at least 10° below vertical, e.g., less than about 15°, less than about 20°, less than about 25°, less than about 30°, less than about 35°, less than about 40°, less than about 45°, less than about 50°, less than about 55°, less than about 65°, less than about 70°, less than about 75°, less than about 80°, less than about 85°, or less than about 90° from vertical, including all values ​​and ranges therebetween. For example, when the composition is formulated as an ODT, the ODT disintegrates rapidly in the mouth of a supine patient to form a suspension containing a corticosteroid, which is swallowed.The suspension then passes through the patient's esophagus, thereby providing localized contact of the corticosteroid to the esophagus to locally treat esophageal inflammation.As used herein, "upright" refers to a patient in essentially any other position, including, but not limited to, standing or sitting.

[0150]

[0156] In some embodiments, the pharmaceutical composition is administered to the patient before bedtime. In some embodiments, the pharmaceutical composition is administered to a patient when the patient is lying down before going to bed. In some embodiments, the pharmaceutical composition is administered to a patient when the patient is lying down and before going to sleep (e.g., about 1 minute to about 1 hour before falling asleep, e.g., about 1 minute, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, including all values ​​therein). In a preferred embodiment, the pharmaceutical composition is administered to a patient lying down about 30 minutes before going to bed. In some embodiments, the pharmaceutical composition is administered to the patient after dinner, e.g., about 1 minute to about 5 hours after dinner (e.g., about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, including all values ​​and subranges therebetween). In a preferred embodiment, the pharmaceutical composition is administered at least about 30 minutes after dinner.

[0151]

[0157] In some embodiments, the patient is provided with a corticosteroid-containing medication while in bed. Administration of the pharmaceutical composition increases contact of the corticosteroid with the upper gastrointestinal tract (e.g., esophagus) while also decreasing systemic absorption of the corticosteroid. Thus, in embodiments, administration of the pharmaceutical composition while the patient is reclining improves the efficacy and (in further embodiments) reduces the side effects associated with systemic administration of corticosteroids.

[0152]

[0158] The esophageal transit time of a liquid pharmaceutical composition is generally in the range of about 1 to about 5 seconds. Without being limited by any limitation, administration of the pharmaceutical compositions described herein while a patient is bedridden increases the residence time (also referred to as dwell time) of the corticosteroid in the esophagus, thereby increasing the time required for the corticosteroid to reach the stomach and decreasing the amount of corticosteroid that reaches the stomach and is absorbed systemically. In some embodiments, increasing the residence time of the corticosteroid in the esophagus increases contact of the corticosteroid with the esophagus. In some embodiments, the residence time of the corticosteroid in the esophagus and / or contact of the corticosteroid with the esophagus is increased in a bedridden patient when the patient is immediately This increases the retention time of the corticosteroid compared to when administered in a similar composition while in an upright position.

[0153]

[0159] In some embodiments, the corticosteroid after administration while the patient is bedridden. The retention time in the esophagus is within a range of about 1 second to about 5 minutes, for example, about 2 seconds, about 3 seconds, about 4 seconds, about 5 seconds, about 6 seconds, about 7 seconds, about 8 seconds, about 9 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, about 60 seconds, about 65 seconds, about 70 seconds, about 75 seconds, about 80 seconds, about 85 seconds, about 90 seconds, about 95 seconds, about 100 seconds, about 105 seconds, about 110 seconds, about 115 seconds, about 120 seconds, about 125 seconds, about 130 seconds, about 135 seconds, about 140 seconds, about 145 seconds, about 150 seconds, about 160 seconds, about 170 seconds, about 180 seconds, about 190 seconds, about 200 seconds, about 210 seconds, about 220 seconds, about 230 seconds, about 240 seconds, about 250 seconds, about 260 seconds, about 270 seconds, about 280 seconds, about 290 seconds, about 300 seconds, about 310 seconds, about 320 seconds, about 330 seconds, about 340 seconds, about 350 seconds, about 360 seconds, about 370 seconds, about 380 seconds, about 390 seconds, about 400 seconds, about 410 seconds, about 420 seconds, about 430 seconds, about 440 seconds, about 450 seconds, about 460 seconds, about 470 seconds, about 480 seconds, about 490 seconds, about 500 seconds, about 500 seconds, about 510 seconds, The time period may be about 50 seconds, about 155 seconds, about 160 seconds, about 165 seconds, about 170 seconds, about 175 seconds, about 180 seconds, about 185 seconds, about 190 seconds, about 195 seconds, about 200 seconds, about 205 seconds, about 210 seconds, about 215 seconds, about 220 seconds, about 225 seconds, about 230 seconds, about 235 seconds, about 240 seconds, about 245 seconds, about 250 seconds, about 255 seconds, about 260 seconds, about 265 seconds, about 270 seconds, about 275 seconds, about 280 seconds, about 285 seconds, about 290 seconds, or about 295 seconds, including all values ​​and subranges therebetween. In certain embodiments, the esophageal transit time of the corticosteroid after administration when the patient is recumbent is in the range of about 5 seconds to about 60 seconds.

[0154]

[0160] In some embodiments, administration of the pharmaceutical composition while the patient is bedridden comprises administering The retention time of corticosteroids in the esophagus (compared to the retention time of corticosteroids in the esophagus when the patient is upright) was about 5 seconds, about 10 seconds, about 15 seconds, about 20 seconds, about 25 seconds, about 30 seconds, about 35 seconds, about 40 seconds, about 45 seconds, about 50 seconds, about 55 seconds, about 60 seconds, about 65 seconds, about 70 seconds, about 75 seconds, about 80 seconds, about 85 seconds, about 90 seconds, about 95 seconds, about 100 seconds, about 105 seconds, about 110 seconds, about 115 seconds, about 120 seconds, about 125 seconds, about 130 seconds, about 135 seconds, about 140 seconds, about 145 seconds, about 146 seconds, about 147 seconds, about 148 seconds, about 149 seconds, about 150 seconds, about 151 seconds, about 152 seconds, about 153 seconds, about 154 seconds, about 155 seconds, about 156 seconds, about 157 seconds, about 158 ​​seconds, about 159 seconds, about 160 seconds, about 161 seconds, about 162 seconds, about 163 seconds, about 164 seconds, about 165 seconds, about 166 seconds, about 167 seconds, about 168 seconds, about 169 seconds, about 170 seconds, about 171 seconds, about 172 seconds, about 173 seconds, about 174 seconds, about 175 seconds, about 176 seconds, about 177 seconds, about 178 seconds, about 179 seconds, about 180 seconds, about 182 seconds, about 183 seconds, about 184 seconds, about 185 seconds, about 186 seconds, about 187 0 seconds, about 145 seconds, about 150 seconds, about 155 seconds, about 160 seconds, about 165 seconds, about 170 seconds, about 175 seconds, about 180 seconds, about 185 seconds, about 190 seconds, about 195 seconds, about 200 seconds, about 205 seconds, about 210 seconds, about 215 seconds, about 220 seconds, about 225 seconds, about 230 seconds, about 235 seconds, about 240 seconds, about 245 seconds, about 250 seconds, about 255 seconds, about 260 seconds, about 265 seconds, about 270 seconds, about 275 seconds, about 280 seconds, about 285 seconds, about 290 seconds, about 295 seconds, or about 300 seconds. In certain embodiments, the esophageal residence time of the corticosteroid after administration when the patient is recumbent is increased by a time in the range of about 5 seconds to about 60 seconds.

[0155]

[0161] In some embodiments, the maximum dose of corticosteroid for a patient who is bedridden is The mean time to reach the plasma concentration (Tmax) is within a range of about 80% to about 125% of about 8 hours to about 20 hours, for example, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46 hours, about 47 hours, about 48 hours, about 49 hours, about 50 hours, about 51 hours, about 52 hours, about 53 hours, about 54 hours, about 55 hours, about 56 hours, about 57 hours, about 58 hours, about 59 hours, about 60 hours, about 61 hours, about 62 hours, about 63 hours, about 64 hours, about 65 hours, about 66 hours, about 67 hours, about 68 hours, about In a preferred embodiment, the T of oral corticosteroids for bedridden patients is about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours, about 24 hours, about 24.5 hours, about 25 hours, about 25.5 hours or about 26 hours, including all values ​​and subranges therebetween. max is a range from about 80% to about 125% of about 14 hours ±6 hours, including all values ​​and subranges therebetween.

[0156]

[0162] In some embodiments, the T of oral corticosteroids in bedridden patients is max is the T of a patient in an upright position (e.g., AM postprandial or fasting conditions) max In comparison, a time in the range of about 1 hour to about 15 hours, for example, about 1.5 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, The increase in time can be about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, including all values ​​and subranges therebetween.

[0157]

[0163] In some embodiments, the drug is administered to a patient in an upright position in the postprandial state (and the patient is then T of oral corticosteroids if the patient does not lie down after maxis a range of about 80% to about 125% of about 1 hour to about 10 hours, for example, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, and about 13 hours, including all values ​​and subranges therebetween.

[0158]

[0164] In some embodiments, the drug is administered to a patient in an upright position in the postprandial state (and the patient is then T of oral corticosteroids if the patient does not lie down after max is in the range of about 80% to about 125% of about 2 hours to about 30 hours, for example, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours, about 20.5 hours, about 21 hours, about 21.5 hours, about 22 hours, about 22.5 hours, about 23 hours, about 23.5 hours, about 24 hours, about 24.5 hours, about 25 hours, about 25.5 hours, about 26 hours, about 26.5 hours, about 27 hours, about 27.5 hours, about 28 hours, about 28.5 hours, about 29 hours, about 29.5 hours, about 30 hours, about 30.5 hours, about 31 hours, about 31.5 hours, about 32 hours, about 32.5 hours, and about 33 hours, including all values ​​and subranges therebetween.

[0159]

[0165] Conventionally, food is usually T max thus delaying the postprandial T m ax is usually in a fasting stateT maxHowever, pharmacokinetic studies have shown that fasting T max The value is the postprandial state T max It has been found that fasting T max is the postprandial state T max For example, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours, about 6 hours, about 6.5 hours, about 7 hours, about 7.5 hours, about 8 hours, about 8.5 hours, about 9 hours, about 9.5 hours, about 10 hours, about 10.5 hours, about 11 hours, about 11.5 hours, about 12 hours, about 12.5 hours, about 13 hours, about 13.5 hours, about 14 hours, about 14.5 hours, about 15 hours, about 15.5 hours, about 16 hours, about 16.5 hours, about 17 hours, about 17.5 hours, about 18 hours, about 18.5 hours, about 19 hours, about 19.5 hours, about 20 hours or more.

[0160]

[0166] Local contact of oral corticosteroids with the esophagus and low systemic bioavailability Due to the use of corticosteroids with low systemic bioavailability (or modified to have low systemic bioavailability), the methods and compositions described herein can treat EoE at surprisingly low plasma corticosteroid levels. The advantage of low plasma corticosteroid levels is the reduction or avoidance of side effects associated with systemic administration of corticosteroids. Thus, in some embodiments, the methods and compositions described herein provide corticosteroids to the upper gastrointestinal tract (e.g., esophagus) to treat inflammation therein (e.g., EoE). In some embodiments, the corticosteroid is administered locally in an amount effective to locally treat In the form, the oral corticosteroid provides a mean maximum plasma concentration (Cmax) of about 1000 pg / mL or less, e.g., about 950 pg / mL, about 900 pg / mL, about 850 pg / mL, about 800 pg / mL, about 750 pg / mL, about 700 pg / mL, about 650 pg / mL, about 600 pg / mL, about 550 pg / mL, about 500 pg / mL, about 450 pg / mL, about 400 pg / mL, about 350 pg / mL, about 300 pg / mL, about 250 pg / mL, about 200 pg / mL, about 150 pg / mL, about 100 pg / mL, or about 50 pg / mL or less, following oral administration of about 0.01 mg to about 20 mg of oral corticosteroid. In a preferred embodiment, the oral corticosteroid provides a Cmax of about 500 pg / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid.

[0161]

[0167] In a preferred embodiment, the C max The patient is lying down. After administration of 6 mg of fluticasone propionate at that time, the concentration is within the range of about 80% to about 125% of about 15 pg / mL to about 40 pg / mL, for example, about 10 pg / mL, about 11 pg / mL, about 12 pg / mL, about 13 pg / mL, about 14 pg / mL, about 15 pg / mL, about 16 pg / mL, about 17 pg / mL, about 18 pg / mL, about 19 pg / mL, about 20 pg / mL, about 21 pg / mL, about 22 pg / mL, about 23 pg / mL, about 24 pg / mL, about 25 pg / mL, about 26 pg / mL, about 27 pg / mL, about 28 pg / mL, about 29 pg / mL, about 30 pg / mL, about 31 pg / mL, pg / mL, about 32 pg / mL, about 33 pg / mL, about 34 pg / mL, about 35 pg / mL, about 36 pg / mL, about 37 pg / mL, about 38 pg / mL, about 39 pg / mL, about 40 pg / mL, about 41 pg / mL, about 42 pg / mL, about 43 pg / mL, about 44 pg / mL, about 45 pg / mL, about 46 pg / mL, about 47 pg / mL, about 48 pg / mL, about 49 pg / mL, about 50 pg / mL, about 51 pg / mL, about 52 pg / mL, about 53 pg / mL, about 54 pg / mL or about 55 pg / mL, including all values ​​and subranges therebetween. In some embodiments, the low plasma concentrations achieved to treat EoE also reduce the side effects associated with systemic administration of corticosteroids. For example, in embodiments involving HS administration, local delivery of the corticosteroid reduces systemic administration and associated side effects, even though HS administration is generally known to increase systemic absorption.

[0162]

[0168] In some embodiments, the C of oral corticosteroids in bedridden patients is max The C of oral corticosteroids in postprandial patients who were upright and not lying down immediately after administration of oral corticosteroids maxis at least about 1%, e.g., at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 11%, at least about 12%, at least about 13%, at least about 14%, at least about 15%, at least about 16%, at least about 17%, at least about 18%, at least about 19%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, or at least about 50%, including all values ​​and subranges therebetween.

[0163]

[0169] In some embodiments, the oral corticosteroid is about After oral administration of 0.01 mg to about 20 mg, the concentration is about 10,000 pg·h / mL or less, for example, about 9,000 pg·h / mL, about 8,000 pg·h / mL, about 7,000 pg·h / mL, about 6,000 pg·h / mL, about 5,000 pg·h / mL, about 4,000 pg·h / mL, about 3,000 pg·h / mL, about 2 Mean AUC of approximately 1,000pg·h / mL, approximately 900pg·h / mL, approximately 800pg·h / mL, approximately 700pg·h / mL, approximately 600pg·h / mL, approximately 500pg·h / mL, approximately 400pg·h / mL, approximately 300pg·h / mL, approximately 200pg·h / mL, and approximately 100pg·h / mL 0~24 In certain embodiments, the oral corticosteroid provides a blood glucose level of about 3,000 pg·h / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid. Average AUC 0~24 results.

[0164]

[0170] In some embodiments, the AUC 0~24 (pg·h / mL) After administration of 1.5, 3.0, 4.5, 6.0 or 7.5 mg of fluticasone propionate while in bed, the patient is in the range of about 80% to about 125% of about 50 pg·h / mL to about 1,000 pg·h / mL, for example, about 10 pg·h / mL, about 20 pg·h / mL, about 30 pg·h / mL, about 40 pg·h / mL, about 50 pg·h / mL, about 60 pg·h / mL, about 70 pg·h / mL, about 80 pg·h / mL, about 90 pg·h / mL, about 100 pg·h / mL, about 110 pg·h / mL, about 120 pg·h / mL, about 130 pg·h / mL, about 140 pg·h / mL, or about 150 pg·h / mL. L, approximately 150 pg h / mL, approximately 160 pg h / mL, approximately 170 pg h / mL, approximately 180 pg h / mL, approximately 190 pg h / mL, approximately 200 pg h / mL, approximately 210 pg h / mL, approximately 220 pg h / mL, approximately 230 pg h / mL, approximately 240 pg h / mL, approximately 2 50 pg h / mL, approximately 260 pg h / mL, approximately 270 pg h / mL, approximately 280 pg h / mL, approximately 290 pg h / mL, approximately 300 pg h / mL, approximately 310 pg h / mL, approximately 320 pg h / mL, approximately 330 pg h / mL, approximately 340 pg h / mL, approximately 350 pg h / mL h / mL, approximately 360 pg h / mL, approximately 370 pg h / mL, approximately 380 pg h / mL, approximately 390 pg h / mL, approximately 400 pg h / mL, approximately 410 pg h / mL, approximately 420 pg h / mL, approximately 430 pg h / mL, approximately 440 pg h / mL, approximately 450 pg h / mL , about 460 pg h / mL, about 470 pg h / mL, about 480 pg h / mL, about 490 pg h / mL, about 500 pg h / mL, about 510 pg h / mL, about 520 pg h / mL, about 530 pg h / mL, about 540 pg h / mL, about 550 pg h / mL, about 560 pg·h / mL, about 570pg·h / mL, about 580pg·h / mL, about 590pg·h / mL or about 600pg·h / mL, about 610pg·h / mL, about 620pg·h / mL, about 630pg·h / mL, about 640pg·h / mL, about 650pg·h / mL, about 660pg·h / mL, about 670pg·h / mL, about 680pg·h / mL, about 690pg·h / mL, about 700pg·h / mL, about 710pg·h / mL, about 720pg·h / mL, about 730pg·h / mL, about 740pg·h / mL, about 750pg·h / mL, about 760pg·h / mL,Approx. 770 pg h / mL, approx. 780 pg h / mL, approx. 790 pg h / mL, approx. 800 pg h / mL, approx. 810 pg h / mL, approx. 820 pg h / mL, approx. 830 pg h / mL, approx. 840 pg h / mL, approximately 850 pg h / mL, approximately 860 pg h / mL, approximately 870 pg h / mL, approximately 880 pg h / mL, approximately 890 pg h / mL, approximately 900 pg h / mL, approximately 910 pg h / mL / mL, approx. 920 pg h / mL, approx. 930 pg h / mL, approx. 940 pg h / mL, approx. 950 pg h / mL, approx. 960 pg h / mL, approx. 970 pg h / mL, approx. 980 pg h / mL, Approx. 990 pg h / mL, approx. 1000 pg h / mL, approx. 1010 pg h / mL, approx. 1020 pg h / mL, approx. 1030 pg h / mL, approx. 1040 pg h / mL, approx. 1050 pg h / m L, approx. 1060 pg h / mL, approx. 1070 pg h / mL, approx. 1080 pg h / mL, approx. 1090 pg h / mL, approx. 1100 pg h / mL, approx. 1110 pg h / mL, approx. 1120 pg h / mL h / mL, approx. 1130 pg h / mL, approx. 1140 pg h / mL, approx. 1150 pg h / mL, approx. 1160 pg h / mL, approx. 1170 pg h / mL, approx. 1180 pg h / mL, approx. 1190 pg·h / mL, about 1200 pg·h / mL, about 1210 pg·h / mL, about 1220 pg·h / mL, about 1230 pg·h / mL, about 1240 pg·h / mL, about 1250 pg·h / mL, about 1260 pg·h / mL, about 1270 pg·h / mL, about 1280 pg·h / mL, about 1290 pg·h / mL, about 1300 pg·h / mL, including all values ​​and subranges therebetween.

[0165]

[0171] In some embodiments, the AUC 0~24 (pg·h / mL) is the After administration of 1.5, 3.0, 4.5, 6.0, or 7.5 mg of fluticasone propionate (taken in the morning after a meal or on an empty stomach) while in an upright position, 00pg·h / mL, for example, about 10pg·h / mL, about 20pg·h / mL, about 30pg·h / mL, about 40pg·h / mL, about 50pg·h / mL, about 60pg·h / mL, about 70pg·h / mL, about 80pg·h / mL, about 90pg·h / mL, about 100pg·h / mL, about 110pg·h / mL, about 120pg·h / mL, about 130pg·h / mL, about 140pg·h / mL, about 150pg·h / mL, about 160pg·h / mL, about 170pg·h / mL, about 180pg·h / mL, about 190pg·h / mL, Approx. 200 pg h / mL, approx. 210 pg h / mL, approx. 220 pg h / mL, approx. 230 pg h / mL, approx. 240 pg h / mL, approx. 250 pg h / mL, approx. 260 pg h / mL, approx. 270 pg h / mL, approx. 280 pg h / mL, approx. 290 pg h / mL, approx. 300 pg h / mL, approximately 310 pg h / mL, approximately 320 pg h / mL, approximately 330 pg h / mL, approximately 340 pg h / mL, approximately 350 pg h / mL, approximately 360 pg h / mL, approximately 370 pg h / mL, approximately 380 pg h / mL, approximately 390 pg h / mL, approximately 400 pg h / mL, about 410pg·h / mL, about 420pg·h / mL, about 430pg·h / mL, about 440pg·h / mL, about 450pg·h / mL, about 460pg·h / mL, about 470pg·h / mL, about 480pg·h / mL, about 490pg·h / mL, about 500pg·h / mL, about 510pg·h / mL, about 520pg·h / mL, about 530pg·h / mL, about 540pg·h / mL, about 550pg·h / mL, about 560pg·h / mL, about 570pg·h / mL, about 580pg·h / mL, about 590pg·h / mL or about 600pg·h / mL, about 61 0 pg h / mL, approximately 620 pg h / mL, approximately 630 pg h / mL, approximately 640 pg h / mL, approximately 650 pg h / mL, approximately 660 pg h / mL, approximately 670 pg h / mL, approximately 680 pg h / mL, approximately 690 pg h / mL, approximately 700 pg h / mL, approximately 710 pg h / mL h / mL, approximately 720 pg h / mL, approximately 730 pg h / mL, approximately 740 pg h / mL, approximately 750 pg h / mL, approximately 760 pg h / mL, approximately 770 pg h / mL, approximately 780 pg h / mL, approximately 790 pg h / mL, approximately 800 pg h / mL, approximately 810 pg h / mL,Approx. 820 pg h / mL, approx. 830 pg h / mL, approx. 840 pg h / mL, approx. 850 pg h / mL, approx. 860 pg h / mL, approx. 870 pg h / mL, approx. 880 pg h / mL, approx. 890 pg h / mL, approx. 900 pg h / mL, approx. 910 pg h / mL, approx. 920 pg h / mL, approx. 930 pg h / mL, approx. 940 pg h / mL, approx. 950 p g h / mL, approximately 960 pg h / mL, approximately 970 pg h / mL, approximately 980 pg h / mL, approximately 990 pg h / mL, approximately 1000 pg h / mL, approximately 1010 pg h / mL , about 1020 pg h / mL, about 1030 pg h / mL, about 1040 pg h / mL, about 1050 pg h / mL, about 1060 pg h / mL, about 1070 pg h / mL, about 1 080 pg h / mL, approximately 1090 pg h / mL, approximately 1100 pg h / mL, approximately 1110 pg h / mL, approximately 1120 pg h / mL, approximately 1130 pg h / mL, approximately 114 0 pg h / mL, approximately 1150 pg h / mL, approximately 1160 pg h / mL, approximately 1170 pg h / mL, approximately 1180 pg h / mL, approximately 1190 pg h / mL, approximately 1200 pg 1200pg·h / mL, about 1210pg·h / mL, about 1220pg·h / mL, about 1230pg·h / mL, about 1240pg·h / mL, about 1250pg·h / mL, about 1260pg·h / mL, about 1270pg·h / mL, about 1280pg·h / mL, about 1290pg·h / mL, and about 1300pg·h / mL, including all values ​​and subranges therebetween.

[0166]

[0172] In some embodiments, the AUC 0~24 (pg·h / mL) After administration of 6 mg of fluticasone propionate while in the bed, the patient is in the range of about 80% to about 125% of about 250 pg·h / mL to about 475 pg·h / mL, for example, about 150 pg·h / mL, about 160 pg·h / mL, about 170 pg·h / mL, about 180 pg·h / mL, about 190 pg·h / mL, about 200 pg·h / mL, about 210 pg·h / mL, about 220 pg·h / mL, about 230 pg·h / mL, about 240 pg·h / mL, about 250 pg·h / mL, about 260 pg·h / mL, about 270 pg·h / mL, about 280 pg·h / mL, about 290 pg·h / mL, about 300 pg·h / mL, about 310 pg·h / mL, about 320 pg·h / mL, about 330 pg·h / mL, about 340 pg·h / mL, about 350 pg·h / mL, about 360 pg·h / mL, about 370 pg·h / mL, about 380 pg·h / mL, about 390 pg·h / mL, about 400 pg·h / mL, about 410 pg·h / mL, about 420 pg·h / mL, about 430 pg·h / mL, about 440 pg·h / mL, about 450 pg·h / mL, about 460 pg·h / mL, about 470 pg·h / mL, about 480 pg·h / mL, about 490 pg·h / mL, about 500 pg·h / mL, about 510 pg·h / mL, g h / mL, approx. 330 pg h / mL, approx. 340 pg h / mL, approx. 350 pg h / mL, approx. 360 pg h / mL, approx. 370 pg h / mL, approx. 380 pg h / mL, approx. 390 pg h / mL, approx. 400 pg h / mL, approximately 410 pg h / mL, approximately 420 pg h / mL, approximately 430 pg h / mL, approximately 440 pg h / mL, approximately 450 pg h / mL, approximately 460 pg h / mL, approximately 470 pg h / mL, about 480 pg·h / mL, about 490 pg·h / mL, about 500 pg·h / mL, about 510 pg·h / mL, about 520 pg·h / mL, about 530 pg·h / mL, about 540 pg·h / mL, about 550 pg·h / mL, about 560 pg·h / mL, about 570 pg·h / mL, about 580 pg·h / mL, about 590 pg·h / mL or about 600 pg·h / mL, including all values ​​and subranges therebetween.

[0167]

[0173] In some embodiments, the AUC 0~24 (pg·h / mL) is the After administration of 6 mg of fluticasone propionate in an upright position, the patient's blood glucose level is within the range of about 80 to about 125% of about 250 pg·h / mL to about 475 pg·h / mL, for example, about 150 pg·h / mL, about 160 pg·h / mL, about 170 pg·h / mL, about 180 pg·h / mL, about 190 pg·h / mL, about 200 pg·h / mL, about 210 pg·h / mL, about 220 pg·h / mL, or about 230 pg·h / mL. h / mL, approx. 230 pg h / mL, approx. 240 pg h / mL, approx. 250 pg h / mL, approx. 260 pg h / mL, approx. 270 pg h / mL, approx. 280 pg h / mL, approx. 290 pg h / mL, approx. 300 pg h / mL, approx. 310 pg h / mL, approx. 320 pg h / mL, approx. 330 pg h / mL, approx. 340 pg h / mL, approx. 350 pg h / mL, approx. 3 60 pg h / mL, approximately 370 pg h / mL, approximately 380 pg h / mL, approximately 390 pg h / mL, approximately 400 pg h / mL, approximately 410 pg h / mL, approximately 420 pg h / mL , approx. 430 pg h / mL, approx. 440 pg h / mL, approx. 450 pg h / mL, approx. 460 pg h / mL, approx. 470 pg h / mL, approx. 480 pg h / mL, approx. 490 pg h / mL, about 500pg·h / mL, about 510pg·h / mL, about 520pg·h / mL, about 530pg·h / mL, about 540pg·h / mL, about 550pg·h / mL, about 560pg·h / mL, about 570pg·h / mL, about 580pg·h / mL, about 590pg·h / mL or about 600pg·h / mL, including all values ​​and subranges therebetween.

[0168]

[0174] In some embodiments, the pharmaceutical composition is administered at least about 2 hours after dinner (without snacks). In some embodiments, the pharmaceutical composition is administered to the patient at least about 4 hours after dinner (without a snack) when the patient is lying down. In some embodiments, the pharmaceutical composition is administered to the patient within about 2 hours after dinner (without a snack) when the patient is lying down. In some embodiments, the pharmaceutical composition is administered to the patient within about 4 hours after dinner (without a snack) when the patient is lying down. In some embodiments, after the pharmaceutical composition is administered to the patient while the patient is lying down, the patient falls asleep. In some embodiments, after the pharmaceutical composition is administered to the patient while the patient is lying down, the patient does not stand up for at least 1 hour.

[0169]

[0175] In some embodiments, the patient receives the pharmaceutical composition in a manner sufficient to swallow the composition. In another embodiment, the patient holds the pharmaceutical composition in the oral cavity for a sufficient period of time to allow dissolution of the pharmaceutical composition in saliva. Those skilled in the art will appreciate that the period of time required for a pharmaceutical composition depends in part on its dosage form. For example, an orally disintegrating composition disintegrates in saliva within about 60 seconds (e.g., about 50 seconds, about 40 seconds, about 30 seconds, about 20 seconds, or about 10 seconds) to form a suspension, which is then swallowed. In an embodiment in which the pharmaceutical composition is a lozenge or lollipop, the lozenge or lollipop may remain in the patient's oral cavity for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes.

[0170]

[0176] In some embodiments, the pharmaceutical composition is administered to a patient 1 to 5 times daily. In some embodiments, the pharmaceutical composition is administered to the patient at least once a day, at least twice a day, at least three times a day, at least four times a day, or at least five times a day. In some embodiments, the pharmaceutical composition is administered to the patient at least 1-5 times a day for one week to 10 years or more. In some embodiments, the pharmaceutical composition is administered to the patient at least once a day, at least twice a day, at least three times a day, at least four times a day, or at least five times a day for at least one week, at least two weeks, at least three weeks, at least four weeks, at least five weeks, at least six weeks, at least seven weeks, at least eight weeks, at least nine weeks, at least ten weeks, at least twenty weeks, at least thirty weeks, at least forty weeks, at least fifty weeks, at least fifty weeks, at least fifty weeks, at least sixty weeks, at least seventy weeks, at least eighty weeks, at least ninety weeks, or at least one hundred weeks, or more. In some embodiments, the pharmaceutical composition is administered to the patient indefinitely. In some embodiments, the pharmaceutical composition is administered twice a day for at least 6 weeks, at least 8 weeks, at least 10 weeks, or at least 12 weeks. In some embodiments, the pharmaceutical composition is administered twice a day during the induction and / or maintenance phase. In some embodiments, the pharmaceutical composition is administered twice a day for at least about 6 weeks, at least about 8 weeks, at least about 10 weeks, or at least about 12 weeks during the induction phase.

[0171]

[0177] In some embodiments, the pharmaceutical composition is administered in a dose of 0.75 mg, 1.5 mg, 3.0 mg, , 4.5 mg or 6.0 mg at least once a day, at least twice a day, at least three times a day, at least four times a day, or at least five times a day. In some embodiments, the pharmaceutical composition is administered to the patient at the same dose multiple times a day. In some embodiments, the pharmaceutical composition is administered to the patient at the same dose at least twice a day, at least three times a day, at least four times a day, or at least five times a day. In some embodiments, the pharmaceutical composition is administered to the patient at the same dose two to five times a day for one week to ten years or more. In some embodiments, the pharmaceutical composition is administered to a patient at least twice a day, at least three times a day, at least four times a day, or at least five times a day, at least in the same dose, for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 15 weeks, at least 20 weeks, at least 30 weeks, at least 40 weeks, at least 50 weeks, at least 52 weeks, at least 60 weeks, at least 70 weeks, at least 80 weeks, at least 90 weeks, or at least 100 weeks or more, or indefinitely.

[0172]

[0178] In some embodiments, the pharmaceutical composition is administered in different doses twice daily. In some embodiments, the pharmaceutical composition is administered twice daily, with the morning dose being higher than the evening dose, hi some embodiments, the pharmaceutical composition is administered twice daily, with the morning dose being lower than the evening dose.

[0173]

[0179] In some embodiments, patients are administered different doses of the pharmaceutical composition depending on the phase of the regimen. The composition is administered. For example, the regimen may be divided into at least an induction, treatment, withdrawal, or maintenance phase. In some embodiments, the regimen includes at least one of these phases. In some embodiments, the regimen includes a combination of one or more of these phases. In some embodiments, the regimen includes all of these phases.

[0174]

[0180] In some embodiments, the regimen includes an induction and a withdrawal. In some embodiments, the regimen includes multiple cycles of induction and rest as needed. In some embodiments, the regimen includes multiple cycles of induction and rest repeated indefinitely. In some embodiments, the induction period does not result in a recurrence of symptoms.

[0175]

[0181] The regimen phase can be of any suitable duration. The induction phase lasts for about 1 to about 10 weeks, about 12 weeks, about 15 weeks, about 20 weeks, about 30 weeks, about 40 weeks, or about 50 weeks. In some embodiments, the induction phase lasts for about 14 weeks. In some embodiments, the holiday phase lasts for about 1 to about 10 weeks, about 15 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 1 year, about 2 years, about 5 years, about 10 years, or indefinitely. In some embodiments, the holiday phase lasts until symptoms recur. In some embodiments, the holiday phase lasts for about 14 weeks. In one embodiment, the maintenance phase lasts for about 1 to about 15 weeks, about 20 weeks, about 30 weeks, about 40 weeks, about 50 weeks, about 1 year, about 2 years, about 5 years, about 10 years or more. In some embodiments, the maintenance phase lasts for about 28 weeks. In some embodiments, the maintenance phase is of indefinite duration.

[0176]

[0182] In some embodiments, the patient is administered one or more phases of the regimen in comparison to others. In some embodiments, the patient is administered a higher dose than the patient in one or more phases of the regimen. In some embodiments, the patient is administered the same dose in each phase of the regimen. In some embodiments, the patient is administered no dose during one or more phases.

[0177]

[0183] In some embodiments, the patient is administered more In some embodiments, the patient is administered a lower dose during the induction stage compared to the maintenance stage. In some embodiments, the patient is administered no dose during either the induction stage or the maintenance stage. In some embodiments, the patient is administered no dose during either the induction stage or the maintenance stage. In some embodiments, the patient is administered the same dose during the induction and maintenance stages. In some embodiments, the patient is administered substantially the same dose during the induction and maintenance stages. In some embodiments, the patient is administered 3.0 mg BID during the induction stage and 1.5 mg BID during the maintenance stage. In some embodiments, the patient is administered 3.0 mg BID during the induction stage and 1.5 mg HS during the maintenance stage. In some embodiments, the patient is administered 1.5 mg BID during the induction stage and 3.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 1.5 mg HS during the induction stage and 3.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 1.5 mg HS during the induction stage and 3.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 1.5 mg BID during both the induction and maintenance stages. In some embodiments, the patient is administered 1.5 mg HS during the induction and maintenance stages. In some embodiments, the patient is administered 3.0 mg BID during the induction and maintenance stages. In some embodiments, the patient is administered 6.0 mg BID during the induction stage and 3.0 or 1.5 mg BID during the maintenance stage. In some embodiments, the patient is administered 6.0 mg BID during the induction stage and 3.0 or 1.5 mg HS during the maintenance stage. In some embodiments, the patient is administered 1.5 or 3.0 mg BID during the induction stage and 6.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 1.5 or 3.0 mg HS during the induction stage and 6.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 6.0 or 3.0 mg BID during the induction stage and 6.0 mg BID during the maintenance stage. In some embodiments, the patient is administered 6.0 or 3.0 mg BID during both the induction and maintenance stages. In some embodiments, patients are administered 6.0 or 3.0 mg HS during the induction and maintenance stages.In some embodiments, patients are administered 6.0 mg BID during the induction and maintenance stages.

[0178]

[0184] In some embodiments, the patient is also receiving a potent cytochrome P4503A4 inhibitor. In some embodiments, the patient is not concomitantly administered ritonavir or ketoconazole.

[0179]

[0185] In certain embodiments, the patient is a human, while in other embodiments, the patient is a non-human The mammal may be, for example, a domestic pet (eg, a dog or cat), or a farm animal or livestock (eg, a horse, cow, sheep or pig).

[0180] Patient population

[0186] Any patient diagnosed or suspected to have an inflammatory digestive disorder In some embodiments, the patient is an adult. In some embodiments, the patient is an adolescent. In some embodiments, the patient is a child. In some embodiments, the patient is an infant.

[0181]

[0187] In some embodiments, the inflammatory digestive disorder is EoE. The patient may be diagnosed using any suitable means. In some embodiments, the patient is diagnosed with EoE based on symptoms, tissue diagnosis, and / or a failed record of proton pump inhibitors. In some embodiments, the patient received PPI treatment prior to administration of the pharmaceutical composition of the present disclosure. In some embodiments, the patient did not receive PPI treatment prior to administration of the pharmaceutical composition of the present disclosure. In some embodiments, the patient failed to improve after 8 weeks of high dose (e.g., 40 mg) PPI. Lack of response to PPI treatment may be defined as peak eosinophils > 15 / HPF in at least one biopsy location after 8 weeks of treatment with high dose PPI. In some embodiments, the failure of PPI treatment is documented prior to administration of the pharmaceutical composition of the present disclosure. In some embodiments, the failure of PPI treatment is documented after administration of the pharmaceutical composition of the present disclosure. In some embodiments, patients who have not responded to previous PPI treatment are administered a high dose of oral corticosteroid according to (or for use in) the methods disclosed herein, e.g., 6.0 mg, 7.5 mg or more (e.g., about 9.0 mg to about 20 mg, including about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, and about 19 mg, including all values ​​and subranges therebetween).

[0182]

[0188] In some embodiments, a patient diagnosed with EoE has an esophageal stricture. In embodiments, the patient is administered a high dose of oral corticosteroid according to (or for use in) the methods of the present disclosure, e.g., 6.0 mg, 7.5 mg or more (e.g., from about 9.0 mg to about 20 mg, including about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, and about 19 mg, including all values ​​and subranges therebetween).

[0183]

[0189] In some embodiments, a patient diagnosed with EoE has a severe food allergy (e.g., In some embodiments, the patient is administered a high dose of an oral corticosteroid according to (or for use in) the methods of the present disclosure, e.g., 6.0 mg, 7.5 mg or more (e.g., about 9.0 mg to about 20 mg, including about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, and about 19 mg, including all values ​​and subranges therebetween).

[0184]

[0190] In some embodiments, the patient has been diagnosed with EoE by histological analysis. In some embodiments, the patient is diagnosed with a peak eosinophil count of ≧15 per HPF (magnification 400×) in at least one biopsy sample. In some embodiments, there are a minimum of six biopsy samples taken from the patient. In some embodiments, at least three biopsy samples are taken from each of the proximal and distal esophagus.

[0185]

[0191] In some embodiments, the patient is diagnosed with EoE in their EEsAI, comprehensive EoE, EREFS In some embodiments, patients are diagnosed with EoE by ESCA, PROSE, and / or endoscopic measurement of esophageal features (e.g., EndoFlip). In some embodiments, patients are diagnosed with EoE based on a 7-day recall EEsAI score of >30. In some embodiments, patients are diagnosed with EoE based on a 7-day recall global EoE score of >5. In some embodiments, patients are diagnosed with EoE based on the EREFS score (see Table 3), which scores endoscopic features. In some embodiments, EoE is diagnosed in patients with a score higher than grade 0 in any of the five features disclosed in Table 3.

[0186]

[0192] In some embodiments, the patient may have a history of, including but not limited to, an episode of food impaction. A patient is diagnosed with EoE based on symptoms, including dysphagia, episodes of food impaction requiring endoscopy, food aversion, vomiting, regurgitation, and / or dysphagia. In some embodiments, a patient is diagnosed with EoE based on dysphagia (difficulty swallowing). In some embodiments, a patient is diagnosed with EoE based on experiencing dysphagia at least three times per week within two weeks.

[0187]

[0193] Patient outcomes and responses to administration of the pharmaceutical compositions of the present disclosure are within the skill of the art. The condition can be monitored or measured using any appropriate means in the field (eg, endoscopy, tissue analysis, questionnaires).

[0188]

[0194] Patients who demonstrate improvement in symptoms and / or histologic response after initiation of treatment are considered responders. In some embodiments, patients who exhibit a peak eosinophils / HPF of <15 are broadly classified as responders. In some embodiments, patients who exhibit a peak eosinophils / HPF of <6 are broadly classified as responders. In some embodiments, patients who exhibit a peak eosinophils / HPF of <6 and no worsening of symptoms (e.g., no increase in EEsAI score once a week compared to baseline; no strictures requiring dilation) are broadly classified as responders. In some embodiments, patients who exhibit a peak eosinophils / HPF of <6 and no episodes of food impaction are broadly classified as responders. In some embodiments, responders show evidence of endoscopic remission of inflammation, such as the absence of white exudates and / or grooves. In some embodiments, responders show evidence of fibrosis remission, including the absence of strictures and esophageal rings or moderate-severe esophageal rings. In some embodiments, responders show improved vascularity. In some embodiments, responders show improved biomarkers (e.g., IL-5, IgE levels).

[0189]

[0195] In some embodiments, patients classified as responders are those who maintain a maintenance status of the regimen. In some embodiments, patients classified as responders are administered a different dose of the pharmaceutical composition of the present disclosure after classification. In some embodiments, the responders receive a higher dose after classification. In some embodiments, the responders receive a lower dose after classification. In some embodiments, the responders receive the same dose after classification. In some embodiments, the responders receive substantially the same dose after classification.

[0190]

[0196] In some embodiments, the patient is administered the pharmaceutical compositions disclosed herein during the induction phase and A patient is classified as a responder if, during the induction phase, improvement in peak eosinophil count in at least one esophageal biopsy sample is observed and / or at least no worsening of the patient's weekly average EESAI score is observed, and then the maintenance phase includes a dose at least equal to, greater than, or less than the induction phase.

[0191]

[0197] Patients who do not meet the definition of a responder disclosed above are broadly classified as non-responders. Patients who experience a worsening of histological score and / or symptoms are broadly classified as recurrent. In some embodiments, patients who experience a worsening of histological score and / or symptoms at any time during treatment are broadly classified as recurrent. In some embodiments, patients who experience a worsening of histological score and / or symptoms at any time during treatment are broadly classified as recurrent. , and / or patients who experience a clinically significant worsening of symptoms are classified as relapsing. In some embodiments, patients classified as non-responders or relapsers are administered a different dose of the pharmaceutical composition of the present disclosure after classification. In some embodiments, non-responders and / or relapsers receive a higher dose after classification. In some embodiments, non-responders and / or relapsers receive a lower dose after classification. In some embodiments, non-responders and / or relapsers receive the same dose after classification. In some embodiments, non-responders and / or relapsers receive substantially the same dose after classification.

[0192]

[0198] In some embodiments, the patient is administered the pharmaceutical compositions disclosed herein during the induction phase and and a maintenance phase, and a patient is classified as a responder if, during the induction phase, there is observed to be no improvement in peak eosinophil count in at least one esophageal biopsy sample and / or there is observed to be a worsening in the patient's weekly average EESAI score, and then the maintenance phase includes a dose at least equal to, greater than or less than, the induction phase.

[0193]

[0199] In some embodiments, the present disclosure provides a method for treating Eo The present invention provides a method for assessing the suitability of a subject for a clinical trial to measure the effect of an oral corticosteroid on EoE. In some embodiments, the recruitment of subjects to the clinical trial is assessed based on the patient's eosinophil count or previous treatment. In some embodiments, the patient selected for the clinical trial has a peak eosinophil count per HPF of greater than about 6, greater than about 10, greater than about 15, or greater than about 20. In some embodiments, the patient selected for the clinical trial has a peak eosinophil count per HPF of greater than about 15. In some embodiments, the patient selected for the clinical trial has had a previous treatment that was unsuccessful. In some embodiments, the previous treatment was administration of a PPI for at least about 8 weeks that was not effective in substantially improving one or more symptoms of EoE.

[0194] Purpose-specific products

[0200] In line with the above, the present disclosure provides a method for treating EoE in a patient. The present invention provides an oral corticosteroid for use, which is administered immediately before or while the patient is lying down. In some embodiments, a therapeutically effective amount of the oral corticosteroid contacts the patient's esophagus. The term "therapeutically effective amount" can refer to an amount capable of eliciting beneficial biological activity in vivo, and in some embodiments, an amount capable of treating EoE as measured using any of the metrics disclosed herein. The doses of oral corticosteroid disclosed herein suitably deliver a therapeutically effective amount of oral corticosteroid to the patient.

[0195]

[0201] The oral corticosteroids, methods of treatment and patients are all as described herein. Indeed, any and all of the features described herein for the disclosed compositions, methods of treatment, dosing, administration, and patient populations may be used in connection with the disclosed products for limited purposes. Any and all such features are expressly encompassed by the disclosed invention, except for combinations in which at least some of such features are mutually exclusive.

[0196]

[0202] Thus, in an embodiment, lying down is lying down in a supine, prone or lateral position. Ugh.

[0197]

[0203] Oral corticosteroids can be administered within approximately 30 minutes before the desired bedtime. The oral corticosteroid can be administered at least about 30 minutes after a meal. In certain embodiments, the patient is unable to eat or drink for at least about 30 minutes after administration of the oral corticosteroid.

[0198]

[0204] Oral corticosteroids can be given once daily. The steroids may also be administered twice daily, with the first daily dose being administered while the patient remains upright.

[0199]

[0205] Administer oral corticosteroids at a dose of about 0.01 mg to about 20 mg. The oral corticosteroid can be fluticasone propionate administered in a dose of about 1.5 mg to about 7.5 mg, and preferably about 1.5, 3.0, 4.5, 6.0 or 7.5 mg.

[0200]

[0206] In some embodiments, the patient has a lactose allergy or a starch allergy. It may also have.

[0201]

[0207] Oral corticosteroids should be administered at about 20% or less of their original dose, about 15% or less, about 10% or less. %, less than about 5%, or less than about 1% systemic bioavailability.

[0202]

[0208] Oral corticosteroids are administered in doses ranging from about 0.01 mg to about 20 mg of oral corticosteroids. mg oral dose can result in a mean maximum plasma concentration (Cmax) of about 500 pg / mL or less.

[0203]

[0209] Oral corticosteroids are administered in doses ranging from about 0.01 mg to about 20 mg of oral corticosteroids. A mean AUC of approximately 3,000 pg h / mL or less after oral administration of 0~24 can result.

[0204]

[0210] In embodiments, the oral corticosteroid is budesonide, fluticasone, fluticasone, It may be nisolide, ciclesonide, mometasone, tixocortol or beclomethasone, or a pharma- ceutically acceptable salt, solvate, ester, polymorph or prodrug thereof.

[0205]

[0211] In some embodiments, the oral corticosteroid may be formulated as a liquid composition. In another embodiment, the oral corticosteroid can be formulated as a solid composition. The oral corticosteroid can be formulated to form a solution or suspension prior to oral administration. The oral corticosteroid can be formulated to form a solution, suspension or gel upon oral administration. When formulated as a liquid composition, the oral corticosteroid can be in the form of a solution, suspension or slurry. When formulated as a solid composition, the oral corticosteroid can be in the form of a gel, a lozenge, a lollipop, an effervescent tablet, a powder, granules, or an orally disintegrating composition. The orally disintegrating composition can be in the form of a tablet, an oblate, a film, or a lyophilized matrix.

[0206]

[0212] In one embodiment, the oral corticosteroid is administered in a dose ranging from about 1.5 mg to about 7.5 mg 1. An orally disintegrating tablet comprising an oral corticosteroid in an amount according to USP 150.1, a pharma- ceutically acceptable carrier in combination with the corticosteroid, and rapidly dispersing microgranules, <701> It is formulated as an orally disintegrating tablet that disintegrates within 60 seconds when tested using a disintegration test.

[0207]

[0213] In one embodiment, the patient receives about 1.5 mg to about 7.5 mg of oral corticosteroid. mg oral dose can have a Cmax of about 200 pg / mL or less of oral corticosteroids.

[0208]

[0214] The mean time to reach maximum plasma concentrations (Tmax) of oral corticosteroids is approximately 1 It can range from about 80% to about 125% of 2 hours to about 15 hours.

[0209]

[0215] In one embodiment, the oral corticosteroid is fluticasone propionate. Possibly, the Cmax may be within the range of about 80% to about 125% of about 15 pg / mL to about 40 pg / mL after administration of 6 mg fluticasone propionate or 3 mg fluticasone propionate.

[0210]

[0216] In embodiments, after 12 weeks of daily administration of an oral corticosteroid, the eosinophil count reduction in esophageal inflammation measured by: reduction in dysphagia-free days, reduction in dysphagia episodes, improvement in EREFS scores, EndoFLIP documentation of improved esophageal compliance, evaluation of biomarkers, reduction in food impaction episodes, improvement in EEsAI scores (patient, physician, endoscopy, pathology scores), EoE-QOL-A, Visual Dysphagia Questionnaire (VDQ), Aversion, Modification and Slow Feeding (AMS) scores, or tissue diagnosis.

[0211]

[0217] In one embodiment, the patient's eosinophil count is reduced by at least about 50%. can.

[0212] Combination treatment

[0218] The therapeutic agent or agents may be administered as separate pharmaceutical compositions or in a single pharmaceutical composition. The pharmaceutical compositions can be mixed with the pharmaceutical composition and administered together in a coordinated manner to a subject for "co-administration", i.e., co-administration. With respect to "co-administration", one or more therapeutic agents can also be administered simultaneously with the pharmaceutical composition or separately, including at different times and with different frequencies. One or more therapeutic agents can be administered by any known route, such as orally, intravenously, intramuscularly, nasally, subcutaneously, vaginally, rectally, etc., and the therapeutic agents can be administered by any conventional route.

[0213]

[0219] When two or more drugs are used in combination, the dosage of each drug should be determined independently. The dosages of the drugs when used will generally be the same, but if one drug interferes with the metabolism of the other, the dosage of each drug will be adjusted appropriately. Each drug may be administered simultaneously or separately at appropriate time intervals.

[0214]

[0220] The pharmaceutical compositions disclosed herein can be used to treat, but are not limited to, esophageal inflammation, Inflammation of the glottis, inflammation of the epiglottis, inflammation of the tonsils, inflammation of the oropharynx, eosinophilic esophagitis (EoE), gastroesophageal The present invention may be administered in combination with a variety of therapies used to treat, prevent, delay, and / or ameliorate inflammatory conditions of the digestive tract, including gastroesophageal reflux disease (GERD), nonerosive gastroesophageal reflux disease (NERD), erosive esophagitis, Barrett's esophagus, eosinophilic gastroenteritis, hypereosinophilic syndrome, corrosive (corrosive) chemical esophagitis, radiation-induced esophagitis, chemotherapy-induced esophagitis, transient drug-induced esophagitis (also known as drug-esophagitis), persistent drug-induced esophagitis, esophageal Crohn's disease, and pseudomembranous esophagitis.

[0215]

[0221] The therapeutic agent or agents exert a therapeutic effect on a subject in need thereof. The compound, molecule or substance may be any compound, molecule or substance that is

[0216]

[0222] In some embodiments, the pharmaceutical compositions disclosed herein comprise one or more Concomitantly administered with a corticosteroid. Suitable corticosteroids include, but are not limited to, hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, and the like, or mineralocorticoid potency (e.g., aldosterone), budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, tixocortol, and salts or esters and mixtures thereof.

[0217]

[0223] In some embodiments, the pharmaceutical compositions disclosed herein comprise one or more It is administered in combination with a proton pump inhibitor (PPI). A suitable PPI is omeprazole. Examples of PPIs include, but are not limited to, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole, and esomeprazole. In some embodiments, the PPI is administered in a high dose.

[0218]

[0224] In some embodiments, the pharmaceutical compositions disclosed herein are co-administered with an antifungal agent. Suitable antifungal agents include, but are not limited to, mitotic inhibitor antifungals, pyrimidine analog antifungals, polyene antifungals, benzimidazole antifungals, imidazole antifungals, polyene antifungals, triazole antifungals, thiazole antifungals, arylamine antifungals, echinocandin antifungals, and other "generalized" antifungals recognized in the art that do not fall into any of the above categories (e.g., tolnaftate and ciclopirox). For example, suitable antifungal agents that may be included in the solid pharmaceutical compositions of the present disclosure include abafungin, amorolfine, anidulafungin, bifonazole, butenafine, butoconazole, candicin, caspofungin, ciclopirox, clotrimazole, econazole, fenticonazole, filipin, fluconazole, flucytosine, griseofulvin, isavuconazole, isoconazole, itraconazole, ketoconazole, micafungin, miconazole, miconazole nitrate, naftifine, natamycin, nystatin, oxiconazole, posaconazole, paramyconazole, ravuconazole, rimocidin, cetaconizole, sulconazole, terbafine, terconazole, tioconazole, tolnaftate, undecylenic acid, and voriconazole.

[0219]

[0225] In other embodiments, the pharmaceutical compositions disclosed herein are administered in combination with an antiviral agent. Antiviral agents that can be used in the present disclosure include, but are not limited to, interferons, nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, fusion inhibitors, maturation inhibitors, guanosine analogs, purine analogs, pyrimidine analogs, and other "unclassified" antiviral agents recognized in the art that do not fall into any of the above classes (e.g., foscarnet and miltefosine). For example, suitable antifungal agents that can be included in the solid pharmaceutical composition of the present disclosure include abacavir, aciclovir (also known as acyclovir), adefovir, amantadine, amdovir, amantadine ... Xovir, amprenavir, aplaviroc, apricitabine, arbidol, atazanavir, bevirimat, BMS-488043, boceprevir, brivudine, cidofovir, DCM205, docosanol, delavirdine, didanosine, darunavir, efavirenz, elvitegravir, elvucitabine, emtricitabine, enfuvirtide, epigallocatechin gallate, etravirine, fumarate These include amciclovir, fosamprenavir, ganciclovir, globoidnan A, griffithsin, ibalizumab, idoxuridine, indinavir, lamivudine, lopinavir, loviride, maraviroc, nelfinavir, nevirapine, oseltamivir, pegylated interferon alfa-2a, pegylated interferon alfa-2b, penciclovir, peramivir, plerixafor, PRO 140, rasibir, raltegravir, ritonavir, ribavirin, rimantadine, rilpivirine, saquinavir, stampidine, stavudine, tenofovir, tipranavir, TNX-355, trifluridine, tromantadine, valacyclovir, valganciclovir, vicriviroc, vidarabine, viramidine, vibecon, zalcitabine, zanamivir, and zidovudine.

[0220]

[0226] In some embodiments, the pharmaceutical compositions disclosed herein comprise one or more It is administered in combination with an immunosuppressant. Suitable immunosuppressants include cyclosporine and tacrolimus. Exemplary anti-inflammatory drugs include, but are not limited to, sirolimus, prednisolone, hydrocortisone, sirolimus, everolimus, azathioprine, mycophenolic acid, methotrexate, basiliximab, daclizumab, rituximab, antithymocyte globulin, and antilymphocyte globulin.

[0221] kit

[0227] The present disclosure also provides kits for the treatment of gastrointestinal inflammatory disorders. In one embodiment, the kit includes a pharmaceutical composition of the present disclosure (fluticasone propionate, ODT) in unit dosage form. In some embodiments, the kit comprises 1.5 mg or 3.0 mg of the pharmaceutical composition of the present disclosure. In some embodiments, the kit comprises a maintenance dose of the pharmaceutical composition of the present disclosure. In some embodiments, the kit comprises an induction dose of the pharmaceutical composition of the present disclosure. In some embodiments, the kit comprises both an induction dose and a maintenance dose of the pharmaceutical composition of the present disclosure. The kit can further comprise a label or printed instructions directing the use of the described reagents. The kit can further comprise a treatment to be tested.

[0222] INCORPORATION BY REFERENCE

[0228] All publications, patents and patent applications cited are incorporated herein in their entirety for any purpose. and is incorporated herein by reference.

[0223]

[0229] This application incorporates by reference the following publications and applications in their entirety for all purposes: No. 8,771,729, filed October 1, 2010; U.S. Patent Application Publication No. 2016 / 0206627, filed September 5, 2014; U.S. Patent Application No. 61 / 874,450, filed September 6, 2013; WO2015 / 034678, filed August 21, 2014; and WO2015 / 035114, filed September 5, 2014.

[0224]

[0230] The present disclosure is further illustrated by the following non-limiting examples. EXAMPLES

[0225] Example 1 - A randomized, double-blind, dose-ranging study of fluticasone propionate orally dissolving tablets

[0231] This Phase 2b study will enroll 320 patients with eosinophilic esophagitis (EoE) between the ages of 14 and 75 years. To be eligible for this study, patients must have had proven failure of high-dose (i.e., esomeprazole 40 mg BID) proton pump inhibitors (PPIs) for ≥8 weeks. Must have a subsequent diagnosis of EoE (>15 peak eosinophils per HPF). I treatment may be continued during the study only if the subject was on PPI treatment at the time of enrollment in the study. No new initiation or changes in PPI treatment were permitted during the study. Subjects must also be symptomatic and have a 7-day recall global EoE score of ≥ 5 and a 7-day recall EEsAI score of > 20 to enter the placebo run-in period, and an increase in EEsAI score based on a daily diary.

[0226]

[0232] Primary objective: To evaluate the efficacy of fluticasone propionate orally disintegrating tablets (APT-1011) in adolescents and adults with eosinophilic esophagitis (EoE).

[0227]

[0233] Secondary Objective: Efficacy and safety of APT-1011 (propionate) in adolescents and adults with EoE To evaluate the safety of fluticasone dihydrotestosterone (ODT) and the dose-response of APT-1011. To define: To evaluate the pharmacokinetics (PK) of APT-1011 in patients with EoE. To evaluate the effects of treatment vs. holiday, including time to recurrence and effect of retreatment. To evaluate the maintenance of efficacy and long-term safety of treatment. To evaluate the effect on endoscopic appearance using the EoE Endoscopic Criteria Score (ERES).

[0228]

[0234] Study Rationale and Design: Detailed doses of 1.5mg HS to 3.0mg BID were administered. The study will explore the efficacy and safety of APT-1011 in patients with rheumatoid arthritis and define the exposure-response and minimal effective dose of APT-1011. This is a randomized, double-blind, placebo-controlled, dose-ranging study of three daily doses of APT-1011 (1.5 mg, 3 mg, and 6 mg) administered as 1.5 mg HS, 1.5 mg BID, or 3.0 mg BID, compared with matching placebo doses. The effects of treatment withdrawal, retreatment, and long-term maintenance will also be evaluated.

[0229]

[0235] The formulations of APT-1011 (fluticasone propionate, ODT) used in the clinical trials are listed in the table below.

[0230] [Table A]

[0231]

[0236] Dosage: Three dose groups received blinded tablets of 1.5 mg and 3.0 mg active ingredient strength. The fourth dose group will receive a matching placebo. Tablets are administered BID - 30 minutes before breakfast and HS (before bedtime). Subjects in the 1.5 mg dose group take a placebo tablet 30 minutes before breakfast and APT-1011 Please note that 1.5 mg will be taken HS (before bedtime). To maintain the blind, all tablets will be labeled for "before breakfast" or "before bedtime" dosing.

[0232]

[0237] Screening: Subjects are screened using upper endoscopy (EGD) at 2-4 weeks. Subjects who meet other inclusion criteria and have ≥15 eosinophils per HPF, a global symptom score of >5, and a 7-day recall EEsAI score of >20 may enter a placebo run-in period. Subjects who meet all other inclusion criteria and have an increasing EEsAI score based on a daily diary, >80% adherence to the daily diary, and >90% adherence to the study drug will be randomized. Subjects will be randomized 1:1:1:1 to the three active doses and placebo.

[0233]

[0238] The study will be conducted in three parts as shown in Figures 1 and 2. Parts 1 and 2 are , represents a treatment-withdrawal design. Part 1 will assess the efficacy of treatment. Part 2 will assess the effects of withdrawal, including time to relapse and difference in relapse rate between active treatment and placebo.

[0234]

[0239] Part 1: Treatment (Day 1-Week 14). Subjects were randomly sorted by age (<18 and ≥18 years) Patients will be stratified by CI and by concomitant PPI use during the study (yes or no), and then randomly assigned (ratio 1:1:1:1) to one of four dose groups.

[0235]

[0240] All subjects were to visit the hospital once a month, and if symptoms worsened between visits, Unscheduled visits will be performed at week 14. Subjects will be treated for 12 weeks and undergo EGD to assess histologic and endoscopic improvement. Symptom improvement will be assessed continuously. EoE responders, defined as subjects who achieve a histologic response of <6 peak Eos per HPF, and no worsening of symptoms (e.g., increase in weekly EEsAI score compared to baseline) and no episodes of food impaction, will be randomly assigned again to Part 2 at week 14. Non-responders, defined as subjects who do not meet the definition of response, will receive open-label (OL) 3 mg BID until week 28 and undergo EGD at week 28. EoE responders at the end of the OL period are eligible to enter Part 3. Non-responders to OL treatment will enter a 2-week follow-up period.

[0236]

[0241] Part 2: Treatment and off-drug (weeks 14-28). EoE responders from Part 1 are randomly assigned in a 3:1 randomization to either continue their dose or receive placebo. Few expected placebo responders will continue to use placebo. Subjects who experience worsening symptoms (e.g., return to baseline weekly EEsAI scores or complaints of worsening symptoms) or food impaction will undergo endoscopy at an unscheduled visit. Subjects with food impaction requiring endoscopy or strictures requiring dilation will enter a 2-week follow-up period and withdraw from the study. Subjects who are expected to relapse will return to their previous dose, except those who have continued on placebo to date, who will receive 3 mg BID. Subjects on study drug who relapse will also receive 3 mg BID to avoid unblinding of the study. Relapsers will enter part 3. All subjects in this study will undergo endoscopy at weeks 12, 26, and 52. EoE responders at week 28 will continue into part 3. Non-responders at the end of part 2 will receive 3 mg BID once they enter part 3.

[0237]

[0242] Part 3: Maintenance (Weeks 28-54). Response to open-label 3 mg BID Non-responders from Part 1 will continue on this dose in Part 3. Note that this group will not participate in Part 2. EoE responders from Part 2 will continue on the same dose. Relapsers and non-responders from Part 2 will take 3 mg BID in Part 3. Relapses in Part 3 (e.g., food impaction requiring endoscopy, or clinically significant decline in symptoms) will be considered. Subjects who experience a significant worsening of the disease will undergo an unscheduled endoscopy, enter a 2-week follow-up, and withdraw from the study. All continuing subjects will undergo an endoscopy at Week 52 and complete a final on-treatment visit at Week 54.

[0238]

[0243] Follow-up: (2 weeks after taking the last dose). All subjects were Patients must have had their last endoscopy within 2 weeks. Exceptions include withdrawal of consent for endoscopy or contraindication to endoscopy. Reasons for entry into follow-up included completion of week 54; adverse events requiring early withdrawal, including food impaction requiring endoscopy; failure to respond to open-label 3 mg BID; or relapse in part 3.

[0239]

[0244] Pharmacokinetics: HS should be administered before bedtime or 30 minutes before breakfast. All doses of APT-1011, except for the .5 mg dose, will be administered twice daily, once with breakfast and once 30 minutes prior to bedtime. Population PK analyses will be performed based on a combination of serial and sparse plasma concentration data.

[0240]

[0245] Population PK: Sparse PK samples were collected from all subjects (+ / - 3 days) with multiple doses. In Week 4, on Day 1 (+ / - 3 days) of the repeat dose period, PK samples will be collected within 15 minutes prior to and 0.5, 1.5, and 3 hours after the morning dose. Document the evening dosing time (e.g., bedtime) along with the actual PK sampling time.

[0241]

[0246] Intensive PK subset to be conducted in Part 1: Selected sites: Intensive serial PK sampling of 24 evaluable subjects (6 subjects per dose group) will be performed after the single dose on Day 1 of Week 1, and after the repeat dose on Day 1 (+ / - 3 days) of Week 4. On the morning of Day 1 of Week 1, subjects will take a single dose of APT-1011 and PK samples will be collected within 15 minutes prior to taking the AM dose, and at 0.5, 1, 2, 4, 8, 24, and 48 hours after dose administration. Note: The 48 hour sample should be collected after taking the single dose and before the start of the repeat dose period. This sample will be collected at the visit when the subject returns to receive drug for the repeat dose outpatient period.

[0242]

[0247] The multiple dose period begins on Day 3 of Week 1 after the 48 hour PK sample collection. On Week 4, Day 1 (+ / - 3 days) of the repeat dose period, PK samples will be collected within 15 minutes prior to and 0.5, 1, 2, 4, 8, and 12 hours after the AM dose, and immediately after the PM dose. Note: The 12 hour PK sample after the AM dose is "optional." This 12 hour PK sample should be collected immediately prior to taking the PM dose. Time of dosing (before bedtime the night before and the following morning) will be documented along with the actual PK sampling time.

[0243]

[0248] Study Duration: This study has an expected participant recruitment period of 12 months. Subjects who enter and complete Part 1, Part 2, and Part 3 will remain in the study for up to 15 months.

[0244]

[0249] Study Population: This study included adolescents and young adults diagnosed with EoE who met the inclusion criteria. Approximately 320 adult and adult subjects will be enrolled and randomly assigned to one of four dose groups (including placebo) with 80 subjects per dose group.

[0245]

[0250] Inclusion criteria: Men and women aged between 14 and 75 years, inclusive and female subjects. Patients, including those with recurrence, must have a diagnosis or presumptive diagnosis of EoE, which may be based on symptoms and histological diagnosis; prior to the initial diagnosis; or Later documented high dose (e.g., 40 mg BID) proton pump therapy for 8 weeks or more This must be corroborated by documentation of a history of unsuccessful treatment with prostate cancer inhibitors (PPIs). Lack of response to PI therapy is defined as a peak eosinophil count of ≥ 15 per HPF in at least one biopsy site after 8 weeks of high-dose treatment. Subjects may continue PPI therapy during this study only if they were on PPI therapy at the time of the screening endoscopy biopsy. No new initiation or changes in PPI therapy during this study will be permitted.

[0246]

[0251] Subjects were randomly assigned to receive a biopsy at any esophageal site (≥3 biopsies from each of the proximal and distal esophagus). In at least one of the biopsy specimens (minimum 6 in total), one high power field (HPF, magnification 400 Patients must have evidence of eosinophilic esophagitis, defined as a peak esophageal mucosal eosinophil count of ≥ 15 per 1000 s. Biopsy specimens should be obtained within 30 days prior to the screening visit, and the central pathologist must receive slides within 30 days after the screening visit or 2 weeks prior to randomization. Eligibility is based solely on the central pathologist's assessment.

[0247]

[0252] Subjects were asked to rate their symptoms on a scale of 0 to 10, with 0 representing no symptoms and 10 representing the most severe symptoms. Patients must have a 7-day recall global EoE score of ≥ 5 as measured by the Epidemiological Assessment and Response Assessment (EoE) scale (which represents the state of morbidity and mortality).

[0248]

[0253] Subjects were required to have a 7-day recall EEsAI score of >20 to enter the placebo run-in period. For randomization, subjects must have an increased EEsAI based on a daily diary and clinical symptoms of dysphagia (difficulty swallowing) at least three times per week within two weeks.

[0249]

[0254] Exclusion Criteria: Known contraindication, hypersensitivity or intolerance to corticosteroids; Any medical, mental or social condition, or abnormal medical history or laboratory findings that, in the opinion of the Investigator, may interfere with the study procedures or the subject's ability to comply with and perform the study; the presence of any type of oral or esophageal mucosal infection; any condition affecting the esophageal mucosa or altering esophageal motility other than EoE, including erosive esophagitis, hiatal hernia longer than 3 cm, and Barrett's esophagus; any condition present within 30 days prior to the esophageal biopsy required for entry into this study, or prior to EGD if performed during the prescreening period. use of systemic, oral, or parenteral corticosteroids within 30 days, or inhaled or chronic use of high-potency topical corticosteroids within 30 days; morning (between 0700 and 0800, or as close to that time as possible) serum cortisol level ≤ 5 μg / dL (138 nmol / L); ingestion of grapefruit juice is prohibited during the procedure; adrenocorticotropic hormone (ACTH) stimulation with cosyntropin 250 μg at 60 minutes is required to achieve a serum cortisol level of < 18 μg / mL (497 nmol / L) at 60 minutes. use of biologic immunomodulators within the past 6 months; use of calcineurin inhibitors, purine analogs (azathioprine, 6-mercaptopurine) within the past 3 months; contraindication to EGD or esophageal biopsy, or esophageal stricture precluding EGD with a standard 9 mm endoscope; gastrointestinal bleeding within 1 month prior to the screening visit or between the screening visit and the randomization visit; currently present chronic infection, immunosuppression, or immunodeficiency; history or presence of other inflammatory diseases of the gastrointestinal tract, including Crohn's disease, celiac disease, or eosinophilic gastroenteritis; currently present alcohol or drug abuse; pregnant or breastfeeding women; sexually active women of childbearing potential who do not agree to adhere to a highly effective method of contraception during this study, including the follow-up period (abstinence is acceptable for adolescent girls; female subjects who have undergone artificial menopause or whose menopause has been confirmed by FSH do not require contraception or pregnancy testing during this study); participation in a clinical study involving the investigational drug within 30 days of the screening visit.

[0250]

[0255] The methodology / study procedures are shown in Tables 4-7.

[0251]

[0256] Primary Efficacy Endpoints: EoE response had two coprimary efficacy endpoints: There is an int.

[0257] Subjects with peak eosinophil counts <6 / HPF at all biopsy esophageal locations at week 12 The percentage of patients with EoE who underwent endoscopic surgery and the change from baseline in the weekly mean EEsAI score were assessed. EoE endoscopic response and no deterioration in the weekly mean EEsAI score were the criteria for entry into Part 2.

[0252]

[0258] Secondary efficacy endpoints: placebo and placebo to assess the effects of treatment and withdrawal In comparison, EoE response will also be assessed at week 26. EoE response will also be assessed by dose and subgroup at week 52. EoE remission and response will also be assessed after 12 weeks of OL treatment for non-responders to part 1.

[0253]

[0259] For subjects continuing on the same dose, sustained EoL was observed at 24 and 52 weeks. Evaluate response: assessment of recurrence and treatment failure; non-responders at each endoscopic endpoint; recurrence on placebo in part 2; percentage of subjects by dose and part of the study requiring urgent endoscopic removal of food impaction; percentage of subjects requiring esophageal dilation.

[0254]

[0260] To assess EoE response by treatment group in part 2 relapsers at week 52 The effectiveness of retreatment will be evaluated.

[0255]

[0261] At all major time points assessing EoE response, peak Eos per HPF was < Percent of subjects with 1 and <15.

[0256]

[0262] Weekly mean EEsAI score <20 at all primary time points assessing EoE response A percentage of a given subject.

[0257]

[0263] Endoscopic changes were based on five endoscopic features: edema, groove, exudate, esophageal ring, and stricture. Based on EREFS score based on OL score and physician assessment of global disease activity (absent, mild, moderate, severe); percentage of subjects with "improved," "unchanged," and "worsened" global assessment from baseline (screening visit) at Weeks 12, 26, and 52 and at the end of OL treatment for non-responders from Part 1; change from baseline in 7-day global EoE score assessed before the run-in period, baseline, Weeks 12, 26, and 52.

[0258]

[0264] Pharmacokinetic endpoints: Steady-state population PK (sparse PK and intent PK) Single-dose PK analysis; single-dose PK analysis.

[0259]

[0265] Exploratory endpoints: assessing change from baseline in all Collin's histological score for EoE on biopsy; dose- and subgroup-specific assessment of quality of life based on EoE-QOL-A at weeks 12, 26, 52 and 12 of OL treatment; patient assessment of symptoms compared to previous visits. This question will be assessed at weeks 8, 12, 18, 26, 30 and 52.

[0260]

[0266] Safety: All treatment-emergent adverse events (TEAEs), TEAEs leading to withdrawal, and Safety will be assessed by monitoring and recording adverse events (AEs) and serious adverse events (SAEs). All TEAEs will be coded according to the MedDRA version 14.0 adverse event (AE) classification and classified by the investigator according to severity (mild, moderate, severe) and relationship to study drug (related or unrelated). TEAEs occurring within 2 days of a dose change will be attributed to the previous dose. This attribution period may vary based on the half-life of that dose. A physical examination will be performed to document the subject's baseline condition and to highlight any changes related to AEs. Vital signs will also be recorded. Patients will be assessed at each visit and clinically significant deviations will be reported.

[0261]

[0267] Hematology, blood chemistry, urinalysis, and electrocardiogram as shown in the evaluation schedule. Routine laboratory tests, including electrocardiograms (ECG), will be performed throughout the study. Laboratory tests or ECG Summarize clinically significant changes in

[0262]

[0268] Cortisol problems: abnormal AM cortisol, urine sugar or serum glucose Subjects should be followed until resolution. The CRF should document the presence or absence of known glucocorticoid AEs, such as moon face, acne, hirsutism, mood swings, insomnia, or depression. The ICF should emphasize that stress steroids may be required during significant medical illness. ACTH stimulation tests (cosyntropin 250 mcg) should be performed for all subjects at baseline and at week 12, early withdrawal, and week 52. ACTH tests should be performed for all subjects with plasma cortisol >5 mcg / dL (138 mmol / L). All subjects with positive tests should be excluded. Any positive results at the end of treatment should be followed until restoration of adrenal function. The number of subjects discontinuing due to HPA suppression or positive ACTH stimulation tests will be summarized. The sponsor will provide safety follow-up guidelines to each site and investigator and will document recovery of adrenal function for all subjects demonstrating evidence of hyperadrenocorticism or HPA axis suppression during the course of the study. Subjects aged 18 years or younger will be monitored for growth parameters, e.g., height, weight, body mass index (BMI) and corresponding z-scores. The safety endpoints of interest were the incidence of treatment-emergent adverse events (TEAEs), TEAEs leading to withdrawal, and treatment-emergent serious adverse events (SAEs), as well as serum corticosteroids. The percentage of subjects with cortisol levels ≦5 μg / dL (138 nmol / L) or a positive ACTH stimulation test (serum cortisol <18 μg / mL (497 nmol / L) at 60 minutes) will be recorded. The number of subjects discontinued due to HPA axis suppression will be recorded.

[0263]

[0269] Statistical Methods: Sample Size Determination: Part 1 Sample Size Determination , based on planned comparisons between each dose group for the following EOE responses: 1) percentage of subjects with peak eosinophil counts <6 eosinophils / HPF at all biopsy esophageal locations at week 12, and 2) change from baseline in EEsAI score. For this study, assuming that the percentage of placebo-treated subjects with peak eosinophil counts <6 / HPF at all biopsy esophageal locations after 12 weeks of treatment is 15% for placebo and 60% for the active arm, a difference of 45 would be expected. For weekly mean EEsAI score, symptomatic EoE response at week 12, we would expect a 65% efficacy in the active arm, assuming a placebo rate of 35%, a difference of 30%. Based on comparable randomization, approximately 60% of subjects would enter part 2 of the study. To ensure that the sample size is sufficient to detect a 30% difference in part 1, and to ensure that enough subjects are included in part 2 to analyze, a minimum of 320 subjects (80 per group) will be enrolled, assuming 20% ​​active and 80% placebo will develop symptomatic relapse. With 320 per group and assuming a 20% guess and overall dropout rate, we expect approximately 35 subjects per active group to be evaluable for assessment of sustained remission at week 52.

[0264]

[0270] The primary efficacy analysis population was defined as all randomized subjects. The safety analysis population consisted of at least 1 The safety analysis population is defined as all subjects receiving any dose of study drug in the Part 1 ITT analysis population. The single-dose PK analysis population is defined as all subjects in the Part 1 ITT analysis population who were randomly assigned to one of the three APT-1011 dosing arms, received their first dose of APT-1011, and have at least one PK sample included in the final unit dose population PK analysis. The steady-state PK analysis population is defined as all subjects in the Part 1 ITT analysis population who were randomly assigned to one of the three APT-1011 arms, received their first dose of APT-1011, and have at least one PK sample included in the final unit dose population PK analysis. Part 1 is defined as all subjects in the ITT analysis population who are assigned and take their APT-1011 dose corresponding to the steady-state PK sampling period and have at least one PK sample included in the final steady-state population PK analysis. An additional per-protocol analysis population who complete Parts 1, 2, and 3 and OL treatment may be defined in the statistical analysis plan (SAP). Descriptive statistics will be used to analyze continuous and ordinal variables (e.g., Baseline and demographic information will be summarized for numbers and percentages of subjects (age, weight, height), as well as categorical variables (eg, sex, race).

[0265]

[0271] Primary efficacy in part 1

[0272] Part 1 has two co-primary efficacy endpoints: The percentage of subjects with peak eosinophil counts <6 / HPF at all biopsy esophageal locations, and the change from baseline in average weekly EEsAI scores at Week 12. To keep the overall significance level of this study at 0.05, each of the two co-primary efficacy endpoints will be assessed at the 0.05 level.

[0266]

[0273] For each coprimary endpoint, the primary treatment comparison of interest was The comparison is to one dose group versus placebo. The hypothesis of efficacy of APT-1011 versus placebo will be tested in the following order:

[0274] H0: μ of APT-1011 3.0 mg BID = μ of placebo

[0275] H0: μ of APT-1011 1.5mg BID = μ of placebo

[0276] H0: μ of APT-1011 1.5mg HS = μ of placebo

[0277] where μ is the total number of patients at week 12 for one coprimary efficacy endpoint. shows the proportion of subjects with peak eosinophil counts <15 / HPF at each biopsy esophageal location, and μ shows the change from baseline in weekly mean EEsAI score at Week 12 for the other co-primary efficacy endpoint.

[0267]

[0278] Statistical tests were performed to evaluate the efficacy and safety of APT-1 for each of the two co-primary efficacy endpoints. The study begins with a comparison of APT-1011 3.0 mg BID versus placebo. If both comparisons are statistically significant at the 0.05 level, the next lower dose is tested versus placebo for both co-primary efficacy endpoints. This procedure stops when the first pairwise comparison produces a statistically non-significant result for one or both of the co-primary efficacy endpoints. Statistical testing of treatment differences between APT-1011 and placebo will be driven by a priori ordering assumptions and therefore will not require adjustment of significance levels for multiplicity.

[0268]

[0279] Subjects with peak eosinophil counts <6 / HPF at all biopsy esophageal locations at week 12 Pairwise comparisons between each APT-1011 arm and placebo for the proportion of patients with ≥ 18% CI, 0.01 to 0.05% were performed using the Cochran-Mantel-Haenszel (CMH) test, adjusting for the two randomization stratification factors of age group and PPI use, as well as geographic region (North America; non-North America). Pairwise comparisons between each APT-1011 group and placebo for change from baseline in weekly mean EEsAI score at week 12 are performed by comparing corresponding least squares means from an analysis of covariance (ANCOVA), with treatment, the two randomization stratification factors, and geographic region as fixed effects in the model, and baseline SQ score as a covariate. This method is used to adjust for multiple comparisons. Sample sizes were increased accordingly.

[0269]

[0280] At least one of the APT-1011 dose groups demonstrated superiority over placebo in 2 If one coprimary endpoint is demonstrated, the dose-response relationship will be assessed for the two coprimary endpoints with total daily dose among the explanatory variables in an appropriate statistical model.

[0270]

[0281] Efficacy of OL treatment

[0282] For non-responders from Part 1 receiving OL treatment at 3.0 mg BID, Take a similar approach to part 1.

[0271]

[0283] Primary efficacy in part 2

[0284] Part 2 includes subjects who relapse at or before the end of double-blind treatment in Part 2. There is one primary endpoint, percentage of patients with relapse, with relapse defined as return to baseline EEsAI score or verbal complaint of "my symptoms are worse and are about the same as when I entered the study" and peak eosinophil count ≥ 15 / HPF in at least one biopsied esophageal site at or before the end of Part 2 assessment at Week 26. To maintain an overall significance level of 0.05 for the study, statistical testing of efficacy endpoints in Part 2 will be performed only if statistical significance versus placebo in favor of at least one APT-1011 dose group is demonstrated for the two Part 1 coprimary efficacy endpoints. The efficacy hypotheses for APT-1011 3.0 mg QD versus placebo are as follows:

[0285] H0: μ of APT-1011 3.0 mg QD = μ of placebo

[0286] (where μ is the mean mean of relapse at or before the end of 12 weeks of blinded treatment in Part 2) (The proportion of subjects who received 1.5 mg QD, 1.5 mg BID, and 3.0 mg BID in Part 1 are shown.) This test is performed using the CMH test, adjusting for two randomization stratification factors (from Part 1): geographic region, and the previous treatment that the subject received before randomly assigned to double-blind treatment in Part 2. Previous treatments are placebo, APT-1011 1.5 mg QD, 1.5 mg BID, and 3.0 mg BID in Part 1 for subjects randomly assigned to the treatment.

[0272]

[0287] Part 3 Effectiveness

[0288] Patients who achieved EoE response in Part 1 and Part 2 will be evaluated at Week 52. For the subgroup of subjects who complete, sustained EoE response will be assessed.

[0273]

[0289] Secondary and preliminary efficacy results

[0290] Statistical tests comparing each APT-1011 treatment group with placebo were performed as secondary efficacy endpoints. Results will be analyzed for efficacy endpoints, but the corresponding p-values ​​will be considered descriptive rather than inferential. Secondary endpoints will be analyzed in the same manner as described above for the primary efficacy endpoints, i.e., using the CMH test for categorical endpoints and ANCOVA for change or percentage change from baseline endpoints, except for the endpoint of time to relapse after initiation of double-blind treatment in Part 2, which will be analyzed using the Kaplan-Meier method. No statistical testing of exploratory efficacy endpoints will be performed.

[0274]

[0291] safety

[0292] Summarize the incidence of TEAEs by system organ class and preferred term. Separate summaries will be provided by risk and relationship to study drug. The incidence of TEAEs leading to withdrawal from the study and treatment-emergent SAEs will also be summarized. For subjects who change dose groups, TEAEs will be attributed to the previous dose if they occurred within 2 days of the change. This attributable period may vary depending on the half-life of that dose. Potential clinically interesting and clinically significant changes in laboratory tests, including hematology, chemistry, urinalysis, ECG, cortisol, vital signs, growth-related assessments for adolescents, and bone mineral density will be summarized. No statistical testing of safety endpoints will be performed. Shift tables will be performed as appropriate.

[0275]

[0293] Pharmacokinetic and pharmacodynamic analysis

[0294] The study compared daily 1.5 mg QD before bedtime with a prothrombin time of 1.5 mg after breakfast. All doses of APT-1011, except for placebo, were administered twice daily (before breakfast and at bedtime) A population PK analysis will be performed based on a combination of serial and sparse plasma concentration data. Historical serial PK data for APT-1011 may be included in this analysis to facilitate development of a base PK model.

[0276]

[0295] Nonlinear mixed effects software, NONMEM, version 7.2.0 or later version (ICON Development Solutions, Ellicott City, MD), or other A population PK analysis will be performed using an appropriate nonlinear mixed-effects modeling software. The structural PK model will include CL / F and V / F as fixed effect parameters. In addition, subject-to-subject (intersubject) variability in parameter estimates and random residuals in the data will be estimated with an appropriate error model. The optimal base model will be selected according to standard criteria such as minimum objective function value and diagnostic plots. Given the relatively small number of subjects in this study, no covariate analysis is planned. Relevant information (e.g., dose and sampling times) will be extracted from the bioanalytical and clinical databases and integrated for the generation of the population PK input file. Every effort possible will be made to obtain any missing information. Any additional information obtained regarding missing data, and the procedures followed to handle any missing data will be recorded and discussed in the clinical study report. After the final model is constructed, secondary parameters such as AUC and Cmax will be calculated to characterize the extent of FP systemic exposure. Further simulations may be performed, if necessary, to inform decisions made for future studies. In general, the simulation process involves running a simulation with a desired number of iterations using dummy subjects with the desired sampling times and dosing regimens and the final model output parameters in the control file to generate a data file. Generate outputs from the final population model, including appropriate diagnostic plots, lists, and summaries of PK parameters. Additionally, generate graphical and tabular representations of any PK simulations.

[0277]

[0296] If data permit, we will evaluate the relationship between systemic exposure to FPs and changes in cortisol levels. Exploratory analyses to determine the optimal dose for each study can also be performed as described above. Potential exploratory PK / PD analyses can be used to facilitate selection of a safe and effective dose for future studies.

[0278] [Table 4-1]

[0279] [Table 4-2]

[0280] [Table 4-3]

[0281] [Table 5]

[0282] [Table 6]

[0283] [Table 7-1]

[0284] [Table 7-2]

[0285] Example 2 - Randomized, double-blind, placebo-controlled trial of fluticasone propionate orally disintegrating tablets in adult and adolescent patients with eosinophilic esophagitis: A phase 1 / 2a safety and tolerability study

[0297] BACKGROUND AND OBJECTIVE: Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by the presence of tissue eosinophilia and symptoms of esophageal dysfunction. This is a randomized controlled trial comparing two dosing regimens of APT-1011 with placebo (PBO) in adolescent and adult patients with EoE. This was the first clinical study to evaluate the tolerability and safety of APT-1011, a novel orally disintegrating tablet (ODT) of fluticasone propionate (FP).

[0286]

[0298] Methods: Subjects were randomized to receive APT-1011 1.5 mg BID (n=8). Patients were randomly assigned 1:1:1 to receive either APT-1011 3.0 mg QD (n=8), or PBO (n=8). Patients underwent esophagogastroduodenoscopy (EGD) and esophageal biopsy at baseline (BL) and end of treatment [EOT] (week 8) to assess change in median eosinophil count. Secondary endpoints were progression-free survival (PFS) and progression-free survival (PFS) in patients with EoE. Patients with regard to endoscopic characteristics and disease severity as determined by the Endoscopic Reference Score (EREFS) The study included improvements in the comprehensive assessment (PatGA). Safety was also assessed.

[0287]

[0299] Results: Twenty-four subjects (including nine adolescent patients, three in each treatment group) underwent an 8-week double The blinded period was completed. Baseline and EOT esophageal eosinophil counts (cells / high power field mm) for the PBO, BID, and QD groups 2 ) and median EREFS scores, as well as median PatGA, are shown (Table 8). At EOT, median esophageal eosinophil counts were significantly reduced from BL in biopsies from patients receiving APT-1011 (both regimens), but not in biopsies from patients receiving placebo. There was a significant reduction in median EREFS (compared to BL) of one in both patient groups receiving APT-1011, but not placebo. There was a significant improvement (trend in the QD group) in Patient Global Assessment of Disease Severity in patients receiving APT-1011 BID, but not placebo. Table 8 shows median esophageal eosinophil counts (and IQR) and median EREFS scores. <0. A p-value of .05 is considered significant.

[0288] [Table 8]

[0289]

[0300] Treatment-emergent adverse event (TEAE) rates were 75% (PBO) and 75% (APT-1011) (QD). All TEAEs were mild in intensity, except for one subject in the placebo group who reported moderate fatigue and one subject who reported moderate depression.

[0290]

[0301] Conclusion: Eight weeks of treatment with APT-1011 was well tolerated. The use of APT-1011 in adolescent patients with EoE resulted in a significant reduction in esophageal eosinophilia and improvement in the severity of EoE-associated endoscopic findings.

[0291] Example 3 - Effect of APT-1011 on Adolescents and Adults with Eosinophilic Esophagitis (EoE) Randomized, double-blind, placebo-controlled, dose-ranging and maintenance study

[0302] Primary Objective: To evaluate the efficacy of APT-1011 in adolescents and adults with eosinophilic esophagitis (EoE).

[0292]

[0303] Secondary Objective: Safety of APT-1011 in Adolescents and Adults with EoE to evaluate the efficacy and long-term safety of APT-1011 in patients with EoE; to define the dose-response of APT-1011; to select a dose for Phase 3; to evaluate the individual pharmacokinetics of APT-1011 in a subset of adolescents and adults with EoE; to evaluate the population pharmacokinetics (PopPK) of APT-1011 in patients with EoE; To evaluate the effect on endoscopic appearance using the Endoscopic Reference Scores (EREFs) (Hirano 2015; van Rhijn 2014); to assess change from baseline in the 7-day EEsAI and global EoE symptom score.

[0293]

[0304] Safety Objective: To evaluate the safety profile of acute and chronic administration of FP and HP systems. To determine its effect on

[0294]

[0305] Exploratory objective: EoE Histopathological Scoring System (EoEHSS) from baseline To assess change in EoE score (Collins 2016); to assess quality of life with the Eosinophilic Esophagitis Quality of Life Questionnaire in Adults (EoE-QoL-A) (Taft 2011); to evaluate symptoms (7 scales) compared to previous visits; to evaluate PK / PD (cortisol) and exposure-response (efficacy) relationships.

[0295]

[0306] Rationale: A detailed investigation of doses of 1.5mg HS to 3.0mg BID To define the exposure-response of APT-1011 and to define the minimally effective dose without achieving any clinically significant hypothalamic-pituitary-adrenal (HPA) axis effects.

[0296]

[0307] Study design

[0308] This was a 1.5 mg study in 320 adults and adolescents with EoE. This is a randomized, double-blind, placebo-controlled, dose-ranging study of three total daily doses of APT-1011 (1.5, 3, and 6 mg) administered as HS, 1.5 mg BID, and 3.0 mg BID, compared with matching placebo doses. Maintenance of efficacy and long-term safety will also be evaluated.

[0297]

[0309] Eligible subjects were aged 14-75 years (inclusive) and had been Failure of high-dose (i.e., twice-daily) proton pump inhibitors (PPIs) Subjects must have a diagnosis of EoE (≧15 peak Eos per HPF) after certification. Subjects who have not had an appropriate trial of PPI therapy must have this trial done prior to screening for this study. Subjects may continue PPI therapy during this study only if they were on PPI therapy at the time of signing informed consent. No new initiation or change of PPI therapy during this study is permitted. Subjects must also exhibit symptoms of dysphagia, have a 7-day recall global EoE symptom score of >3 to enter the 2-week baseline symptom assessment, and report at least 3 dysphagia episodes in the past 7 days, and report no exclusion requirements for this study. Subjects must report at least 3 dysphagia episodes per week in each of the 2 weeks of baseline symptom assessment in the daily diary to be eligible for randomization.

[0298]

[0310] In Part 1, subjects were divided by age (<18 and ≥18 years) and by P Patients will be stratified by concomitant PI therapy (yes or no) and then randomly assigned (ratio (1.7):1:1:1) to one of four treatment arms.

[0299]

[0311] All subjects were to visit the hospital once a month, and if symptoms worsened between visits, Unscheduled visits are made to the hospital.

[0300]

[0312] This study will be carried out in several parts:

[0313] screening:

[0314] 1-4 weeks including upper endoscopy (EGD)

[0315] Baseline Symptom Assessment: 2 weeks

[0316] A global EoE symptom score of >3 and at least 3 swallowing episodes in the past 7 days If a participant reports a disability episode and there are no exclusion requirements for this study, a baseline symptom assessment can be entered.

[0301]

[0317] Randomization: Randomized subjects were randomized to receive either 2x the baseline symptom ratings in a daily diary. Patients must report at least 3 dysphagia episodes per week for each week of the study, have >75% daily diary compliance, have ≥15 peak Eos per HPF, and meet all other inclusion and exclusion criteria. Subjects will be randomized 1.7:3 to placebo vs. active dose. Response-adaptive randomization will be used between active doses, updated at each interim analysis.

[0302]

[0318] Subjects will be stratified by age and current PPI use.

[0303]

[0319] The overall protocol is shown in Figures 3 and 4. Part 1 is the induction of the EoE response. and parts 2 and 3 assess maintenance.

[0304]

[0320] Open-label treatment will be administered to non-responders in Part 1.

[0305]

[0321] Part 1: Treatment (Day 1-Week 14)

[0322] Subjects will be treated for 12 weeks and undergo EGD to assess histological and endoscopic improvement. Symptom improvement will be assessed continuously. EoE responders, defined as subjects who achieve a histologic response of ≦6 peak Eos per HPF, and no worsening of symptoms (i.e., no increase in dysphagia based on daily diary compared to baseline) and no episodes of food impaction, will enter Part 2 Maintenance at Week 14. This part will incorporate adaptive sample sizes and response-adaptive randomization into active arms. Frequent interim analyses will be performed after randomization of 160 subjects, at which randomization probabilities will be revised and early stopping criteria will be evaluated.

[0306]

[0323] Open label (OL) treatment (weeks 14-28)

[0324] Non-responders at week 14 (those without histological response and / or those with dysphagia) Subjects with a worsening of the harm will receive open label (OL) 3 mg BID until week 28 along with an EGD at week 28, after which if they are responders (same definition as above) at the end of the OL period, they will be eligible to enter part 3. Non-responders to OL treatment will enter a 2-week follow-up period and then be withdrawn from the study.

[0307]

[0325] Part 2: Maintenance (Weeks 14-28)

[0326] EoE responders from Part 1 (with histological response and no worsening of dysphagia) They will continue to use the same dose as in Part 1. Placebo responders, who are expected to be few, will continue to use placebo. Worsening of either dysphagia or food impaction will prompt endoscopy at an unscheduled visit. After endoscopy, all "relapsers" will immediately enter Part 3, except those with food impaction requiring endoscopy or strictures requiring dilation. Subjects with food impaction requiring endoscopy or strictures requiring dilation will enter a 2-week follow-up period and then withdraw from the study. All subjects in this study will undergo endoscopy at week 26. EoE responders at week 28 will continue into Part 3. Non-responders at the end of Part 2, or early relapsers, will take 3 mg BID once they enter Part 3.

[0308]

[0327] Part 3: Maintenance (Weeks 28-54)

[0328] Non-responders from Part 1 who respond to open-label 3 mg BID will be enrolled in Part 3. The subjects will continue to receive the dose of 10 mg / kg / day. Note that this group will not participate in Part 2.

[0309]

[0329] EoE responders from Part 2 will continue to use the same dose.

[0310]

[0330] Non-responders and early relapsers from part 2 were randomized to open-label 3 mg B Get your ID.

[0311]

[0331] Recurrence in Part 3 (food impaction requiring endoscopy or clinical symptoms) Subjects with significant recurrent symptoms will undergo unscheduled endoscopy, enter a 2-week follow-up, and be withdrawn from the study.

[0312]

[0332] All continuing subjects underwent endoscopy at week 52 and final opioid intake at week 54. Complete a treatment visit.

[0313]

[0333] Follow-up (2 weeks after last dose)

[0334] All subjects were required to have their last endoscopy within 3 weeks prior to follow-up. Exceptions include withdrawal of consent for endoscopy or contraindication to endoscopy. Reasons for entry into follow-up: completed week 54; adverse events requiring early withdrawal including food impaction requiring endoscopy; failure to respond to open-label 3 mg BID; relapse in part 3.

[0314]

[0335] Pharmacokinetics: This study included doses of APT-1011 at 1.5mg BID and 3. The 0 mg BID dose is administered at least 30 minutes after breakfast and before bedtime (at least 2 hours after dinner). The 1.5 mg dose is administered before bedtime (at least 2 hours after dinner). Subjects taking the 1.5 mg dose take a placebo in the morning at least 30 minutes after breakfast. No food or drink is permitted for at least 1 hour after dosing.

[0315]

[0336] Intensive PK sampling from a subset of subjects and sampling from the remaining subjects A combination of per-sample PK sampling will be collected to characterize FP exposure in the patient population. Non-compartmental analysis (NCA) will be performed on the intensive PK data to Population PK analysis will be performed based on a combination of sparse and sequential plasma concentration data.

[0316]

[0337] Intensive PK: A subset of adult subjects (1 year) in a pre-specified PK facility Intensive PK serial sampling will be performed at baseline and steady state in a subset of adolescent subjects (approximately 5 per dose group) and in adolescent subjects (8 per dose group). These subjects will receive their daily doses (both tablets) on day 1. Blood samples for determination of fluticasone plasma concentrations will be collected prior to dosing on days 1 and week 4 and at 0.5, 1, 2, 4, 8, and 12 hours after taking the morning dose. If subjects are unable to stay for 12 hours on week 4, steady state samples may be collected at the week 8 or week 12 visit. The collection of intensive PK samples over 12 hours is related to the BID dosing schedule and the need to avoid hospital stays for these EoE patients.

[0317]

[0338] Sparse PK: All adult and adolescent subjects (intensive PK subset) Sparse PK samples will be collected from all subjects (except for subjects with a low dose of 100 mg / kg / day) at the time of dosing the previous night (before going to bed the night before), and at the time of the morning dose. A baseline pre-dose sample will be collected prior to dosing on Day 1. At weeks 4, 8, and 12 of the repeat dose, subjects will take their AM dose at home and have two samples taken during their scheduled clinic visits. One sample will be collected upon arrival at the site, and the other 1-1.5 hours later, immediately prior to leaving the site. Record the time of day (day of planned visit). Also document the actual PK sampling time. Sites are encouraged to vary site visits throughout the day. Due to variability in site visits, sparse PK samples will be taken to generally cover the majority of the 12-hour post-dose period.

[0318]

[0339] Study Duration: This study has an expected recruitment period of approximately 12-18 months. Subjects who enter and complete the study (Part 1, Part 2, and Part 3) will remain in the study for up to 14 months.

[0319]

[0340] Study Population: This study will involve adult subjects diagnosed with EoE who meet the inclusion criteria. An adaptive sample size ranging from 60 to 320 subjects will be used. The study is expected to enroll approximately 25% female and 5% geriatric subjects.

[0320]

[0341] Inclusion Criteria:

[0342] Males and females aged ≥14 and ≤75 years at the time of informed consent elephant.

[0321]

[0343] Have signed an Informed Consent Form (ICF) (which must be signed by a parent or guardian, if applicable) and an Assented Form (required for adolescents under 18 years of age or the age of legal majority according to local law) and are willing and able to comply with all procedures.

[0322]

[0344] A diagnosis or presumptive diagnosis of EoE, which is made by symptoms and histological examination, and High-dose proton pump inhibitors (PPIs) for 8 weeks or more (i.e., 20 mg BID carbazole or 20–40 mg BID of a licensed prescription PPI. Maintenance or OTC doses are too low This must be corroborated by documentation of a history of treatment failure with a PPI (including those listed in Table 1), documentation of PPI failure before the first diagnosis, or documentation of PPI failure at screening. Lack of response to PPI treatment is defined as a peak eosinophil count ≥ 15 / HPF in at least one biopsy site after 8 weeks of high-dose treatment. Subjects may continue PPI treatment during the study only if they were on PPI treatment at the time of biopsy for screening endoscopy. Subjects on PPI treatment may stop PPI treatment after endoscopy or have their dose reduced if this is before the baseline run-in period. After this dose change, subjects must continue using a stable dose thereafter. Once a PPI is stopped, it cannot be started again. No new initiations or changes in PPI treatment are permitted during the study.

[0323]

[0345] Esophageal sites where biopsies were performed (≥3 biopsies from each of the proximal and distal esophagus; total At least one high power field (HPF, magnification 400x (0 .3mm 2 Evidence of eosinophilic esophagitis defined by a peak esophageal mucosal eosinophil count of ≥ 15 per 1000 mg / day. Additional mid-esophageal biopsy specimens may be taken at the discretion of the investigator. If biopsy specimens are taken, they must be received by the central pathologist within 30 days after the screening visit or 2 weeks prior to randomization and before the start of the baseline period. Eligibility is based solely on central pathologist assessment. Optional biopsy specimens may be taken and processed locally for local use if specified in the local ICF. Subjects must have a 7-day recall global EoE score of > 3; subjects must report at least 3 dysphagia episodes per week in each week of baseline symptom assessment; and must be willing and able to comply with study-related treatment regimens, procedures, and visit schedules.

[0324]

[0346] Exclusion criteria: known contraindication, hypersensitivity or intolerance to corticosteroids. Any medical, mental or social condition, abnormal medical history or laboratory findings that, in the judgment of the Investigator, may interfere with the study procedures or the subject's ability to comply with and perform in the study. Presence of any type of oral or esophageal mucosal infection. Any oral or dental condition that interferes with normal feeding. Any condition affecting the esophageal mucosa or altering esophageal motility other than EoE, including erosive esophagitis (LA grade B or greater), hiatal hernia longer than 3 cm, Barrett's esophagus and achalasia. Prior to esophageal biopsy required for entry into the study; prior to EGD if performed during the prescreening period, use of systemic, oral or parenteral corticosteroids within 30 days, or inhaled or chronic use of high-potency cutaneous topical corticosteroids within 30 days. Use of swallowing / topical steroids within 30 days. Initiation of an elimination diet or elemental diet within 30 days of screening. No dietary therapy may be initiated during the study. Morning (0700-0800 hours, or as close to these hours as possible) serum cortisol level ≤ 5 μg / dL (138 nmol / L). Serum cortisol level < 18 μg / mL (497 nmol / L) at 60 minutes using an adrenocorticotropic hormone (ACTH) stimulation test using cosyntropin 250 μg. Intake of grapefruit juice is prohibited during the procedure. Use of biological immunomodulators within the past 6 months. Use of calcineurin inhibitors, purine analogs (azathioprine, 6-mercaptopurine) within the past 3 months. Contraindications to esophageal, gastroduodenal endoscopy (EGD) or esophageal biopsy, or standard Esophageal stricture precluding EGD with a standard 9 mm endoscope. Overt gastrointestinal bleeding within 1 month prior to the screening visit or between the screening and randomization visits. Current chronic infection, immunosuppression, or immunodeficiency. History or presence of other inflammatory diseases of the gastrointestinal tract, including Crohn's disease, celiac disease, or eosinophilic gastroenteritis. Current alcohol or drug abuse. Pregnant or breastfeeding women. Sexually active women of childbearing potential who do not agree to use highly effective contraception during the study, including the follow-up period. Abstinence is acceptable for adolescent girls. Women who have undergone artificial menopause or whose menopause has been confirmed by FSH do not require contraception or pregnancy testing during the study. Participation in a clinical study involving the investigational drug within 30 days of the screening visit.

[0325]

[0347] Study Drug Administration: Three dose groups were administered APT-1011 (fluroic acid propionate) Cazone, ODT) will be provided as blinded tablets in active ingredient strengths of 1.5 mg and 3.0 mg. There will be a matching dose of placebo for the fourth dose group. Tablets will be administered BID - 30 minutes after breakfast and at least 2 hours after dinner, HS (before bedtime). Note that subjects in the 1.5 mg dose group will take a placebo tablet 30 minutes after breakfast and will take 1.5 mg APT-1011 HS. To maintain blinding, all tablets will be labeled for "after breakfast" or "before bedtime" administration. Subjects should not eat or drink for 1 hour after study drug administration. The bedtime dose should be administered after all beverages and snacks, as well as brushing teeth, and immediately prior to going to bed.

[0326]

[0348] Primary Efficacy Endpoint at Week 12:

[0349] EoE Response has two co-primary efficacy endpoints: all biopsies Peak eosinophil count ≤6 / HPF at esophageal location, and change from baseline in dysphagia episodes over the past 14 days.

[0327]

[0350] Secondary Efficacy Endpoints:

[0351] Change from baseline in dysphagia-free days over the past 14 days; EoE persistence Endoscopic response will be assessed using co-primary endpoints at weeks 26 and 52; change from baseline in 7-day global EoE score will be assessed prior to baseline symptom assessment, at baseline, weeks 12, 26 and 52. 7-day global EoE score will be assessed at each visit. Change from baseline in EREFS score at weeks 12, 26 and 52. Endoscopic change will be based on the EREFS score, which is based on five endoscopic features: edema, groove, exudate, esophageal ring, stricture. Peak EoE per HPF was assessed at all primary time points to assess EoE response. Percentage of subjects with a s <1 and <15. Change from baseline in 7-day EEsAI scores and percent of subjects with weekly average EEsAI scores <20 and change from baseline in subscores will be assessed at weeks 12, 26 and 52. 7-day EEsAI scores will be assessed at each visit.

[0328]

[0352] Assessment of recurrence and treatment failure: (a) Non-responders at each endoscopy time point. (b) Percentage of subjects requiring emergency endoscopic removal of food impaction by dose and study part. (c) Percentage of subjects requiring esophageal dilation.

[0329]

[0353] OL treatment: EoE after 12 weeks of OL treatment for non-responders to Part 1 Responses (coprimaries above) are also rated.

[0330]

[0354] Pharmacokinetic endpoints

[0355] For subjects who underwent intensive PK sampling, non-pharmacokinetic (NP) Compartmental methods are used to calculate the following PK parameters: Cmax, Tmax, AUC 0~12 , CLss / F and cumulative ratio.

[0331]

[0356] Population pharmacokinetic parameters, including oral clearance (CL / F) and volume of distribution (V / F), will be estimated if data permits. If necessary, additional parameters will be estimated based on the final structural pharmacokinetic model.

[0332]

[0357] Preliminary Endpoints:

[0358] EoE tissue diagnosis scoring system for all biopsies performed. Baseline To assess change from baseline. Quality of life assessment based on EoE-QoL-A by dose and subgroup at weeks 12, 26, 52, and at week 12 of OL treatment. Patient assessment of symptoms compared to previous visits. This question will be assessed at weeks 8, 12, 18, 26, 36 and 52. Assessment of PK / PD (cortisol) and exposure-response (efficacy) relationships.

[0333]

[0359] Safety endpoints: All treatment-emergent adverse events (TEAEs), including those leading to withdrawal Safety is ensured by monitoring and recording any TEAEs or serious adverse events (SAEs) that may occur. All TEAEs will be coded according to the MedDRA version 14.0 classification of adverse events (AEs) and classified by the investigator according to severity (mild, moderate, severe) and relevance to the study drug (related or unrelated). TEAEs occurring within 3 days of a dose change will be attributed to the previous dose. A physical examination will be performed to document the subject's baseline condition and to highlight any changes related to AEs. Vital signs will also be assessed at all visits and any clinically significant deviations will be reported.

[0334]

[0360] Hematology, blood chemistry, urinalysis, and electrocardiogram as shown in the evaluation schedule. Routine laboratory tests, including electrocardiograms (ECG), will be performed throughout the study. Laboratory tests or ECG Summarize clinically significant changes in

[0335]

[0361] Cortisol problems: abnormal AM cortisol, urine sugar or serum glucose Subjects should be followed until resolution. The CRF should document the presence or absence of known glucocorticoid AEs, such as moon face, acne, hirsutism, mood swings, insomnia, or depression. The ICF should emphasize that stress steroids may be required during significant medical illness. ACTH stimulation tests (cosyntropin 250 mcg) should be performed for all subjects at baseline and at week 12, early withdrawal, and week 52. AM serum cortisol >5 mcg / dL (138 mmol / L ACTH testing should be performed on all subjects who are overweight or obese. All subjects with a positive test should be excluded. Any positive results at the end of treatment should be followed up until restoration of adrenal function. The number of subjects who are discontinued due to HPA suppression or a positive ACTH stimulation test will be summarized. Subjects under 18 years of age will be evaluated for growth parameters, e.g., height, weight, body mass index (BMI) and corresponding z-scores. Linear growth is not complete. For adolescents under the age of 18, Tanner stage and bone age are also determined.

[0336]

[0362] The safety endpoints of interest were treatment-emergent adverse events (TEAEs), events leading to withdrawal, and The incidence of TEAEs and treatment-emergent serious adverse events (SAEs) and serum corticosteroids were The percentage of subjects with HPA axis suppression is recorded.

[0337]

[0363] Statistical methods:

[0364] Sample size determination

[0365] Part 1 will include an adaptive sample size ranging between 160 and 320 adult patients. The trial will include randomization of at least 160 subjects followed by frequent interim analyses to assess criteria for success and futility. If evidence of treatment efficacy on the coprimary outcomes is sufficiently low, the trial may be stopped early for futility. If the predicted probability of obtaining sufficient evidence to demonstrate treatment efficacy is very high, the trial may cease recruitment as success is anticipated, with a final analysis when all enrolled patients have completed 12 weeks of follow-up (Broglio 2014). Simulations will be used to estimate expected sample sizes, type I errors, and statistical tests under various assumed treatment profiles (specified in the SAP). Calculate the output.

[0338]

[0366] Approximately 60% of subjects are expected to enter Part 2 of the study. Given that there will be a minimum of 102 patients on treatment, at least 61 patients are expected to enter part 2. Approximately 17 placebo responders are expected to enter part 2. It is expected that 70% of placebo responders and approximately 20% of those on active treatment may relapse before week 26. Approximately 82 subjects on active treatment are expected to enter part 3.

[0339]

[0367] In addition, there were few subjects in the active treatment group, assuming a 20% dropout rate to Part 3. At least 66 patients (22 per dose) are expected to be available to assess sustained remission at week 52, with at least 4 expected for control. This provides a minimum expected power of 73% for a comparison of 80% vs. 20% sustained remission rates for each active dose vs. control, and 80% for a comparison of pooled active treatment remission rates vs. control. However, the primary focus of Part 3 is descriptive in nature.

[0340]

[0368] Statistical methodology:

[0369] Summary statistics were presented by dose group and subgroup (where applicable), or by OL treatment. Each part of the study, including the placement, is presented in a table format.

[0341]

[0370] The primary efficacy analysis population was defined as all randomized subjects, with treatment This is the intention-to-treat (ITT) analysis population. The safety analysis population includes patients who The safety analysis population was defined as all subjects receiving study drug for 10 days after the initial dose of APT-1011. The single-dose PK analysis population was defined as all subjects in the ITT analysis population from Part 1 who were randomly assigned to one of the three APT-1011 dose arms, received their first dose of APT-1011, and had at least one PK sample included in the final unit dose population PK analysis. The steady-state PK analysis population is defined as all subjects in the Part 1 ITT analysis population who were randomly assigned to one of the three APT-1011 groups, received their APT-1011 dose corresponding to the steady-state PK sampling period, and had at least one PK sample included in the final steady-state population PK analysis. An additional per-protocol analysis population who complete Parts 1, 2, and 3 and OL treatment may be defined in the Statistical Analysis Plan (SAP).

[0342]

[0371] Use descriptive statistics to analyze continuous and ordinal variables (e.g., age, weight, height), Baseline and demographic information will be summarized for numbers and percentages as well as for categorical variables (eg, sex, race).

[0343]

[0372] Pharmacokinetic and pharmacodynamic analysis

[0373] In this study, 1.5 mg BID and 3.0 mg BID doses were administered daily, before and after breakfast. Administer at least 30 minutes after and before bedtime (at least 2 hours after dinner). 1.5 mg The HS dose will be administered prior to bedtime (at least 2 hours after dinner). Subjects receiving 1.5 mg HS daily will also receive a placebo at least 30 minutes after breakfast.

[0344]

[0374] Use PK data from intensively sampled subjects when available The following PK parameters for FP are calculated using non-compartmental methods:

[0375] Cmax: Observed by examination of plasma concentration-time plots for individual study participants. The maximum observed concentration.

[0376] Tmax: The time of maximum observed concentration, obtained directly from the observed concentration-time data.

[0377] AUC0-12: A combination of linear up- and log-trapezoidal methods (linear up- / log-trapezoidal method) The area under the plasma concentration-time curve from 0 to 12 hours after taking a dose, calculated by the Down's method.

[0378] CLss / F: apparent clearance at steady state.

[0379] Cumulative ratio: AUC0-12 at steady state and AUC0-12 after a single dose The cumulative ratio that is calculated.

[0345]

[0380] Individual and mean plasma concentration-time curves (both linear and semi-logarithmic) Detailed methodology for concentration data and summary statistics for PK parameters will be documented in SAP.

[0346]

[0381] Based on a combination of serial and sparse plasma concentration data, A population PK analysis will be performed. Historical serial PK data for APT-1011 (Study PR-023 and food effect) may be included in this analysis to facilitate development of a base PK model.

[0347]

[0382] Population PK parameters, including oral clearance (CL / F) and volume of distribution (V / F), will be estimated if data permits. If necessary, additional parameters will be estimated based on the final structural PK model.

[0348]

[0383] Output including appropriate diagnostic plots, lists, and summaries of PK parameters is generated from the Generate from the final population model. In addition, generate graphical and tabular representations of any PK simulations. Generate separate PopPK reports and link to clinical study reports.

[0349]

[0384] If data permit, we will evaluate the relationship between systemic exposure to FPs and changes in cortisol levels. Exploratory analyses to determine coprimary endpoints or components thereof may also be performed as described above to facilitate selection of safe and effective doses for future studies and clinical use. Further exploratory exposure-response analysis may be performed based on the composition.

[0350] [Table 9-1]

[0351] [Table 9-2]

[0352] [Table 9-3]

[0353] [Table 9-4]

[0354] [Table 10-1]

[0355] [Table 10-2]

[0356] [Table 10-3]

[0357] [Table 11-1]

[0358] [Table 11-2]

[0359] Example 4 - Fluticasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, and Maintenance Study of APT-1011 in Elephants

[0385] Primary Objective: The primary objective of this study is to evaluate the efficacy (histological response) of APT-1011 in adults (age ≥ 18 years) with Eosinophilic Esophagitis (EoE).

[0360]

[0386] Secondary Objectives: The secondary objectives of this study are: Dose of APT-1011 - To define response; to select the dose of APT-1011 for Phase 3; to evaluate the effect of APT-1011 on histologic and endoscopic appearance; APT-101 To evaluate the maintenance of efficacy and long-term safety of APT-1011; To evaluate the population pharmacokinetics (PopPK) of APT-1011; To evaluate the effect of APT-1011 on dysphagia episodes To do.

[0361]

[0387] Preliminary Objectives: The preliminary objectives of this study were to:

[0388] To evaluate the effect of APT-1011 on dysphagia and other symptoms of EoE to assess quality of life; to assess symptom symptoms over time; to evaluate pharmacokinetic (PK) / pharmacodynamic (PD) relationships (with cortisol as the primary endpoint); to evaluate dose-response relationships for histological and symptomatic responses; to derive a scoring structure from the Patient Reported Outcomes Symptoms of EoE (PROSE) and to derive various endpoints; To evaluate the measurement properties of the PROSE, including its reliability, construct validity, and sensitivity to change; to generate guidelines for interpreting clinically meaningful change and to derive treatment response cut-offs, or responder definitions, for the PROSE.

[0362]

[0389] Study design

[0390] This was a randomized controlled trial of 100 adult subjects (age ≥ 18 years) diagnosed with EoE. This is a randomized, double-blind, placebo-controlled, dose-ranging study of a total of four daily doses of APT-1011 versus sebo.

[0363]

[0391] During the single-blind run-in period / baseline symptom assessment, subjects were Placebo was taken before sleep (HS; before going to bed), 30 minutes after breakfast, and 1.5 mg of APT-1011 was taken before sleep (HS; before going to bed); 1.5 mg twice daily (BID) (30 minutes after breakfast) Four doses of study drug will be administered: APT-1011 30 minutes after breakfast and before bedtime; total daily dose of 3 mg; placebo and 3 mg HS 30 minutes after breakfast (before bedtime); and 3 mg BID (30 minutes after a meal and before bedtime; total daily dose of 6 mg) with matching doses of placebo 30 minutes after breakfast and HS (before bedtime).

[0364]

[0392] 100 subjects were randomly assigned to receive either a placebo or one of the active doses in part 1. Part 2 will be randomly assigned 1:1:1:1:1 to receive either the first or second dose of the treatment. As described below, the treatment subjects receive in Part 2 will depend on their histologic response status at Week 12.

[0365]

[0393] Randomization was performed in a double-blind manner using the Integrated Interactive Web Response System (IWRS). The subjects will be stratified by history of esophageal stricture at screening or the presence or absence of esophageal stricture at that time, and by history of a positive steroid response to any corticosteroid treatment previously administered to treat EoE, stored along with the subjects' demographics.

[0366]

[0394] Efficacy of APT-1011, including durable EoE responses and patient-reported outcomes (including clinical trials) and to investigate safety and PK.

[0367]

[0395] FLUTE was administered in several parts (screening [4 weeks], followed by 4 weeks There will be a single-blind placebo run-in period and baseline symptom assessments, as well as two treatment parts [Part 1 and Part 2], with a follow-up visit 2 weeks after the last dose of study drug. The maximum number of days to screen will be 28 days. Eligibility (Inclusion Criterion #7: Evidence of EOE defined by ≥ 15 peak eosinophils / high power field [HPF] in at least 5-6 biopsy specimens including both proximal and distal specimens [3 each]) will be assessed. Esophageal, gastro, and duodenal endoscopy (EGD) for Physicians must receive their biopsy specimens by the time stated in this inclusion criterion. To enter the 4-week baseline symptom assessment, subjects must have at least 5 biopsies confirmed during this phase (Inclusion Criterion #7: At least 5 proximal and distal specimens [3 each]). Evidence of EOE, defined by ≥ 15 peak eosinophils / HPF in one to six biopsy samples; inclusion criterion #8: reporting dysphagia episodes ≥ 3 days per week in the last 2 weeks of the 4-week baseline symptom assessment in a daily diary; inclusion criterion #9: completion of episode entry for at least 5 of each 7 days during the 4-week baseline symptom assessment; and exclusion criterion #23: must meet all eligibility criteria, including a global EoE score > 3 (inclusion criterion #5), except for serum corticosteroid levels < 18 μg / dL (497 nmol / L) at 60 minutes using an adrenocorticotropic hormone [ACTH] stimulation test using cosyntropin 250 μg [i.e., a positive result on the ACTH stimulation test]). At the start of the 4-week placebo run-in period / baseline symptom assessment, subjects will be provided with placebo along with their electronic diaries.

[0368]

[0396] During the 4-week baseline symptom assessment, baseline symptom severity was assessed and recorded in a diary. Assess the subject's ability to comply with the force. Subjects must have a peak eosinophils / HPF of ≥15 in their esophageal biopsy specimen to undergo randomization. At least five to six biopsy specimens should be taken from both the proximal and distal sites (three of each) so that a diagnosis can be made with certainty. A history of esophageal stricture on EGD or the presence or absence of esophageal stricture at the time, along with a history of a previous positive steroid response to any corticosteroid treatment administered in the past to treat the subject's EoE, stored with demographics, are stratification variables at the time of randomization.

[0369]

[0397] Following verification of these eligibility criteria, eligible subjects will be randomized as described above. It is possible.

[0370]

[0398] During treatment, all subjects will be seen approximately monthly for scheduled visits and Return to the facility for an unscheduled visit due to any unexpected adverse event or worsening symptoms, including food impaction.

[0371]

[0399] Definitions of histologic response, histologic non-response, and treatment failure.

[0400] Response or non-response status was assessed 2 weeks prior to the planned end of treatment in Part 1 (12 weeks Part 2 will be assessed at week 26 (week 26) and 2 weeks prior to the planned end of treatment in Part 2 (weeks 26 and 52).

[0372]

[0401] Histological responders were defined as those with a peak eosinophil / HPF count ≤6 (as the primary determinant). HPF is defined as a subject achieving a histologic response of 0.235 square millimeters under a microscope with a 40x lens and a field of view of 22 mm.

[0373]

[0402] Histological non-responders have no histological response (i.e., peak eosinophils / H Subjects are defined as those who do not achieve a histological response with a PF count ≦6.

[0374]

[0403] Patients with food impaction with or without esophageal dilation at any time during the study Elephants will be considered treatment failures, and they will complete an early termination assessment and be withdrawn from the study after the 2-week post-treatment follow-up period. Subjects who voluntarily withdraw from the study due to symptomatic deterioration prior to any evaluation after the 12th week of the study will also be considered treatment failures. Every effort should be made to perform an EGD on subjects who wish to withdraw due to symptomatic deterioration. They must also complete an early termination assessment and be withdrawn from the study after the 2-week post-treatment follow-up period.

[0375]

[0404] Part 1: Induction (Day 1-Week 14)

[0405] During Part 1, subjects are treated with study drug for 14 weeks (Figure 5). At week 12, Subjects undergo a response assessment, including an EGD to assess endoscopic and histologic status.

[0376]

[0406] Histologic responders and histologic non-responders (at week 12) will enter part 2.

[0377]

[0407] Part 2: Maintenance (Weeks 14-52)

[0408] In Part 2, all subjects classified as histological responders at Week 12 were Starting at week 14, subjects will continue to be treated according to the dose group to which they were randomly assigned for part 1 for an additional 14 weeks (Figure 5). Subjects may continue to use this dose for up to 9 months after completion of part 1.

[0378]

[0409] Subjects who were histological non-responders at Week 12 were randomized to single-blind 3 mg BI in Part 2. Take D.

[0379]

[0410] At week 26, subjects were randomized to receive response assessments, including EGD to assess histologic response. Symptoms will also be assessed. The 14 days prior to week 26 will be compared to the 14 days prior to randomization. Subjects who are histological non-responders will stop treatment at week 28, enter a 2-week follow-up period, and withdraw from the study. Histological responders will continue on the same dose.

[0380]

[0411] Subjects completing the study at week 52 will undergo follow-up to assess endoscopic and histologic status. Patients will undergo response assessment, including EGD for seroconversion. Symptoms will also be assessed. The 14 days prior to week 52 will be compared to the 14 days prior to randomization.

[0381]

[0412] Subjects will complete a follow-up visit two weeks after taking the last dose of study drug.

[0382]

[0413] Follow-up visit

[0414] Subjects complete a follow-up visit for one or more of the following reasons: Subjects who complete week 52 of treatment (post-EGD);subjects who experience an adverse event (AE) requiring early discontinuation, including food impaction requiring EGD;subjects with no histologic response at week 26, including subjects on single-blind 3 mg BID;subjects who voluntarily withdraw or experience symptomatic worsening during the study. A follow-up visit will occur 2 weeks after the subject receives their final dose of study drug. All subjects must have a final EGD within 3 weeks prior to completing the follow-up visit, unless they withdraw consent or have a contraindication to EGD.

[0383]

[0415] Pharmacokinetics

[0416] To characterize fluticasone propionate (FP) exposure in the study population Sparse PK sampling will be performed. PopPK analysis will be performed using sparse plasma concentration data.

[0384]

[0417] Pharmacokinetic samples were collected from subjects in all five dose groups to maintain blinding Samples collected from subjects receiving placebo will also be analyzed. Samples collected from subjects receiving active doses will be analyzed for PopPK results.

[0385]

[0418] For this sparse PK sampling, a pre-dose sample was collected on Day 1. At weeks 4, 8, and 12, subjects will take their "post-breakfast" dose as scheduled on the day of the visit (most likely at home) and two samples will be collected during their scheduled visit, upon arrival at the site, and approximately 1-1.5 hours after the first sample (just before leaving the site). Sites are encouraged to schedule subject visits throughout the day. Due to this variability, sparse PK samples are expected to represent most of the 12-hour interval following dose intake.

[0386]

[0419] Plan target number

[0420] Approximately 100 subjects were randomly selected based on their history of esophageal stricture or the presence or absence of esophageal stricture at the time of the procedure. Part 1 will be randomly assigned in a 1:1:1:1:1:1 fashion stratified by the presence or absence of EGFR-positive steroids and by the subject's history of a positive prior steroid response to any prior corticosteroid treatment received to treat EoE.

[0387]

[0421] We recommend that both men and women register, but approximately 25% of those who register It is expected that the majority of subjects will be female. Subjects up to age 75 will be accepted, but it is expected that 5% of those enrolled will be elderly (>= 65 years).

[0388]

[0422] No interim analyses are planned.

[0389]

[0423] Inclusion Criteria:

[0424] Subjects must meet all of the following criteria:

[0425] Prior to entering the 4-week baseline symptom assessment: year at time of informed consent Male or female, aged ≥18 and ≤75 years; have signed and are willing and able to comply with all study procedures; a diagnosis or presumed diagnosis of EoE; the diagnosis of EoE must be confirmed by documentation of symptoms, histology, and a history of unsuccessful treatment with high-dose proton pump inhibitors (PPIs) for ≥8 weeks. For FLUTE, high-dose PPI is defined as 20 mg BID omeprazole, or 20-40 mg BID of any commercially available PPI. Maintenance doses of PPI are not permitted. Lack of response to PPI treatment is defined as ≥ 15 peak eosinophils / HPF in at least 5 biopsy samples, including both proximal and distal specimens, after 8 weeks of high-dose PPI treatment.

[0426] Documentation of PPI failure before first diagnosis or PPI failure at screening Documentation of I failure is required. If the subject does not meet the diagnostic criteria for EoE, which requires an unsuccessful 8-week trial of high-dose PPI, the subject may be prescreened but should not consent and sign an ICF and should not be offered to participate in FLUTE, unless the person taking the PPI for 8 weeks will use EGD during the study for this documentation. The investigator and potential subject must decide to complete the PPI trial regardless of any considerations in this study. There is not enough time to do an 8-week trial during the study. If the subject consents from this point on errors and screening failures, the subject may be prescreened as described in the protocol. Have them report a history of ≥ 3 episodes of dysphagia (difficulty swallowing food) in the 7 days prior to screening; have a 7-day recall global EoE symptom score of > 3 at baseline (EoE scores are calculated at each of visits 1, 2, and 3 prior to randomization). (must remain >3 on the scale.) This will be done in writing during the Screening Visit; willing and able to comply with study-related treatment regimens, procedures, and visit schedules.

[0390]

[0427] Pre-randomization: Prior to randomization, determinations should be made: both proximal and distal specimens Evidence of EoE defined by ≥ 15 peak eosinophils / HPF for at least 5-6 biopsy specimens including FLUTE (three of each); any EGD and biopsy performed other than FLUTE will not be accepted to meet eligibility criteria. Optional biopsy specimens may be taken and processed locally for local use if specified in the local ICF. Biopsy specimens should be obtained prior to the 4-week baseline symptom assessment. Eligibility from a histological perspective will be based solely on central pathologist assessment.

[0391]

[0428] Prior to randomization, measures were taken: daily diary, 4-week baseline symptom assessments report at least 3 episodes of dysphagia (difficulty swallowing food) during each of the last 7 days of the last 2 weeks of the study;

[0429] Prior to randomization, the last 14 of 4-week baseline symptom ratings should be assessed. Completion of episode entry for at least 5 of each 7 day period.

[0392]

[0430] Exclusion criteria:

[0431] A subject does not enter FLUTE for any of the following reasons:

[0432] Before entering the 4-week baseline symptom assessment: known effects of corticosteroids have a contraindication, hypersensitivity or intolerance to any of the following: any medical, mental or social condition or abnormal medical history or laboratory findings that, in the opinion of the investigator, may interfere with the study procedures or the subject's ability to comply with and perform the study; the presence of any type of oral or esophageal mucosal infection; have any oral or dental condition that interferes with normal eating; have any condition that affects the esophageal mucosa or alters esophageal motility other than EoE, including erosive esophagitis (grade B or higher according to the Los Angeles Classification of Gastroesophageal Reflux Disease), hiatal hernia longer than 3 cm, Barrett's esophagus and achalasia; have used systemic (oral or parenteral) corticosteroids within 60 days prior to screening. use of inhaled / swallowed corticosteroids within 30 days prior to screening, or long-term use of high-potency topical corticosteroids within 30 days prior to screening; initiation of an elimination diet or elemental diet within 30 days prior to screening; morning (between 0700 and 0800, or as close to that time as possible) serum cortisol level ≤ 5 μg / dL (138 nmol / L); use of a biologic immunomodulator in the 24 weeks prior to screening; use of a calcineurin inhibitor or purine analogue (azathioprine, 6-mercaptopurine) in the 12 months prior to screening; use of a strong cytochrome P450 (CYP) 3A4 inhibitor (e.g., ritonavir) in the 12 months prior to screening. use of EGD or esophageal biopsy (e.g., ketoconazole and ketoconazole); contraindications to or factors that substantially increase the risk of EGD or esophageal biopsy, or esophageal strictures that preclude EGD with a standard 9 mm endoscope; history of esophageal stricture requiring dilation for the past 12 weeks prior to screening; subjects who have started, stopped, or changed a medication regimen of PPIs, H2 antagonists, antacids, or antihistamines for any condition, such as GERD for allergic rhinitis, within 4 weeks prior to the qualifying endoscopy. These medications must remain constant throughout the study. Infection with Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (should be tested for during screening).

[0433] The following parameters are used to determine Hepatitis B and C infection: Positive for hepatitis surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody. However, subjects who are positive for hepatitis B surface antibody but negative for HBsAg and anti-HBc are eligible.

[0434] Randomization within 4 weeks prior to or on the screening visit have gastrointestinal (GI) bleeding between visits; have chronic infection, immunosuppression, or immunodeficiency currently present (>30 days); have a history or presence of other inflammatory disease of the GI tract, including Crohn's disease, celiac disease, or eosinophilic gastroenteritis; have currently present alcohol or drug abuse in the opinion of the investigator; are pregnant, breastfeeding, or planning pregnancy during the study. For women of childbearing potential, serum pregnancy tests at screening and urine pregnancy tests during the 4-week baseline symptom assessment must be negative; women of childbearing potential with high sexual desire who do not agree to adhere to a highly effective method of contraception until the end of the follow-up period. For systemic contraceptives, use must be stable for ≥28 days prior to screening. Women who have undergone artificial menopause or whose menopause has been confirmed by follicle-stimulating hormone / luteinizing hormone do not require contraception or pregnancy testing during the study; participation in a clinical study involving the investigational drug within 30 days (or 5 half-lives, whichever is longer) of screening;

[0435] Before randomization:

[0436] Adrenocorticotropic hormone (ACTH) stimulation test using cosyntropin 250 μg and serum corticosteroid levels <18 μg / mL (497 nmol / dL) at 60 minutes (i.e., a positive ACTH stimulation test result).

[0393]

[0437] Test drug, dose and method of administration:

[0438] APT-1011 is an orally disintegrating tablet that contains FP as its active ingredient.

[0394]

[0439] This protocol does not include any blinded medication administered (i.e., any dose of A We use the term investigational drug to refer to either the primary treatment (PT-1011 or placebo).

[0395]

[0440] Subjects are instructed to take the study drug orally without water or other fluids. The tablet should be placed in the mouth and manipulated between the tongue and roof of the palate until it completely disintegrates on the subject's tongue. Once the tablet is completely disintegrated, without biting or chewing, it should be swallowed. Do not rinse with water or any other liquid after administration.

[0396]

[0441] Take the dose in the morning ("after breakfast"; ≥30 min after breakfast) and before bedtime ("before bedtime"; evening meal) The study drug will be administered ≥2 hours after sleep. A "bedtime" dose of the study drug will be administered while lying down, just before sleep. All eating, drinking, and tooth brushing should be completed before dosing.

[0397]

[0442] The study drug was administered BID (30 min after breakfast and Before bedtime). During the placebo run-in period, subjects will take placebo BID. Subjects in the HS group will take placebo in the morning, 30 minutes after breakfast, and their dose before bedtime. Placebo subjects will take placebo BID after randomization.

[0398]

[0443] 1.5mg BID APT-1011, 3mg BID APT-1011 Subjects in the 1.5 mg HS and 3 mg HS APT 1011 groups will receive a placebo after breakfast and 1.5 mg or 3 mg APT 1011 before bed.

[0399]

[0444] Subjects should refrain from oral intake of solids or liquids for ≥ 1 hour after dosing.

[0400]

[0445] Evaluation criteria:

[0446] Efficacy was assessed using histological (eosinophils per HPF), endoscopic (eosinophilic esophagitis endoscopic criteria scores [EREFs]), and clinical exploratory endpoints (number of dysphagia episodes per dysphagia episode). (by PROSE, which is completed at the end of each day) and the following additional patient-reported outcomes: The following measures will be assessed: global EoE symptom score, Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC), 7-day recall Eosinophilic Esophagitis Activity Index (EEsAI) total and subscores, and patient symptom ratings. Health-related quality of life (HRQoL) will be assessed with the Eosinophilic Esophagitis Quality of Life Questionnaire for Adults (EoE-QoL-A) as a preliminary endpoint. It is scored as points.

[0401]

[0447] Primary efficacy endpoints: The following primary efficacy endpoints were used to assess EoE response: Endpoints will be assessed at week 12:

[0448] Histology: At least five to six biopsies from the proximal and distal esophagus (approximately three each) were Percentage of subjects with a peak eosinophil / HPF count < 6 after assessment of the specimen, where the HPF area is 235 square micrometers (40x magnification lens with a 22 mm field of view).

[0402]

[0449] Secondary Efficacy Endpoints: The following secondary efficacy endpoints will be evaluated: :

[0450] EoE sustained response: Primary endpoint met at 12 weeks, 26 weeks and Percentage of subjects maintaining the primary endpoint at week 52;

[0451] Changes from baseline EREFs at weeks 12, 26, and 52 ification.

[0452] Endoscopic changes were assessed by EREFs based on the following endoscopic features: : edema, esophageal rings, exudates, grooves, strictures, and some miscellaneous features (crepe paper esophagus, narrow caliber esophagus, and esophageal erosions);

[0453] Peak eosinophil / HPF counts <1 and at weeks 12, 26, and 52 Percentage of subjects that are <15;

[0454] Change from baseline global EoE symptom score assessed before randomization, 4 weeks Changes assessed during the 7 days prior to study visits at weeks 8, 12, 18, 22, 26, 28, 36, 44, and 52;

[0455] Dysphagia: 14 days prior to time points (weeks 12, 26, and 52) change in number of dysphagia episodes at baseline (14 days prior to randomization) compared with;

[0456] Baseline 7-day recall EEsAI at weeks 12, 26 and 52 Change from total score;

[0457] Baseline 7-day recall EEsAI at weeks 12, 26 and 52 Change from subscore;

[0458] Mean 7-day recall EEsAI total score at weeks 12, 26 and 52 percentage of subjects with <20;

[0459] From baseline PGIS assessed before randomization at weeks 4, 8, and 12 , changes to be assessed at weeks 14, 18, 22, 26, 28, 36, 44 and 52.

[0460] Week 4, Week 8, Week 12, Week 14, Week 18, Week 22, Week 26, Week 28 PGIC at weeks 1, 36, 44, and 52.

[0403]

[0461] Assessment of treatment failure and recurrence including:

[0462] Dosage for Histological Non-Responders at Weeks 12, 26, and 52 Percentage per;

[0463] Before the 14th week, between the 14th and 28th weeks, and between the 28th and 52nd weeks Percentage of subjects per dose requiring urgent endoscopic removal of food impaction;

[0464] Percentage of subjects requiring esophageal dilation by dose group and part of study entage.

[0404]

[0465] Preliminary Efficacy Endpoints: The following preliminary efficacy endpoints will be evaluated: :

[0466] Dysphagia: compared with the 14 days prior to the time points (12, 26 and 52 weeks) Change in number of dysphagia episodes from baseline (14 days prior to randomization);

[0467] Free of dysphagia during the 14 days prior to study visits at weeks 12, 26, and 52 change from baseline on days;

[0468] Sustained EoE response (dysphagia): secondary endpoint of dysphagia at 12 weeks Percentage of all subjects fulfilling and maintaining dysphagia-related response at weeks 26 and 52;

[0469] assessment of PK / PD (cortisol) and exposure-response (efficacy) relationships;

[0470] Week 4, Week 8, Week 12, Week 14, Week 18, Week 22, Week 26, Week 28 subject's assessment of symptoms compared with previous visits at weeks 1, 36, 44, 52, and early termination visits (if applicable);

[0471] E at randomization, 12, 26, and 52 weeks for all subjects Dose- and subgroup-specific assessment of HRQoL based on the oE-QoL-A.

[0472] Separate tables for subjects receiving single-blind (for subjects) treatment (in part 2);

[0473] Subjects classified as histological non-responders at Week 12 and Percentage of subjects with peak eosinophil / HPF count ≤6 across all biopsy esophageal locations at week 52;

[0474] Weeks 26 and 52 for subjects classified as non-responders at Week 12 change from baseline dysphagia episodes in the 14 days prior;

[0475] Subjects classified as histological non-responders at Week 12 and Percentage of subjects meeting the primary endpoint at week 52;

[0405]

[0476] The scoring structure and various endpoints are derived from the DEDI.

[0406]

[0477] evaluate the psychometric measurement properties of the PROSE;

[0478] Anchor and distribution analysis to assess meaningful change in PROSE.

[0407]

[0479] Adverse events

[0480] Any AEs or complications experienced by the subject during any part of FLUTE must be described in detail and thoroughly evaluated by the investigator. The investigator is responsible for recording all AEs observed or reported during the study, regardless of causality and / or clinical significance.

[0408]

[0481] All treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation, and serious Safety will be assessed by monitoring and recording adverse events (SAEs). All TEAEs will be coded using the Dictionary for Regulatory Activities, version 14.0, classification, and classified by severity (mild, moderate, or severe). Investigators will report relationship to study drug (related or unrelated) for SAEs only. Treatment-emergent adverse events occurring within 3 days of a dose change will be attributed to the previous dose.

[0409]

[0482] APT-1011 (fluroic acid propionate), a minimally absorbed corticosteroid Cazone ODT is expected to act locally in the esophagus. Swallowing water after use may reduce efficacy. Because oral candidiasis is very rarely associated with fluticasone use, slurping and spitting is not necessary, as this may be accompanied by inadvertent swallowing of water.

[0410]

[0483] However, oral and esophageal candidiasis are considered AEs of particular interest. Elephants may remain in the study during treatment for these AEs. The Investigator may allow these subjects to swish and spit 30 minutes after dosing. Subjects must be instructed not to swallow the rinse water.

[0411]

[0484] Symptoms of hyperadrenocorticism (see below) are also AEs of particular interest.

[0412]

[0485] Experimental testing

[0486] Routine laboratory tests and assessments, including hematology, blood chemistry, urinalysis and electrocardiograms (ECGs), will be performed throughout the study. Clinically significant changes in laboratory tests or ECGs will be summarized.

[0413]

[0487] Physical Examination and Vital Signs

[0488] To document the subject's baseline status and any changes related to AEs. A physical examination is performed to highlight the presence or absence of any clinically significant deviations. Vital signs are also assessed and any clinically significant deviations are reported.

[0414]

[0489] Cortisol-related findings

[0490] All subjects had morning serum cholesterol levels during the screening period. As per receipt records, patients will undergo a 250 μg ACTH stimulation test during the 4-week baseline assessment, which will also be administered at Week 12 (Visit 6), Week 26 (Visit 10), and Week 52 (Visit 14).

[0415]

[0491] At all visits (scheduled or unscheduled), Particular attention will be paid to symptoms as well as changes that may be related to corticosteroids. If subjects undergo surgery or trauma during the study, close attention should be paid to observing the subjects for evidence of inappropriate adrenal response.

[0416]

[0492] If hyperadrenocorticism or adrenal suppression is suspected, appropriate workup should be performed. These findings should be confirmed or excluded. Specifically, hypothalamic-pituitary-adrenal (HPA) axis suppression of potential clinical concern should be monitored if any of the following occur: A 250 μg ACTH stimulation test will also be performed post-screening to monitor:

[0493] At the last on-treatment visit for some subjects and, if applicable, Subjects have morning serum cortisol levels ≤ 5 μg / dL (138 nmol / L) (confirmed by two blood draws) during routine laboratory testing performed for the study, including the early termination visit;

[0494] The subject reports symptoms of hyperadrenocorticism;

[0495] Subject discontinues due to HPA axis suppression.

[0417]

[0496] A positive ACTH stimulation test was observed 60 min after treatment with 250 μg of cosyntropin. Adrenal insufficiency is defined as a serum cortisol level <18 μg / dL (497 nmol / L) at the time of admission. This result is an exclusionary factor if it occurs at the Screening / 4-week baseline symptom assessment and will require follow-up until restoration of adrenal function if an ACTH stimulation test is subsequently performed. The procedure for HPA axis suppression is discussed in the full protocol. The sponsor will provide safety follow-up guidelines and will document restoration of adrenal function for all subjects who demonstrate evidence of hyperadrenocorticism or HPA axis suppression during the course of the study.

[0418]

[0497] electro-cardiogram

[0498] Electrocardiogram signs will also be assessed and clinically significant deviations will be reported.

[0419]

[0499] Safety Endpoints: The safety endpoints of interest are:

[0500] Incidence of TEAEs;

[0501] TEAEs leading to discontinuation;

[0502] Treatment emergent SAE;

[0503] Serum cortisol level ≤ 5 μg / dL (≤ 138 nmol / L) or the percentage of subjects with a positive ACTH stimulation test (serum cortisol <18 μg / mL [≤497 nmol / L] at 60 min).

[0504] The number of subjects who discontinue due to HPA axis suppression will be recorded.

[0505] Incidence of oral and esophageal candidiasis.

[0420]

[0506] Pharmacokinetic variables: If data permit, use sparse sampling to obtain the following Po pPK parameters are estimated: oral clearance; volume of distribution. If necessary, further PopPK parameters are estimated based on the final structural PK model.

[0421]

[0507] Statistical methods:

[0508] Sample size determination: Part 1 consisted of 20 patients receiving 1.5 mg HS, 1.5 mg The study included sample sizes ranging from 100 subjects randomly assigned to 100 mg HS, 3 mg BID, 3 mg HS, 3 mg BID, and placebo (1:1:1:1:1). Based on these randomization ratios, approximately 80% of all patients in part 1 will be treated with the APT-1011 dosing regimen and approximately 20% of all subjects in part 1 will be treated with placebo.

[0422]

[0509] Analysis population:

[0510] The total enrollment population includes all subjects who sign the ICF and are enrolled in the study. The safety population included all subjects who received ≥ 1 dose of study drug. The intention-to-treat (ITT) population included all subjects who received ≥ 1 dose of study drug and had ≥ 1 adverse event after dose intake. All subjects undergoing efficacy assessments are included. Subjects who are enrolled in the study and take study drug but are unable to complete treatment are considered dropouts. The sparse PK subgroup includes all subjects with ≥ 1 quantifiable PK sample collected for sparse PK assessment.

[0423]

[0511] Further analysis populations (e.g., weeks 26 and 52 in Part 1 and Part 2) The per-protocol population (which includes subjects who complete the study) may be defined in the statistical analysis plan.

[0424]

[0512] Statistical methodology:

[0513] Subject characteristics: Descriptive statistics were used to analyze continuous and ordinal variables (e.g., age and Baseline and demographic information will be summarized for numbers and percentages of age, sex, weight, and categorical variables (eg, presence or absence of stenosis, previous response to steroids, sex, and race).

[0425]

[0514] Primary efficacy analysis of Part 1

[0515] Let p0 be the proportion of patients who achieve a histological response to placebo, and Suppose, p j Let be the proportion of patients with a histological response for dose j, where j=1, 2, 3, 4 correspond to the 1.5 mg HS, 1.5 mg BID, 3 mg HS, and 3 mg BID doses, respectively. There are four hypotheses corresponding to the four active doses, and these hypotheses are tested using a gatekeeping strategy to prevent type I errors for each analysis.

[0426]

[0516] 1) Primary hypothesis #1 H0:p4≦p0 H1:p4=p0

[0427]

[0517] A chi-square test of proportions was used to verify primary hypothesis #1, i.e., 3 mg BID vs. Placebo is tested. If the corresponding p-value is less than or equal to 0.05, the null hypothesis is rejected and the following hypotheses are then tested:

[0518] 2) Primary hypothesis #2 H0:p3≦p0 H1:p3=p0

[0428]

[0519] A chi-square test of proportions was used to verify primary hypothesis #2, i.e., 3mg HS vs. progesterone. Test for placebo. If the corresponding p-value is less than or equal to 0.05, reject the null hypothesis and then test the following hypotheses:

[0520] 3) Primary hypothesis #3

[0521] H0:p2≦p0

[0522] H1:p2=p0

[0429]

[0523] Using a chi-square test of proportions, we confirmed primary hypothesis #3, i.e., 1.5mg BI D vs. placebo is tested. If the corresponding p-value is less than or equal to 0.05, the null hypothesis is rejected and the following hypotheses are then tested:

[0524] 4) Primary hypothesis #4 H0:p1≦p0 H1:p1=p0

[0430]

[0525] Using a chi-square test of proportions, we confirmed primary hypothesis #4, i.e., 1.5 mg HS Test versus placebo. Reject the null hypothesis if the corresponding p-value is less than or equal to 0.05.

[0431]

[0526] If the higher dose meets statistical significance, the gatekeeping strategy will result in a 1. Note that only normalization assumptions of 5 mg HS or 1.5 mg BID are possible.

[0432]

[0527] Part 2 Efficacy Analysis

[0528] Complete both Part 1 and Part 2 and complete the Week 26 and 52 assessments. For subjects who receive EoE therapy, sustained EoE response will be assessed. The response will be assessed by the primary endpoint. Other efficacy measures will be assessed at Week 26. Efficacy will be summarized for histological non-responders from Part 1 who are treated in Part 2. Other efficacy measures will be assessed at Week 52.

[0433]

[0529] Secondary and exploratory efficacy analyses

[0530] Statistical tests comparing each APT-1011 treatment group with placebo were performed as secondary efficacy endpoints. This will be performed for efficacy endpoints, but the corresponding p-values ​​will be considered descriptive rather than inferential.

[0434]

[0531] Secondary endpoints will be analyzed using the Kaplan-Meier method. Except for the endpoint of time to relapse after the start of double-blind treatment at 2, the Cochran-Mantel-Haenszel (CMH) test and baseline Changes in endpoints from the in-group were analyzed using analysis of covariance.

[0435]

[0532] No statistical testing of the exploratory efficacy endpoints will be performed.

[0436]

[0533] Safety analysis:

[0534] The incidence of TEAEs by system organ class and preferred term will be summarized. Provide separate summaries by AE (all AEs) and by relationship to the study drug (SAEs only) The incidence of TEAEs leading to discontinuation from the study and treatment-emergent SAEs will also be summarized. For subjects who change dose groups, TEAEs will be considered attributable to the previous dose if they occurred within 3 days of the change.

[0437]

[0535] Hematology, Chemistry, Urinalysis, ECG, Cortisol, Vital Signs and Potential clinically interesting and clinically significant changes in laboratory tests, including schizophrenia and bone mineral density, will be summarized. No statistical testing of safety endpoints will be performed. Shift tables will be generated as appropriate. Numbers of subjects discontinuing due to HPA axis suppression or positive ACTH stimulation tests will be summarized.

[0438]

[0536] Population Pharmacokinetics

[0537] PopPK analysis based on sparse plasma concentration data. Nonlinear mixed effects The software, NONMEM, version 7.2.0 or later (ICON Development Solutions, Ellicott City, MD), or other suitable nonlinear mixed effects model This analysis was performed using the Data Generation software. The structural PK model included oral clearance and volume of distribution as fixed effect parameters. In addition, parameter estimates were compared against each other. Inter-subject variability and random residual error in the data are estimated with appropriate error models. The optimal base model is selected according to standard criteria such as minimum objective function value and diagnostic plots. A separate PopPK report is generated as an appendix to the clinical study report.

[0439]

[0538] Preliminary PK / PD analysis

[0539] If data permit, we will evaluate the relationship between systemic exposure to FPs and changes in cortisol levels. A preliminary PK / PD analysis may also be performed as described above to determine a safe and effective dose for future studies and clinical use. Further preliminary PK / PD analyses may be performed to select a safe and effective dose for future studies and clinical use.

[0440]

[0540] Study rationale and risk-benefit analysis

[0541] The objective of Fluticasone in Eosinophilic Esophagitis (FLUTE) is to explore three total daily doses of APT-1011 to define the exposure-response of APT-1011 and to define the minimum effective dose that also minimizes clinically significant HPA axis effects. APT-1011 is expected to provide the following benefits to EoE patients: oral administration is generally better tolerated and more reliable in terms of accurate dose administration. Currently, the only available formulation of FP is a metered dose inhaler that patients spray into the mouth and swallow. Oral administration of APT-1011 has very low bioavailability compared to similar compounds such as budesonide, which on a mg basis can be more potent, but its low bioavailability further reduces the potential for systemic corticosteroid toxicity.

[0441]

[0542] This study represents the first dose-finding study of APT-1011. Given ioavailability, it is unlikely that APT-1011 will have any significant systemic corticosteroid effects.

[0442] [Table 12-1]

[0443] [Table 12-2]

[0444]

Table 12-3

[0445]

Table 12-4

[0446]

Table 12-5

[0447]

Table 12-6

[0448]

Table 12-7

[0449]

Table 13-1

[0450]

Table 13-2

[0451]

Table 13-3

[0452]

Table 14-1

[0453]

Table 14-2

[0454]

Table 14-3

[0455] [Table 14-4]

[0456]

[0543] screening

[0544] The screening period was 4 weeks (28 days). With the confirmatory report, the Investigator will assess the subject's eligibility criteria (see Sections 4.2.1 and 4.2.2) based on the screening results. A global EoE score of >3 must be achieved for the subject to continue in the study.

[0457]

[0545] EGD procedure to determine eligibility (Inclusion Criterion #7: ≥ 15 peak eosinophils Evidence of EoE as defined by bulbar / HPF, see Table 1. At least 5 specimens, including both proximal and distal esophageal specimens [approximately 3 of each], should be included to ensure a diagnosis. Biopsy (one to six biopsies should be taken) must be completed during the screening period and received by the central pathologist by the time noted in this inclusion criterion. EGD must be performed prior to Visit 2 (4-week baseline assessment).

[0458]

[0546] An ACTH stimulation test must be performed prior to visit 2 (4-week baseline assessment). It must be.

[0459]

[0547] If the previous reason for screening failure no longer exists or the subject If a subject withdraws for personal or family reasons and the reason is subsequently resolved, the subject may be screened again with the approval of the medical monitor. If the subject is screened again, a new informed consent form (ICF) must be signed. A new number will be assigned to each student. All tests and evaluations will have to be repeated.

[0460]

[0548] 4-week baseline symptom assessment (placebo run-in period)

[0549] To enter this phase, the subject: Assessed during the 4-week baseline symptom assessment: Inclusion criterion #7: evidence of EoE defined by ≥ 15 peak eosinophils / HPF; Inclusion criterion #8: daily diary reporting episodes of dysphagia on ≥ 3 days per 7 days during the last 14 days of the 4-week baseline symptom assessment; Inclusion criterion #9: global EoE score > 3, excluding daily diary entries on at least 5 of each of the 7 days during the last 14 days of the baseline symptom assessment (Inclusion criterion #5: EoE score > 3 on each of the 1st, 2nd, and 3rd visits prior to randomization) All inclusion criteria assessable prior to the 4-week baseline symptom assessment must be met, including any symptoms that may be present during the study period (e.g., ≥ 4 weeks of baseline symptom assessment; otherwise, the subject will be considered ineligible for screening); Exclusion criteria assessed prior to the 4-week baseline symptom assessment (i.e., Exclusion Criterion #23: 6 weeks of symptoms assessed using an adrenocorticotropic hormone [ACTH] stimulation test using cosyntropin 250 μg) All requirements except serum corticosteroid level <18 μg / dL (497 nmol / L) at time 0 minutes (i.e., positive ACTH stimulation test) must not be met.

[0461]

[0550] Subjects were given a 4-week period to complete the procedures and assessments described in Table 4-1. A clinic visit will be completed at the beginning of the baseline symptom assessment.

[0462]

[0551] During the 4-week baseline symptom assessment, baseline symptom severity was assessed and recorded in a diary. The subject's ability to comply with the force is assessed. The pathology of the...

Claims

1. 1. A method of treating eosinophilic esophagitis (EoE) in a patient in need thereof, comprising administering orally A method comprising administering a corticosteroid in an induction phase and a maintenance phase, wherein the induction phase results in an improvement in peak eosinophil count in at least one esophageal biopsy sample, and wherein the treatment does not result in a worsening of the patient's average weekly score on a patient-reported outcome assessment, including an assessment of days free of dysphagia.

2. 10. The method of claim 1, wherein the induction phase comprises administration for at least about 6 weeks.

3. 10. The method of claim 1, wherein the induction phase comprises administration for at least about 8 weeks.

4. 10. The method of claim 1, wherein the induction phase comprises administration for at least about 10 weeks.

5. 10. The method of claim 1, wherein the induction phase comprises administration for at least about 12 weeks.

6. The method of any one of claims 2 to 5, wherein administration is at least twice daily.

7. 10. The method of claim 1, wherein the corticosteroid is in an orally dissolving dosage form.

8. 8. The method of claim 7, wherein the corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, tixocortol, and salts, esters, solvates, polymorphs, prodrugs, and mixtures thereof.

9. The method of claim 1, wherein the patient has previously been administered PPI therapy.

10. 10. The method of claim 9, wherein PPI treatment has not been effective in substantially ameliorating one or more symptoms of EoE.

11. 10. The method of claim 1, wherein the patient does not experience a recurrence of active symptoms of EoE.

12. 2. The method of claim 1, wherein the induction phase results in a histological response in which the peak eosinophil count per HPF is reduced to 6 or less.

13. 10. The method of claim 1, wherein the induction phase does not result in food impaction episodes.

14. 10. The method of claim 1, wherein the maintenance dose is substantially the same as or less than the induction dose.

15. The method of claim 1 , wherein the maintenance dose is higher than the induction dose.

16. 2. The method of claim 1, wherein the treatment does not result in a worsening of the patient's average weekly score on the EEsAI assessment.

17. The method according to claim 7, wherein the oral dissolving dosage form is a tablet or an oblate.

18. 10. The method of claim 1, wherein the induction and maintenance doses are between about 1.5 mg and about 3 mg.

19. 20. The method of claim 18, wherein the dose is administered twice daily.

20. 18. The method of claim 17, wherein the corticosteroid is locally deposited in the upper gastrointestinal tract.

21. 2. The method of claim 1, wherein the patient exhibits substantial improvement in esophageal function and morphology, including reduction in esophageal groove, reduction in focal esophageal strictures, increase in esophageal diameter, increase in esophageal compliance, increased distensibility of the esophageal body, increased ease of swallowing, reduced edema, improved vascularity, reduction in esophageal rings, reduced or absent exudate, and / or absence of strictures.

22. A method of treating EoE in a patient in need thereof comprising administering an oral corticosteroid in an induction phase and a maintenance phase, wherein the induction phase does not result in a substantial improvement in peak eosinophil count in at least one esophageal biopsy sample, continuing the treatment results in an improvement in the peak eosinophil count in at least one esophageal biopsy sample, and the treatment does not result in a worsening of the patient's average weekly score on a patient-reported outcome assessment including an assessment of days free of dysphagia.

23. 23. The method of claim 22, wherein the patient experiences at least one episode of food impaction during the induction phase.

24. 23. The method of claim 22, wherein the induction phase comprises at least about 6 weeks.

25. 23. The method of claim 22, wherein the induction phase comprises administration for at least about 8 weeks.

26. 23. The method of claim 22, wherein the induction phase comprises administration for at least about 10 weeks.

27. 23. The method of claim 22, wherein the induction phase comprises at least about 12 weeks.

28. The method of any one of claims 24 to 27, wherein administration is at least twice daily.

29. 23. The method of claim 22, wherein the corticosteroid is in an orally dissolving dosage form.

30. 30. The method of claim 29, wherein the corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, tixocortol, and salts or esters and mixtures thereof.

31. 23. The method of claim 22, wherein the patient has previously been administered PPI therapy.

32. 32. The method of claim 31, wherein PPI treatment has not been effective in substantially ameliorating one or more symptoms of EoE.

33. 23. The method of claim 22, wherein the patient exhibits active symptoms of EoE.

34. 23. The method of claim 22, wherein the maintenance dose is substantially the same as or less than the induction dose.

35. 23. The method of claim 22, wherein the maintenance dose is higher than the induction dose.

36. The method of claim 29, wherein the oral dissolving dosage form is a tablet or an oblate.

37. 23. The method of claim 22, wherein the induction and maintenance doses are between about 1.5 mg and about 3 mg.

38. 38. The method of claim 37, wherein the dose is administered twice daily.

39. 37. The method of claim 36, wherein the corticosteroid is locally deposited in the upper gastrointestinal tract.

40. 10. The method of claim 1, wherein the oral corticosteroid is administered before breakfast and / or before bedtime.

41. 10. The method of claim 1, wherein the treatment results in no significant systemic glucocorticoid or mineralocorticoid effect.

42. 2. The method of claim 1, wherein the peak eosinophil count is measured by esophageal biopsy during the maintenance phase.

43. 43. The method of treating EoE according to any one of claims 1 to 42, wherein the patient, prior to treatment, (i) had a peak eosinophil count per HPF greater than 15, and (ii) had prior treatment with a PPI for at least about 8 weeks, where the prior treatment was ineffective in substantially ameliorating one or more symptoms of EoE.

44. Topical oral corticosteroid therapy for eosinophilic esophagitis (EoE) in patients who need it A method of topically treating a. Administering oral corticosteroids while the patient is in bed or immediately before the patient is in bed wherein a therapeutically effective amount of an oral corticosteroid contacts the esophagus, thereby locally treating EoE.

45. 45. The method of claim 44, wherein the lying down is in a supine, prone or lateral position.

46. 45. The method of claim 44, wherein the oral corticosteroid is administered within about 30 minutes before the target bedtime.

47. 45. The method of claim 44, wherein the oral corticosteroid is administered at least about 30 minutes after a meal.

48. 45. The method of claim 44, wherein the patient does not eat or drink for at least about 30 minutes after administration of the oral corticosteroid.

49. Oral corticosteroids (i) once a day, or (ii) twice a day 45. The method of claim 44, wherein the first daily dose is administered twice daily while the subject remains upright.

50. 45. The method of claim 44, wherein the oral corticosteroid has a systemic bioavailability of about 20% or less of its dose.

51. 45. The method of claim 44, wherein the oral corticosteroid provides a mean maximum plasma concentration (Cmax) of about 500 pg / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid.

52. The oral corticosteroid has a mean AUC of about 3,000 pg·h / mL or less following an oral dose of about 0.01 mg to about 20 mg of oral corticosteroid. 0~24Claim 4 5. The method according to claim 4.

53. 45. The method of claim 44, wherein the oral corticosteroid is budesonide, fluticasone, flunisolide, ciclesonide, mometasone or beclomethasone, or a pharma- ceutically acceptable salt, solvate, ester, polymorph or prodrug thereof.

54. Oral corticosteroids (i) formulated as a liquid composition; (ii) formulated as a solid composition; (iii) are formulated to form a solution or suspension prior to oral administration; or (iv) formulated to form a solution, suspension, or gel upon oral administration; 45. The method of claim 44, wherein (i)-(iv) deliver a therapeutically effective amount of an oral corticosteroid to the esophagus.

55. (i) the liquid composition is in the form of a solution, suspension or slurry; 55. The method of claim 54, wherein (ii) the solid composition is in the form of a gel, a lozenge, a lollipop, an effervescent tablet, a powder, a granule, or an orally disintegrating composition.

56. 56. The method of claim 55, wherein the orally disintegrable composition is a tablet, an oblate, a film, or a lyophilized matrix.

57. The orally disintegrating composition comprises a. an oral corticosteroid in an amount from about 1.5 mg to about 7.5 mg; b. a pharma- ceutically acceptable carrier in combination with a corticosteroid; c. Rapidly dispersing microgranules; A tablet comprising:

57. The method of claim 56, wherein the orally disintegrating tablet disintegrates within 60 seconds when tested for disintegration time using USP <701> method.

58. 45. The method of claim 44, wherein the patient has a Cmax of oral corticosteroid of about 200 pg / mL or less after an oral dose of 1.5 mg to about 7.5 mg of oral corticosteroid.

59. 45. The method of claim 44, wherein the oral corticosteroid is fluticasone propionate and following oral administration of 6 mg fluticasone propionate or 3 mg fluticasone propionate to a bedridden patient, the bedridden patient has a Cmax within the range of about 80% to about 125% of about 15 pg / mL to about 45 pg / mL.

60. 60. The method of claim 59, wherein the Cmax of the oral corticosteroid for a bedridden patient is lower than the Cmax of the oral corticosteroid for a postprandial patient who is upright and not lying down immediately after administration of the oral corticosteroid.

61. 61. The method of claim 60, wherein the Cmax of the oral corticosteroid for a bedridden patient is reduced by about 10% to about 30% compared to the Cmax of the oral corticosteroid for a postprandial patient who is upright and not reclining immediately after administration of the oral corticosteroid.

62. 45. The method of claim 44, wherein the mean time to reach maximum plasma concentration (Tmax) is in the range of about 80% to about 125% of about 12 hours to about 15 hours.

63. 63. The method of claim 62, wherein the Tmax of the oral corticosteroid for a patient who is bedridden is delayed compared to the Tmax of the oral corticosteroid for a patient who is upright and not lying down immediately after administration of the oral corticosteroid.

64. 64. The method of claim 63, wherein the Tmax of the corticosteroid for a patient who is bedridden is delayed by at least about 1 hour as compared to the mean Tmax of the oral corticosteroid for patients who are upright and not reclining immediately after administration of the oral corticosteroid.

65. 65. The method of claim 64, wherein the Tmax of the corticosteroid for a patient who is bedridden is delayed by a time ranging from about 4 hours to about 9 hours compared to the Tmax of the oral corticosteroid for a patient who is upright and not reclining immediately after administration of the oral corticosteroid.

66. 65. The method of claim 64, wherein after 12 weeks of daily administration of oral corticosteroids, there is reduced esophageal inflammation as measured by reduced eosinophil counts, increased dysphagia-free days, reduced dysphagia episodes, improved EREFS scores, EndoFLIP recording of improved esophageal compliance, assessment of biomarkers, reduced food impaction episodes, improved EEsAI scores (Patient, Physician, Endoscopy, Disease Score), EoE-QOL-A, Visual Dysphagia Questionnaire (VDQ), Avoidance, Modification and Slow Feeding (AMS) scores, or histology.

67. 67. The method of claim 66, wherein the patient's eosinophil count is reduced by at least about 50%.

68. 45. The method of claim 44, wherein the patient has a lactose allergy or a starch allergy.

Citation Information

Patent Citations

  • Corticosteroid composition

    JP2011503073A

  • Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

    WO2015035114A1